Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9088588,peak concentration,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),[ng] / [ml],0.74,981,DB01167,Itraconazole
,9088588,peak concentration,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),[ng] / [ml],0.81,982,DB01167,Itraconazole
,9088588,area under the curve from 0 to 24 h,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),[h·ng] / [ml],5.46 to 9.95,983,DB01167,Itraconazole
,9088588,from,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),[h·ng] / [ml],17.4 to 48.2,984,DB01167,Itraconazole
,9088588,0 to infinity,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),[h·ng] / [ml],17.4 to 48.2,985,DB01167,Itraconazole
,9088588,elimination half-life,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),d,2.1 to 3.6,986,DB01167,Itraconazole
,28436712,plasma half-life,"2. The galunisertib plasma half-life was 8.6 h, while the 14C half-life was 10.0 h.","Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28436712/),h,8.6,2718,DB01167,Itraconazole
,28436712,half-life,"2. The galunisertib plasma half-life was 8.6 h, while the 14C half-life was 10.0 h.","Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28436712/),h,10.0,2719,DB01167,Itraconazole
,28436712,AUC ratio,"Mechanistic static modeling that incorporated small non-CYP-mediated metabolic clearance and renal clearance components predicted an AUC ratio of 4.7 for the effect of itraconazole, a strong CYP3A4 inhibitor, on galunisertib.","Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28436712/),,4.7,2720,DB01167,Itraconazole
,15900286,elimination half-life (t (1/2) ),"Gemfibrozil alone raised the mean total area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of pioglitazone 3.2-fold (range, 2.3-fold to 6.5-fold; P < .001) and prolonged its elimination half-life (t (1/2) ) from 8.3 to 22.7 hours ( P < .001) but had no significant effect on its peak concentration (C max ) compared with placebo (control).","Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900286/),h,8.3 to 22.7,4948,DB01167,Itraconazole
,15618678,liver concentrations,"Meanwhile, the liver concentrations of itraconazole after single administration and repeated administration were 38.2 and 20.3 (nmol/g), respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),,38.2,5137,DB01167,Itraconazole
,15618678,liver concentrations,"Meanwhile, the liver concentrations of itraconazole after single administration and repeated administration were 38.2 and 20.3 (nmol/g), respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),,20.3,5138,DB01167,Itraconazole
,15618678,maximum metabolic reaction velocity (V(max)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),[nM] / [mg·min],2.26,5139,DB01167,Itraconazole
,15618678,maximum metabolic reaction velocity (V(max)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),[nM] / [mg·min],3,5140,DB01167,Itraconazole
,15618678,maximum metabolic reaction velocity (V(max)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),μM,8,5141,DB01167,Itraconazole
,15618678,maximum metabolic reaction velocity (V(max)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),[nM] / [mg·min],2.23,5142,DB01167,Itraconazole
,15618678,Michaelis-Menten constant (K(m)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),μM,8,5143,DB01167,Itraconazole
,15618678,Michaelis-Menten constant (K(m)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),[nM] / [mg·min],1,5144,DB01167,Itraconazole
,15618678,Michaelis-Menten constant (K(m)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),μM,7.86,5145,DB01167,Itraconazole
,15618678,Michaelis-Menten constant (K(m)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),μM,4.47,5146,DB01167,Itraconazole
,18294330,"AUC(0,24 h)","After placebo administration, mean AUC(0,24 h) of S- and R-fexofenadine was 474 ng ml(-1) h (95% CI 311, 638) and 798 ng ml(-1) h (95% CI 497, 1101), respectively.",The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294330/),[h·ng] / [ml],474,11102,DB01167,Itraconazole
,18294330,"AUC(0,24 h)","After placebo administration, mean AUC(0,24 h) of S- and R-fexofenadine was 474 ng ml(-1) h (95% CI 311, 638) and 798 ng ml(-1) h (95% CI 497, 1101), respectively.",The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294330/),[h·ng] / [ml],798,11103,DB01167,Itraconazole
,15829116,detection limit,The detection limit of itraconazole was 5.0 microg/L.,Determination of itraconazole in human plasma by high-performance liquid chromatography with solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15829116/),[μg] / [l],5.0,12349,DB01167,Itraconazole
,15829116,area under the plasma concentration-time curve from 0 to 24 h (AUC(0-24) ),We monitored the plasma level of itraconazole for the following 24 h and obtained the mean area under the plasma concentration-time curve from 0 to 24 h (AUC(0-24) ) value of 4358.9 +/- 1933.4 microg h/L.,Determination of itraconazole in human plasma by high-performance liquid chromatography with solid-phase extraction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15829116/),[h·μg] / [l],4358.9,12350,DB01167,Itraconazole
,8712747,clearance,"Mean BU clearance was 7.653 +/- 1.871 l/hr.m2 in the itraconazole patients, 10.103 +/- 2.007 l/hr.",Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712747/),[l] / [h·m2],7.653,12476,DB01167,Itraconazole
,8712747,clearance,"Mean BU clearance was 7.653 +/- 1.871 l/hr.m2 in the itraconazole patients, 10.103 +/- 2.007 l/hr.",Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712747/),[l] / [h],10.103,12477,DB01167,Itraconazole
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],1701,13330,DB01167,Itraconazole
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],3554,13331,DB01167,Itraconazole
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],4308,13332,DB01167,Itraconazole
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],4107,13333,DB01167,Itraconazole
,16928786,AUC(0-48),"Although mean itraconazole AUC(0-48) from 50 mg to 200 mg increased dose dependently from 214 to 772 ng h/ml (p = 0.003), no significant difference was noted in the three parameters, AUC (p = 0.423), C(max) (p = 0.636), and renal clearance (p = 0.495), of fexofenadine among the three doses of itraconazole.",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],214,13334,DB01167,Itraconazole
,16928786,AUC(0-48),"Although mean itraconazole AUC(0-48) from 50 mg to 200 mg increased dose dependently from 214 to 772 ng h/ml (p = 0.003), no significant difference was noted in the three parameters, AUC (p = 0.423), C(max) (p = 0.636), and renal clearance (p = 0.495), of fexofenadine among the three doses of itraconazole.",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],77,13335,DB01167,Itraconazole
,16928786,AUC(0-48),"Although mean itraconazole AUC(0-48) from 50 mg to 200 mg increased dose dependently from 214 to 772 ng h/ml (p = 0.003), no significant difference was noted in the three parameters, AUC (p = 0.423), C(max) (p = 0.636), and renal clearance (p = 0.495), of fexofenadine among the three doses of itraconazole.",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],2,13336,DB01167,Itraconazole
,20210560,entrapment efficiency,The size distribution of the liposomes was 264.5 nm and the entrapment efficiency of ITZ-LPs was 73.82 +/- 0.73%.,Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210560/),%,73.82,15711,DB01167,Itraconazole
,20210560,AUC(0-->24 h),The AUC(0-->24 h) for ITZ-CD was 87.12 mg/L.h and that for ITZ-LPs was 155.47 mg/L.h (p < 0.05).,Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210560/),[mg] / [h·l],87.12,15712,DB01167,Itraconazole
,20210560,AUC(0-->24 h),The AUC(0-->24 h) for ITZ-CD was 87.12 mg/L.h and that for ITZ-LPs was 155.47 mg/L.h (p < 0.05).,Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210560/),[mg] / [h·l],155.47,15713,DB01167,Itraconazole
,20210560,MRT(0-->24 h),The MRT(0-->24 h) value was 1.70 h for ITZ-CD and 3.68 h for ITZ-LPs.,Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210560/),h,1.70,15714,DB01167,Itraconazole
,20210560,MRT(0-->24 h),The MRT(0-->24 h) value was 1.70 h for ITZ-CD and 3.68 h for ITZ-LPs.,Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210560/),h,3.68,15715,DB01167,Itraconazole
,11259329,maximum inactivation rate constant,"The maximum inactivation rate constant and the apparent inactivation constant of EM on MDZ metabolism were 0.0665 min(-1) and 81.8 microM, respectively.","Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259329/),1/[min],0.0665,16036,DB01167,Itraconazole
,11259329,apparent inactivation constant,"The maximum inactivation rate constant and the apparent inactivation constant of EM on MDZ metabolism were 0.0665 min(-1) and 81.8 microM, respectively.","Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259329/),μM,81.8,16037,DB01167,Itraconazole
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),nM,0.0676,17157,DB01167,Itraconazole
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),μM,14.2,17158,DB01167,Itraconazole
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),μM,5.48,17159,DB01167,Itraconazole
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),,0.,17160,DB01167,Itraconazole
,30889695,AUC0-24h,"Furthermore, the pharmacokinetic profiles of obtained nano-formulations were assessed in rats, among which the improved adsorption of SBA-15/EPL/ITZ composites (AUC0-24h sum: 8381.7 nM·h) was identified compared with that of pure ITZ (525.1 nM·h) and the commercial drug of Sporanox (7516.6 nM·h).",Epsilon-poly-l-lysine decorated ordered mesoporous silica contributes to the synergistic antifungal effect and enhanced solubility of a lipophilic drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30889695/),h·nM,8381.7,18164,DB01167,Itraconazole
,30889695,AUC0-24h,"Furthermore, the pharmacokinetic profiles of obtained nano-formulations were assessed in rats, among which the improved adsorption of SBA-15/EPL/ITZ composites (AUC0-24h sum: 8381.7 nM·h) was identified compared with that of pure ITZ (525.1 nM·h) and the commercial drug of Sporanox (7516.6 nM·h).",Epsilon-poly-l-lysine decorated ordered mesoporous silica contributes to the synergistic antifungal effect and enhanced solubility of a lipophilic drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30889695/),h·nM,525.1,18165,DB01167,Itraconazole
,30889695,AUC0-24h,"Furthermore, the pharmacokinetic profiles of obtained nano-formulations were assessed in rats, among which the improved adsorption of SBA-15/EPL/ITZ composites (AUC0-24h sum: 8381.7 nM·h) was identified compared with that of pure ITZ (525.1 nM·h) and the commercial drug of Sporanox (7516.6 nM·h).",Epsilon-poly-l-lysine decorated ordered mesoporous silica contributes to the synergistic antifungal effect and enhanced solubility of a lipophilic drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30889695/),h·nM,7516.6,18166,DB01167,Itraconazole
,20093186,t(max),"HPbetaCD-ITZ demonstrated faster systemic absorption of ITZ across lung epithelium than URF-ITZ, with t(max) values of 1.5 and 3.0 h, and AUC(0-infinity) of 2513 and 3717 ng h/mL, respectively.",In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20093186/),h,1.5,18997,DB01167,Itraconazole
,20093186,t(max),"HPbetaCD-ITZ demonstrated faster systemic absorption of ITZ across lung epithelium than URF-ITZ, with t(max) values of 1.5 and 3.0 h, and AUC(0-infinity) of 2513 and 3717 ng h/mL, respectively.",In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20093186/),h,3.0,18998,DB01167,Itraconazole
,20093186,AUC(0-infinity),"HPbetaCD-ITZ demonstrated faster systemic absorption of ITZ across lung epithelium than URF-ITZ, with t(max) values of 1.5 and 3.0 h, and AUC(0-infinity) of 2513 and 3717 ng h/mL, respectively.",In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20093186/),[h·ng] / [ml],2513,18999,DB01167,Itraconazole
,20093186,AUC(0-infinity),"HPbetaCD-ITZ demonstrated faster systemic absorption of ITZ across lung epithelium than URF-ITZ, with t(max) values of 1.5 and 3.0 h, and AUC(0-infinity) of 2513 and 3717 ng h/mL, respectively.",In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20093186/),[h·ng] / [ml],3717,19000,DB01167,Itraconazole
,23095205,Total run time,Detection was performed by a tandem mass spectrometer coupled to LC via an atmospheric pressure chemical ionization (APCI) and quantification was performed using selected reaction monitoring (SRM) transitions Total run time was 4.5 min.,"Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23095205/),min,4.5,19355,DB01167,Itraconazole
,30119143,peak concentrations,"The concentration range of posaconazole was 0.05-4.0 μg/mL with good linearity (r = 0.9980), the peak concentrations of pure posaconazole and the inclusion complex were 0.565 ± 0.102 μg/mL and 1.12 ± 0.091 μg/mL, the values for AUC0-t were 12.2 ± 2.5 and 19.9 ± 2.5 μg h/mL, and the values for AUC0-∞ were 16.4 ± 3.2 and 25.0 ± 3.5 μg h/mL, respectively.",In vitro and in vivo evaluation of a posaconazole-sulfobutyl ether-β-cyclodextrin inclusion complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30119143/),[μg] / [ml],0.565,19744,DB01167,Itraconazole
,30119143,peak concentrations,"The concentration range of posaconazole was 0.05-4.0 μg/mL with good linearity (r = 0.9980), the peak concentrations of pure posaconazole and the inclusion complex were 0.565 ± 0.102 μg/mL and 1.12 ± 0.091 μg/mL, the values for AUC0-t were 12.2 ± 2.5 and 19.9 ± 2.5 μg h/mL, and the values for AUC0-∞ were 16.4 ± 3.2 and 25.0 ± 3.5 μg h/mL, respectively.",In vitro and in vivo evaluation of a posaconazole-sulfobutyl ether-β-cyclodextrin inclusion complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30119143/),[μg] / [ml],1.12,19745,DB01167,Itraconazole
,30119143,AUC0-t,"The concentration range of posaconazole was 0.05-4.0 μg/mL with good linearity (r = 0.9980), the peak concentrations of pure posaconazole and the inclusion complex were 0.565 ± 0.102 μg/mL and 1.12 ± 0.091 μg/mL, the values for AUC0-t were 12.2 ± 2.5 and 19.9 ± 2.5 μg h/mL, and the values for AUC0-∞ were 16.4 ± 3.2 and 25.0 ± 3.5 μg h/mL, respectively.",In vitro and in vivo evaluation of a posaconazole-sulfobutyl ether-β-cyclodextrin inclusion complex. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30119143/),[h·μg] / [ml],12.2,19746,DB01167,Itraconazole
,30119143,AUC0-t,"The concentration range of posaconazole was 0.05-4.0 μg/mL with good linearity (r = 0.9980), the peak concentrations of pure posaconazole and the inclusion complex were 0.565 ± 0.102 μg/mL and 1.12 ± 0.091 μg/mL, the values for AUC0-t were 12.2 ± 2.5 and 19.9 ± 2.5 μg h/mL, and the values for AUC0-∞ were 16.4 ± 3.2 and 25.0 ± 3.5 μg h/mL, respectively.",In vitro and in vivo evaluation of a posaconazole-sulfobutyl ether-β-cyclodextrin inclusion complex. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30119143/),[h·μg] / [ml],19.9,19747,DB01167,Itraconazole
,30119143,AUC0-∞,"The concentration range of posaconazole was 0.05-4.0 μg/mL with good linearity (r = 0.9980), the peak concentrations of pure posaconazole and the inclusion complex were 0.565 ± 0.102 μg/mL and 1.12 ± 0.091 μg/mL, the values for AUC0-t were 12.2 ± 2.5 and 19.9 ± 2.5 μg h/mL, and the values for AUC0-∞ were 16.4 ± 3.2 and 25.0 ± 3.5 μg h/mL, respectively.",In vitro and in vivo evaluation of a posaconazole-sulfobutyl ether-β-cyclodextrin inclusion complex. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30119143/),[h·μg] / [ml],16.4,19748,DB01167,Itraconazole
,30119143,AUC0-∞,"The concentration range of posaconazole was 0.05-4.0 μg/mL with good linearity (r = 0.9980), the peak concentrations of pure posaconazole and the inclusion complex were 0.565 ± 0.102 μg/mL and 1.12 ± 0.091 μg/mL, the values for AUC0-t were 12.2 ± 2.5 and 19.9 ± 2.5 μg h/mL, and the values for AUC0-∞ were 16.4 ± 3.2 and 25.0 ± 3.5 μg h/mL, respectively.",In vitro and in vivo evaluation of a posaconazole-sulfobutyl ether-β-cyclodextrin inclusion complex. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30119143/),[h·μg] / [ml],25.0,19749,DB01167,Itraconazole
,1681649,Plasma levels,Plasma levels range between 0.1 and 1.0 micrograms/ml.,"Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681649/),[μg] / [ml],0.1 and 1.0,22112,DB01167,Itraconazole
,1681649,half-life,Elimination of drug from tissue occurs with a half-life of 4 to 5 days and with the potential for drug levels above fungicidal concentrations for dermatophytes for more than 3 weeks.,"Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1681649/),d,4 to 5,22113,DB01167,Itraconazole
,32595511,S/P ratio,"Fluconazole and voriconazole demonstrated a good saliva penetration with an average S/P ratio of 1.21 (± 0.31) for fluconazole and 0.56 (± 0.18) for voriconazole, both with strong correlation (r = 0.89-0.98).",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),,1.21,25178,DB01167,Itraconazole
,32595511,S/P ratio,"Fluconazole and voriconazole demonstrated a good saliva penetration with an average S/P ratio of 1.21 (± 0.31) for fluconazole and 0.56 (± 0.18) for voriconazole, both with strong correlation (r = 0.89-0.98).",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),,0.56,25179,DB01167,Itraconazole
,32595511,clearance,"Voriconazole pharmacokinetics was best described by one-compartment PK model with first-order absorption, parameterized by clearance of 4.56 L/h (36.9% CV), volume of distribution of 60.7 L, absorption rate constant of 0.858 (fixed), and bioavailability of 0.849.",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),[l] / [h],4.56,25180,DB01167,Itraconazole
,32595511,volume of distribution,"Voriconazole pharmacokinetics was best described by one-compartment PK model with first-order absorption, parameterized by clearance of 4.56 L/h (36.9% CV), volume of distribution of 60.7 L, absorption rate constant of 0.858 (fixed), and bioavailability of 0.849.",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),l,60.7,25181,DB01167,Itraconazole
,32595511,absorption rate constant,"Voriconazole pharmacokinetics was best described by one-compartment PK model with first-order absorption, parameterized by clearance of 4.56 L/h (36.9% CV), volume of distribution of 60.7 L, absorption rate constant of 0.858 (fixed), and bioavailability of 0.849.",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),,0.858,25182,DB01167,Itraconazole
,32595511,bioavailability,"Voriconazole pharmacokinetics was best described by one-compartment PK model with first-order absorption, parameterized by clearance of 4.56 L/h (36.9% CV), volume of distribution of 60.7 L, absorption rate constant of 0.858 (fixed), and bioavailability of 0.849.",Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32595511/),,0.849,25183,DB01167,Itraconazole
,14643517,flow-rate,"Analysis was run at flow-rate of 0.9 ml/min with excitation and emission wavelengths set at 260 and 365 nm, respectively.",Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643517/),[ml] / [min],0.9,26410,DB01167,Itraconazole
,14643517,limit of quantification,The method was sensitive with limit of quantification of 3 ng/ml for itraconazole and 6 ng/ml for hydroxyitraconazole.,Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643517/),[ng] / [ml],3,26411,DB01167,Itraconazole
,14643517,limit of quantification,The method was sensitive with limit of quantification of 3 ng/ml for itraconazole and 6 ng/ml for hydroxyitraconazole.,Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643517/),[ng] / [ml],6,26412,DB01167,Itraconazole
,28749255,peak concentration,Observed mean peak concentration (1.89 μg/ml) after single dosing PK analysis was determined within the first hour following voriconazole administration.,PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749255/),[μg] / [ml],1.89,27974,DB01167,Itraconazole
,28749255,volume of distribution (V/F),"The mean estimates for volume of distribution (V/F) and clearance (Cl/F) for the multiple-dose study were 3.34 L and 0.18 L/hr, respectively.",PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749255/),l,3.34,27975,DB01167,Itraconazole
,28749255,clearance (Cl/F),"The mean estimates for volume of distribution (V/F) and clearance (Cl/F) for the multiple-dose study were 3.34 L and 0.18 L/hr, respectively.",PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749255/),[l] / [h],0.18,27976,DB01167,Itraconazole
,28749255,area under the curve (AUC0-24),Monte Carlo simulations determined the median area under the curve (AUC0-24) at 84 hr was 37.7 μg·h/ml.,PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749255/),[h·μg] / [ml],37.7,27977,DB01167,Itraconazole
,15286096,CL(T),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],655,28392,DB01167,Itraconazole
,15286096,CL(T),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],486,28393,DB01167,Itraconazole
,15286096,CL(sec),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],410,28394,DB01167,Itraconazole
,15286096,CL(sec),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],311,28395,DB01167,Itraconazole
,16633141,area under the time-concentration curves (AUCs),Itraconazole pretreatment increased the mean area under the time-concentration curves (AUCs) of haloperidol by 55% compared to placebo pretreatment (21.7 +/- 11.3 vs 33.5 +/- 29.3 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],21.7,28806,DB01167,Itraconazole
,16633141,area under the time-concentration curves (AUCs),Itraconazole pretreatment increased the mean area under the time-concentration curves (AUCs) of haloperidol by 55% compared to placebo pretreatment (21.7 +/- 11.3 vs 33.5 +/- 29.3 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],33.5,28807,DB01167,Itraconazole
,16633141,AUC,The subjects with CYP2D6*10/*10 genotype showed 81% higher AUC compared to that of subjects with CYP2D6*1/*1 genotype (27.6 +/- 22.2 vs 50.2 +/- 47.1 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],27.6,28808,DB01167,Itraconazole
,16633141,AUC,The subjects with CYP2D6*10/*10 genotype showed 81% higher AUC compared to that of subjects with CYP2D6*1/*1 genotype (27.6 +/- 22.2 vs 50.2 +/- 47.1 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],50.2,28809,DB01167,Itraconazole
,16633141,AUC,"In the presence of itraconazole, subjects with CYP2D6*10/*10 showed 3-fold higher AUC of haloperidol compared to that of placebo pretreated subjects with CYP2D6*1/*1 genotype (21.7 +/- 11.3 vs 66.7 +/- 62.1 ng h/mL; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],21.7,28810,DB01167,Itraconazole
,16633141,AUC,"In the presence of itraconazole, subjects with CYP2D6*10/*10 showed 3-fold higher AUC of haloperidol compared to that of placebo pretreated subjects with CYP2D6*1/*1 genotype (21.7 +/- 11.3 vs 66.7 +/- 62.1 ng h/mL; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],66.7,28811,DB01167,Itraconazole
,16633141,oral clearance,"In the subjects with both CYP2D6*10 genotype and itraconazole pretreatment, however, the oral clearance was significantly decreased to 42% of subjects with wild genotype in the placebo pretreatment (4.7 +/- 3.6 vs 2.0 +/- 1.9 L/h/kg; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[l] / [h·kg],4.7,28812,DB01167,Itraconazole
,16633141,oral clearance,"In the subjects with both CYP2D6*10 genotype and itraconazole pretreatment, however, the oral clearance was significantly decreased to 42% of subjects with wild genotype in the placebo pretreatment (4.7 +/- 3.6 vs 2.0 +/- 1.9 L/h/kg; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[l] / [h·kg],2.0,28813,DB01167,Itraconazole
,24245252,basal spacing,"According to the powder X-ray diffraction pattern, the basal spacing of the intraconazole-layered aluminosilicate nanohybrid increased from 14.7 to 22.7 A depending on the pH of the aqueous suspension.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),a,14.7,28868,DB01167,Itraconazole
,24245252,basal spacing,"According to the powder X-ray diffraction pattern, the basal spacing of the intraconazole-layered aluminosilicate nanohybrid increased from 14.7 to 22.7 A depending on the pH of the aqueous suspension.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),a,22.7,28869,DB01167,Itraconazole
,24245252,area under the plasma concentration-time curve (AUC,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],2477,28870,DB01167,Itraconazole
,24245252,area under the plasma concentration-time curve (AUC,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],2630,28871,DB01167,Itraconazole
,24245252,maximum concentration (Cmax,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],225.4,28872,DB01167,Itraconazole
,24245252,maximum concentration (Cmax,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],223.6,28873,DB01167,Itraconazole
,23523546,maximum solubility,"F2 and F3 formulations allowed the in vitro formation of an ITZ supersaturated solution with a maximum solubility of 450±124ng/ml (F2) and 498±44ng/ml (F3), in contrast to formulation F1 (<10ng/ml).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ng] / [ml],450,29220,DB01167,Itraconazole
,23523546,maximum solubility,"F2 and F3 formulations allowed the in vitro formation of an ITZ supersaturated solution with a maximum solubility of 450±124ng/ml (F2) and 498±44ng/ml (F3), in contrast to formulation F1 (<10ng/ml).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ng] / [ml],498,29221,DB01167,Itraconazole
<,23523546,maximum solubility,"F2 and F3 formulations allowed the in vitro formation of an ITZ supersaturated solution with a maximum solubility of 450±124ng/ml (F2) and 498±44ng/ml (F3), in contrast to formulation F1 (<10ng/ml).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ng] / [ml],10,29222,DB01167,Itraconazole
,23523546,plasmatic AUC0-24h,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ngh] / [ml],182,29223,DB01167,Itraconazole
,23523546,plasmatic AUC0-24h,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ngh] / [ml],491.5,29224,DB01167,Itraconazole
,23523546,plasmatic AUC0-24h,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ngh] / [ml],376.8,29225,DB01167,Itraconazole
,23523546,tmax,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),min,60,29226,DB01167,Itraconazole
,23523546,tmax,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),min,30,29227,DB01167,Itraconazole
,23523546,tmax,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),min,5,29228,DB01167,Itraconazole
,23523546,minimal inhibitory concentrations,"ITZ lung concentrations after pulmonary administration remained higher than the targeted dose, based on the minimal inhibitory concentrations for Aspergillus fumigatus (2μg/glung), 24h post-administration for both F1 and F2 formulations.",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[μg] / [glung],2,29229,DB01167,Itraconazole
,23523546,elimination half-life,"However, this was not the case for formulation F3, which exhibited a faster elimination rate from the lung, with an elimination half-life of 4.1h vs. 6.5h and 14.7h for F1 and F2, respectively.",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),h,4.1,29230,DB01167,Itraconazole
,23523546,elimination half-life,"However, this was not the case for formulation F3, which exhibited a faster elimination rate from the lung, with an elimination half-life of 4.1h vs. 6.5h and 14.7h for F1 and F2, respectively.",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),h,6.5,29231,DB01167,Itraconazole
,23523546,elimination half-life,"However, this was not the case for formulation F3, which exhibited a faster elimination rate from the lung, with an elimination half-life of 4.1h vs. 6.5h and 14.7h for F1 and F2, respectively.",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),h,14.7,29232,DB01167,Itraconazole
,32304015,elimination half-life,Median maximum concentration was reached 2-6 h following single and repeat dosing of gilteritinib; mean elimination half-life was 113 h.,Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304015/),h,113,29795,DB01167,Itraconazole
,17048974,apparent clearance (CL(itraconazole)),"For itraconazole the apparent clearance (CL(itraconazole)) was 35.5 L/hour, the apparent volume of distribution (V(d(itraconazole)) was 672 L, the absorption rate constant for the capsule formulation was 0.0901 h(-)(1) and for the oral solution formulation was 0.96 h(-1).",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),[l] / [h],35.5,33603,DB01167,Itraconazole
,17048974,apparent volume of distribution (V(d(itraconazole)),"For itraconazole the apparent clearance (CL(itraconazole)) was 35.5 L/hour, the apparent volume of distribution (V(d(itraconazole)) was 672 L, the absorption rate constant for the capsule formulation was 0.0901 h(-)(1) and for the oral solution formulation was 0.96 h(-1).",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),l,672,33604,DB01167,Itraconazole
,17048974,absorption rate constant,"For itraconazole the apparent clearance (CL(itraconazole)) was 35.5 L/hour, the apparent volume of distribution (V(d(itraconazole)) was 672 L, the absorption rate constant for the capsule formulation was 0.0901 h(-)(1) and for the oral solution formulation was 0.96 h(-1).",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),h(-)(1),0.0901,33605,DB01167,Itraconazole
,17048974,absorption rate constant,"For itraconazole the apparent clearance (CL(itraconazole)) was 35.5 L/hour, the apparent volume of distribution (V(d(itraconazole)) was 672 L, the absorption rate constant for the capsule formulation was 0.0901 h(-)(1) and for the oral solution formulation was 0.96 h(-1).",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),1/[h],0.96,33606,DB01167,Itraconazole
,17048974,lag time,The lag time was estimated to be 19.1 minutes and the relative bioavailability between capsules and oral solution (F(rel)) was 0.55.,Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),min,19.1,33607,DB01167,Itraconazole
,17048974,relative bioavailability,The lag time was estimated to be 19.1 minutes and the relative bioavailability between capsules and oral solution (F(rel)) was 0.55.,Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),,0.55,33608,DB01167,Itraconazole
,17048974,volume of distribution,"For the metabolite, volume of distribution, V(m)/(F . f(m)), and clearance, CL/(F . f(m)), were 10.6L and 5.28 L/h, respectively.",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),l,10.6,33609,DB01167,Itraconazole
,17048974,"clearance, CL/(F . f(m))","For the metabolite, volume of distribution, V(m)/(F . f(m)), and clearance, CL/(F . f(m)), were 10.6L and 5.28 L/h, respectively.",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),[l] / [h],5.28,33610,DB01167,Itraconazole
,17048974,minimum therapeutic trough plasma concentration,More appropriate dosing schedules have been developed for the oral solution and the capsules to secure a minimum therapeutic trough plasma concentration of 0.5 mg/L for these patients.,Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),[mg] / [l],0.5,33611,DB01167,Itraconazole
,26333939,g,Nanoemulsion with average globule size of 100.9 nm and zeta potential of -35.9 ± 1.2 mV was able to penetrate well into the intestinal membrane as confirmed by the laser confocal scanning microscopy and ex vivo intestinal permeability study.,Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333939/),,100.9,36034,DB01167,Itraconazole
,26333939,zeta potential,Nanoemulsion with average globule size of 100.9 nm and zeta potential of -35.9 ± 1.2 mV was able to penetrate well into the intestinal membrane as confirmed by the laser confocal scanning microscopy and ex vivo intestinal permeability study.,Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333939/),mv,-,36035,DB01167,Itraconazole
,26333939,zeta potential,Nanoemulsion with average globule size of 100.9 nm and zeta potential of -35.9 ± 1.2 mV was able to penetrate well into the intestinal membrane as confirmed by the laser confocal scanning microscopy and ex vivo intestinal permeability study.,Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333939/),mv,35.9,36036,DB01167,Itraconazole
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],1707,39239,DB01167,Itraconazole
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],695,39240,DB01167,Itraconazole
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],277,39241,DB01167,Itraconazole
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],1707,39242,DB01167,Itraconazole
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],695,39243,DB01167,Itraconazole
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],277,39244,DB01167,Itraconazole
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],4.4,39245,DB01167,Itraconazole
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),%,13,39246,DB01167,Itraconazole
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],27.1,39247,DB01167,Itraconazole
,12885135,half-life (t1/2),"At a 15-mg/kg dosage, the half-life (t1/2) was 75 hr for itraconazole and 55 hr for OH-ITRA.","Steady-state plasma concentrations of itraconazole after oral administration in Kemp's ridley sea turtles, Lepidochelys kempi. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885135/),h,75,42942,DB01167,Itraconazole
,12885135,half-life (t1/2),"At a 15-mg/kg dosage, the half-life (t1/2) was 75 hr for itraconazole and 55 hr for OH-ITRA.","Steady-state plasma concentrations of itraconazole after oral administration in Kemp's ridley sea turtles, Lepidochelys kempi. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885135/),h,55,42943,DB01167,Itraconazole
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.83,43396,DB01167,Itraconazole
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.32,43397,DB01167,Itraconazole
,20347037,clearance,"In vivo data correlated with IPK results as clofarabine clearance decreased 61% (20.2-7.80mL/min/kg), upon co-administration with cimetidine in rats.",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [kg·min],20.2-7.80,43398,DB01167,Itraconazole
,20481649,time to reach the maximum plasma concentration,The time to reach the maximum plasma concentration has been reported to be 5-8 hours following oral administration of a single dose.,Pharmacokinetic/pharmacodynamic profile of posaconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481649/),h,5-8,44290,DB01167,Itraconazole
,20481649,apparent volume of distribution after oral administration (V(d)/F),"Posaconazole has a large mean apparent volume of distribution after oral administration (V(d)/F), which is approximately 5-25 L/kg, suggesting extensive extravascular distribution and penetration into intracellular spaces.",Pharmacokinetic/pharmacodynamic profile of posaconazole. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481649/),[l] / [kg],5-25,44291,DB01167,Itraconazole
,20481649,terminal elimination half-life,Posaconazole has a median terminal elimination half-life of 15-35 hours.,Pharmacokinetic/pharmacodynamic profile of posaconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481649/),h,15-35,44292,DB01167,Itraconazole
less,20481649,renal elimination,"The renal elimination of posaconazole is less than 1 mL/h, which is negligible compared with the mean total oral clearance of 16.3 L/h.",Pharmacokinetic/pharmacodynamic profile of posaconazole. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481649/),[ml] / [h],1,44293,DB01167,Itraconazole
,20481649,total oral clearance,"The renal elimination of posaconazole is less than 1 mL/h, which is negligible compared with the mean total oral clearance of 16.3 L/h.",Pharmacokinetic/pharmacodynamic profile of posaconazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481649/),[l] / [h],16.3,44294,DB01167,Itraconazole
,18339815,F(H),"During the absorption phase, the F(H) of ITZ increased from 0.2 to 1.0, reflecting the time course of hepatic CYP3A inhibition.","Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339815/),,0.2,45475,DB01167,Itraconazole
,18339815,F(H),"During the absorption phase, the F(H) of ITZ increased from 0.2 to 1.0, reflecting the time course of hepatic CYP3A inhibition.","Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339815/),,1.0,45476,DB01167,Itraconazole
,18339815,Ki,"The in vivo Ki for OH-ITZ (38 +/- 3 nM) was estimated from C(IN,OH-ITZ) versus F(H) of ITZ, and is similar to values obtained from inhibition of midazolam hydroxylation in CYP3A4 supersomes (Drug Metab Dispos 32:1121-1131, 2004).","Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339815/),nM,38,45477,DB01167,Itraconazole
,26022135,trough plasma concentration,"Mean trough plasma concentration of itraconazole after oral prophylaxis and intravenous induction were 577.2 and 1659.7 μg/L, respectively.",Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26022135/),[μg] / [l],577.2,47306,DB01167,Itraconazole
,26022135,trough plasma concentration,"Mean trough plasma concentration of itraconazole after oral prophylaxis and intravenous induction were 577.2 and 1659.7 μg/L, respectively.",Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26022135/),[μg] / [l],1659.7,47307,DB01167,Itraconazole
,26022135,area under the concentration-time curve,"Mean area under the concentration-time curve of itraconazole and its metabolite at steady state were 42,837 ± 24,746 μg·h/L and 63,094 ± 19,255 μg·h/L.",Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26022135/),[h·μg] / [l],"42,837",47308,DB01167,Itraconazole
,26022135,area under the concentration-time curve,"Mean area under the concentration-time curve of itraconazole and its metabolite at steady state were 42,837 ± 24,746 μg·h/L and 63,094 ± 19,255 μg·h/L.",Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26022135/),[h·μg] / [l],"63,094",47309,DB01167,Itraconazole
,9256973,mean residence time (MRT),"For E1, itraconazole plasma drug concentration extrapolated to time zero (IV dose) was 5.2 +/- 1.4 micrograms/ml, and mean residence time (MRT) was 37 +/- 16 hours.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),h,37,48639,DB01167,Itraconazole
,9256973,maximal itraconazole concentration,"For oral dosing, maximal itraconazole concentration was 1.69 +/- 0.864 micrograms/ml, MRT was 48 +/- 17 hours, and bioavailability was 78.8 +/- 28%.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),[μg] / [ml],1.69,48640,DB01167,Itraconazole
,9256973,MRT,"For oral dosing, maximal itraconazole concentration was 1.69 +/- 0.864 micrograms/ml, MRT was 48 +/- 17 hours, and bioavailability was 78.8 +/- 28%.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),h,48,48641,DB01167,Itraconazole
,9256973,bioavailability,"For oral dosing, maximal itraconazole concentration was 1.69 +/- 0.864 micrograms/ml, MRT was 48 +/- 17 hours, and bioavailability was 78.8 +/- 28%.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),%,78.8,48642,DB01167,Itraconazole
,9256973,MRT,"For the multiple oral dosing study, MRT (at last dose: 81.1 +/- 97.4 hours for G1, and 63.1 +/- 15.1 hours for G2) was shorter (P = 0.02) at first dose, compared with last dose, for both groups but did not differ between groups.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),h,81.1,48643,DB01167,Itraconazole
,9256973,MRT,"For the multiple oral dosing study, MRT (at last dose: 81.1 +/- 97.4 hours for G1, and 63.1 +/- 15.1 hours for G2) was shorter (P = 0.02) at first dose, compared with last dose, for both groups but did not differ between groups.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),h,63.1,48644,DB01167,Itraconazole
up,9256973,steady-state concentrations,The oral itraconazole solution is preferred to capsules; a 24-hour dosing interval should be sufficient; 10 mg/kg given daily should generate therapeutic concentrations in most cats; steady-state concentrations may take up to 3 weeks to achieve; and cats appear to tolerate itraconazole well.,Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),weeks,3,48645,DB01167,Itraconazole
,17073891,trough target concentration,Dosing schedules were simulated to assess their ability to achieve a trough target concentration of 0.5 mg ml(-1).,A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073891/),[mg] / [ml],0.5,49595,DB01167,Itraconazole
,17073891,absorption rate constants,"For itraconazole the absorption rate constants (between-subject variability) for capsule and solution were 0.0315 h(-1) (91.9%) and 0.125 h(-1) (106.3%), respectively, and the relative bioavailability of the capsule was 0.82 (62.3%) (confidence interval 0.36, 1.97), compared with the solution.",A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073891/),1/[h],0.0315,49596,DB01167,Itraconazole
,17073891,absorption rate constants,"For itraconazole the absorption rate constants (between-subject variability) for capsule and solution were 0.0315 h(-1) (91.9%) and 0.125 h(-1) (106.3%), respectively, and the relative bioavailability of the capsule was 0.82 (62.3%) (confidence interval 0.36, 1.97), compared with the solution.",A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073891/),1/[h],0.125,49597,DB01167,Itraconazole
,17073891,relative bioavailability,"For itraconazole the absorption rate constants (between-subject variability) for capsule and solution were 0.0315 h(-1) (91.9%) and 0.125 h(-1) (106.3%), respectively, and the relative bioavailability of the capsule was 0.82 (62.3%) (confidence interval 0.36, 1.97), compared with the solution.",A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073891/),,0.82,49598,DB01167,Itraconazole
,17073891,relative bioavailability,The relative bioavailability for itraconazole capsules was 82% compared with the solution.,A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073891/),%,82,49599,DB01167,Itraconazole
,15058598,flow rate,"The mobile phase consisted of [0.01% triethylamine solution adjusted to pH 2.8 with orthophosphoric acid-acetonitrile (46:54)]-isopropanol (90:10, v/v) at a flow rate of 1.0 ml/min.",Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058598/),[ml] / [min],1.0,50409,DB01167,Itraconazole
more,15058598,observed recovery,"An observed recovery was more than 70% for drug, metabolite and internal standard.",Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058598/),%,70,50410,DB01167,Itraconazole
,22111976,zeta potential,CMC-ITZ-Lips had an average diameter of 349.3 ± 18 nm with a zeta potential of -35.71 ± 0.62 mV and the in vitro antifungal activity was not inhibited by the entrapment.,Preparation of itraconazole-loaded liposomes coated by carboxymethyl chitosan and its pharmacokinetics and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22111976/),mv,-,51352,DB01167,Itraconazole
,22111976,zeta potential,CMC-ITZ-Lips had an average diameter of 349.3 ± 18 nm with a zeta potential of -35.71 ± 0.62 mV and the in vitro antifungal activity was not inhibited by the entrapment.,Preparation of itraconazole-loaded liposomes coated by carboxymethyl chitosan and its pharmacokinetics and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22111976/),mv,35.71,51353,DB01167,Itraconazole
,27121674,AUC,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[h·ng] / [ml],138,51672,DB01167,Itraconazole
,27121674,AUC,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[ng] / [ml],63.8,51673,DB01167,Itraconazole
,27121674,AUC,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[h·ng] / [ml],106,51674,DB01167,Itraconazole
,27121674,AUC,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[ng] / [ml],49.5,51675,DB01167,Itraconazole
,27121674,Cmax,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[ng] / [ml],63.8,51676,DB01167,Itraconazole
,27121674,Cmax,"The AUC and Cmax of pitavastatin alone were 138 ng h/mL and 63.8 ng/mL, and pitavastatin with itraconazole were 106 ng h/mL and 49.5 ng/mL, respectively.",Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121674/),[ng] / [ml],49.5,51677,DB01167,Itraconazole
,11557912,absorption rate constant,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),1/[h],6.07,52477,DB01167,Itraconazole
,11557912,apparent clearance,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),[l] / [h],8.8,52478,DB01167,Itraconazole
,11557912,apparent central distribution volume,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),l,110,52479,DB01167,Itraconazole
,17517842,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 1,015 +/- 692 ng/ml, 293 +/- 133 ng/ml, and 329 +/- 200 mug/ml, respectively.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[ng] / [ml],"1,015",52791,DB01167,Itraconazole
,17517842,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 1,015 +/- 692 ng/ml, 293 +/- 133 ng/ml, and 329 +/- 200 mug/ml, respectively.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[ng] / [ml],293,52792,DB01167,Itraconazole
,17517842,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 1,015 +/- 692 ng/ml, 293 +/- 133 ng/ml, and 329 +/- 200 mug/ml, respectively.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[μg] / [ml],329,52793,DB01167,Itraconazole
,17517842,area under the concentration-time curve from 0 to 24 h,"The total body exposures (area under the concentration-time curve from 0 to 24 h) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 4,922 +/- 6,784 ng.h/ml, 3,811 +/- 2,794 ng.h/ml, and 641.5 +/- 265.0 mug.h/ml, respectively, with no significant age dependence observed among the children evaluated.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[h·ng] / [ml],"4,922",52794,DB01167,Itraconazole
,17517842,area under the concentration-time curve from 0 to 24 h,"The total body exposures (area under the concentration-time curve from 0 to 24 h) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 4,922 +/- 6,784 ng.h/ml, 3,811 +/- 2,794 ng.h/ml, and 641.5 +/- 265.0 mug.h/ml, respectively, with no significant age dependence observed among the children evaluated.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[h·ng] / [ml],"3,811",52795,DB01167,Itraconazole
,17517842,area under the concentration-time curve from 0 to 24 h,"The total body exposures (area under the concentration-time curve from 0 to 24 h) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 4,922 +/- 6,784 ng.h/ml, 3,811 +/- 2,794 ng.h/ml, and 641.5 +/- 265.0 mug.h/ml, respectively, with no significant age dependence observed among the children evaluated.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[h·μg] / [ml],641.5,52796,DB01167,Itraconazole
,17517842,total body clearance,"Similarly, there was no relationship between age and total body clearance (702.8 +/- 499.4 ml/h/kg); however, weak associations between age and the itraconazole distribution volume (r(2) = 0.18, P = 0.02), C(max) (r(2) = 0.14, P = 0.045), and terminal elimination rate (r(2) = 0.26, P < 0.01) were noted.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[ml] / [h·kg],702.8,52797,DB01167,Itraconazole
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,5,56069,DB01167,Itraconazole
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,0.4,56070,DB01167,Itraconazole
,25914381,flow rate,Chromatographic separation was achieved on a Symmetry Shield RP18 using an isocratic mobile phase at a flow rate of 0.7 mL/min.,Development and validation of an RP-HPLC method for the quantitation of odanacatib in rat and human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25914381/),[ml] / [min],0.7,56911,DB01167,Itraconazole
,25914381,UV detection wave length,The UV detection wave length was 268 nm.,Development and validation of an RP-HPLC method for the quantitation of odanacatib in rat and human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25914381/),,268,56912,DB01167,Itraconazole
,25914381,total run time,"Odanacatib and IS eluted at 5.5 and 8.6 min, respectively with a total run time of 10 min.",Development and validation of an RP-HPLC method for the quantitation of odanacatib in rat and human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25914381/),min,10,56913,DB01167,Itraconazole
,20420905,AUC,"When high enough amounts of HPMC were co-administered with itraconazole-loaded SBA-15 (itraconazole:SBA-15:HPMC 1:4:6), the extent of absorption was increased by more than 60% when compared to SBA-15 without precipitation inhibitors (AUC 14,937+/-1617 versus 8987+/-2726nMh).",Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420905/),nMh,"14,937",59301,DB01167,Itraconazole
,20420905,AUC,"When high enough amounts of HPMC were co-administered with itraconazole-loaded SBA-15 (itraconazole:SBA-15:HPMC 1:4:6), the extent of absorption was increased by more than 60% when compared to SBA-15 without precipitation inhibitors (AUC 14,937+/-1617 versus 8987+/-2726nMh).",Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420905/),nMh,8987,59302,DB01167,Itraconazole
,9832299,elimination half-life,The area under the lignocaine concentration-time curve was similar during all three phases but erythromycin significantly increased the elimination half-life of lignocaine from 2.5 to 2.9 (0.7) h compared with placebo.,Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832299/),h,2.5,59428,DB01167,Itraconazole
,9832299,elimination half-life,The area under the lignocaine concentration-time curve was similar during all three phases but erythromycin significantly increased the elimination half-life of lignocaine from 2.5 to 2.9 (0.7) h compared with placebo.,Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832299/),h,2.9,59429,DB01167,Itraconazole
,9832299,t1/2,"Following itraconazole administration, t1/2 was 2.6 h.",Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832299/),h,2.6,59430,DB01167,Itraconazole
less,3027850,MICs,"The MICs of itraconazole for 16 strains of Aspergillus fumigatus were in the same range as those of amphotericin B: less than 0.09-0.36 microgram/ml vs. less than 0.09-0.78 microgram/ml, respectively.",Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3027850/),[μg] / [ml],0.09-0.36,61359,DB01167,Itraconazole
less,3027850,MICs,"The MICs of itraconazole for 16 strains of Aspergillus fumigatus were in the same range as those of amphotericin B: less than 0.09-0.36 microgram/ml vs. less than 0.09-0.78 microgram/ml, respectively.",Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3027850/),[μg] / [ml],0.09-0.78,61360,DB01167,Itraconazole
,20604833,maximum drug solubility,"The gelatin microcapsule at a weight ratio for itraconazole/gelatin/citric acid of 1 : 3 : 0.3 was spherical in shape with a smooth surface and inner hole, and gave a maximum drug solubility of about 700 microg/ml.",Development of an itraconazole-loaded gelatin microcapsule with enhanced oral bioavailability: physicochemical characterization and in-vivo evaluation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20604833/),[μg] / [ml],700,63418,DB01167,Itraconazole
,8690825,inhibition constants (Ki),"The azole antifungal agent ketoconazole was a highly potent inhibitor of both reactions, having mean inhibition constants (Ki) of 0.037 and 0.34 microM for desalkyl- and hydroxy-terfenadine formation, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.037,66325,DB01167,Itraconazole
,8690825,inhibition constants (Ki),"The azole antifungal agent ketoconazole was a highly potent inhibitor of both reactions, having mean inhibition constants (Ki) of 0.037 and 0.34 microM for desalkyl- and hydroxy-terfenadine formation, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.34,66326,DB01167,Itraconazole
,8690825,Ki,"Itraconazole also was a potent inhibitor, with Ki values of 0.28 and 2.05 microM, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.28,66327,DB01167,Itraconazole
,8690825,Ki,"Itraconazole also was a potent inhibitor, with Ki values of 0.28 and 2.05 microM, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,2.05,66328,DB01167,Itraconazole
,10193676,oral bioavailability,"Lignocaine is metabolized by cytochrome P450 3A4 enzyme (CYP3A4), and has a moderate to high extraction ratio resulting in oral bioavailability of 30%.",Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193676/),%,30,66836,DB01167,Itraconazole
,32857315,terminal elimination half-life (t1/2),The mean terminal elimination half-life (t1/2) for ozanimod was approximately 20-22 h while the mean t1/2 for CC112273 and CC1084037 were approximately 10 days.,"Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32857315/),h,20-22,66946,DB01167,Itraconazole
,32857315,t1/2,The mean terminal elimination half-life (t1/2) for ozanimod was approximately 20-22 h while the mean t1/2 for CC112273 and CC1084037 were approximately 10 days.,"Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32857315/),d,10,66947,DB01167,Itraconazole
,30516093,"Kp,uu,liver","3. PBPK model using each Kp,uu,liver projected the area under the curve (AUC) increase of substrates more accurately than the model assuming a Kp,uu,liver of 1 for the average fold error and root mean square error did.",Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30516093/),,1,67020,DB01167,Itraconazole
,34426442,C max ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,0.99,69654,DB01167,Itraconazole
,34426442,C max ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,1.04,69655,DB01167,Itraconazole
,34426442,AUC17d ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,1.22,69656,DB01167,Itraconazole
,34426442,AUC17d ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,1.18,69657,DB01167,Itraconazole
,9871431,apparent oral clearance,"Mean apparent oral clearance of zolpidem when given with placebo was 422 mL/min, and elimination half-life was 1.9 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],422,71084,DB01167,Itraconazole
,9871431,elimination half-life,"Mean apparent oral clearance of zolpidem when given with placebo was 422 mL/min, and elimination half-life was 1.9 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),h,1.9,71085,DB01167,Itraconazole
,9871431,Clearance,"Clearance was significantly reduced to 250 mL/min when zolpidem was given with ketoconazole, and half-life was prolonged to 2.4 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],250,71086,DB01167,Itraconazole
,9871431,half-life,"Clearance was significantly reduced to 250 mL/min when zolpidem was given with ketoconazole, and half-life was prolonged to 2.4 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),h,2.4,71087,DB01167,Itraconazole
,9871431,clearance,"Coadministration of zolpidem with itraconazole or fluconazole also reduced clearance (320 and 338 mL/min), but differences compared to the zolpidem plus placebo treatment did not reach significance.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],320,71088,DB01167,Itraconazole
,9871431,clearance,"Coadministration of zolpidem with itraconazole or fluconazole also reduced clearance (320 and 338 mL/min), but differences compared to the zolpidem plus placebo treatment did not reach significance.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],338,71089,DB01167,Itraconazole
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),[ng] / [ml],9.53,71178,DB01167,Itraconazole
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),[ng] / [ml],18.00,71179,DB01167,Itraconazole
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),ms,1.,71180,DB01167,Itraconazole
,34285598,Cmax,"Placebo-corrected, change from baseline in corrected QT interval at the observed geometric mean Cmax for trazpiroben alone (9.53 ng/mL) and with itraconazole (18.00 ng/mL) was estimated at 1.31 ms (-0.39, 3.01) and 1.54 ms (-0.15, 3.24), respectively.","Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285598/),ms,1.54,71181,DB01167,Itraconazole
,15232663,total area under the plasma concentration-time curve (AUC,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),[h·ng·rectangle] / [ml],213,79185,DB01167,Itraconazole
,15232663,total area under the plasma concentration-time curve (AUC,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),[h·ng·rectangle] / [ml],326,79186,DB01167,Itraconazole
,15232663,elimination half-life,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),h,12.0,79187,DB01167,Itraconazole
,15232663,elimination half-life,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),h,17.3,79188,DB01167,Itraconazole
,10660641,Cmax,"Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93.2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng.h/ml, OH-ITCZ: Cmax 159.4 ng/ml, T1/2 beta 16.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),[ng] / [ml],93.2,79988,DB01167,Itraconazole
,10660641,T1/2 beta,"Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93.2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng.h/ml, OH-ITCZ: Cmax 159.4 ng/ml, T1/2 beta 16.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),h,11,79989,DB01167,Itraconazole
,10660641,AUC0-24,"Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93.2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng.h/ml, OH-ITCZ: Cmax 159.4 ng/ml, T1/2 beta 16.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),[h·ng] / [ml],999,79990,DB01167,Itraconazole
,10660641,Cmax,"Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93.2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng.h/ml, OH-ITCZ: Cmax 159.4 ng/ml, T1/2 beta 16.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),[ng] / [ml],159.4,79991,DB01167,Itraconazole
,10660641,T1/2 beta,"Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93.2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng.h/ml, OH-ITCZ: Cmax 159.4 ng/ml, T1/2 beta 16.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),,16,79992,DB01167,Itraconazole
,10660641,AUC0-24,"2 hours, AUC0-24 of 1391 ng.h/ml.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),[h·ng] / [ml],1391,79993,DB01167,Itraconazole
,2229205,flow rate,"The mobile phase consisted of ethanol:water:glacial acetic acid (65:34:1, v/v) pumped isocratically at a flow rate of 1.3 ml/min.",High-performance liquid chromatographic analysis of indomethacin in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229205/),[ml] / [min],1.3,80117,DB01167,Itraconazole
,2229205,absolute recoveries,"Quantification was achieved by the measurement of the peak area ratio, and the absolute recoveries ranged from 94 to 97%.",High-performance liquid chromatographic analysis of indomethacin in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229205/),%,94 to 97,80118,DB01167,Itraconazole
,17644287,oral bioavailabilities,"Mean+/-S.D. oral bioavailabilities were 2.6+/-0.4% for raloxifene formulated with microcrystalline cellulose, 7.7+/-2.1% for a solid capsule formulation of raloxifene:HBenBCD complex, and 5.7+/-1.3% for a liquid-filled capsule formulation containing raloxifene:HBenBCD/PEG400/H(2)O.",Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644287/),%,2.6,80402,DB01167,Itraconazole
,17644287,oral bioavailabilities,"Mean+/-S.D. oral bioavailabilities were 2.6+/-0.4% for raloxifene formulated with microcrystalline cellulose, 7.7+/-2.1% for a solid capsule formulation of raloxifene:HBenBCD complex, and 5.7+/-1.3% for a liquid-filled capsule formulation containing raloxifene:HBenBCD/PEG400/H(2)O.",Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644287/),%,7.7,80403,DB01167,Itraconazole
,17644287,oral bioavailabilities,"Mean+/-S.D. oral bioavailabilities were 2.6+/-0.4% for raloxifene formulated with microcrystalline cellulose, 7.7+/-2.1% for a solid capsule formulation of raloxifene:HBenBCD complex, and 5.7+/-1.3% for a liquid-filled capsule formulation containing raloxifene:HBenBCD/PEG400/H(2)O.",Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644287/),%,5.7,80404,DB01167,Itraconazole
,17644287,T(max),"Relative to raloxifene/microcrystalline filled capsules, the presence of HBenBCD in the solid capsule formulation afforded: (i) a decrease in raloxifene T(max) (2.5+/-0.5h versus 4.0+/-0.5h); (ii) a two-fold increase in raloxifene C(max) and a three-fold increase in raloxifene AUC; and (iii) a 12-fold increase in raloxifene glucuronide C(max) and a 6.5-fold increase in raloxifene glucuronide AUC.",Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644287/),h,2.5,80405,DB01167,Itraconazole
,17644287,T(max),"Relative to raloxifene/microcrystalline filled capsules, the presence of HBenBCD in the solid capsule formulation afforded: (i) a decrease in raloxifene T(max) (2.5+/-0.5h versus 4.0+/-0.5h); (ii) a two-fold increase in raloxifene C(max) and a three-fold increase in raloxifene AUC; and (iii) a 12-fold increase in raloxifene glucuronide C(max) and a 6.5-fold increase in raloxifene glucuronide AUC.",Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644287/),h,4.0,80406,DB01167,Itraconazole
,16885720,total time for,"The peaks were monitored with an ultraviolet detector set at a wavelength of 263 nm, and total time for chromatographic separation was about 24 minutes.",Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16885720/),min,24,80462,DB01167,Itraconazole
,16885720,recoveries,Mean recoveries were 59.7% for ITZ and 72.8% for HIT.,Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16885720/),%,59.7,80463,DB01167,Itraconazole
,16885720,recoveries,Mean recoveries were 59.7% for ITZ and 72.8% for HIT.,Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16885720/),%,72.8,80464,DB01167,Itraconazole
,9821410,trough,"Mean trough and peak concentrations of ITZ without famotidine were 332 ng/ml and 476 ng/ml, respectively.",Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821410/),[ng] / [ml],332,81035,DB01167,Itraconazole
,9821410,peak concentrations,"Mean trough and peak concentrations of ITZ without famotidine were 332 ng/ml and 476 ng/ml, respectively.",Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821410/),[ng] / [ml],476,81036,DB01167,Itraconazole
,16273899,plasma concentrations,Itraconazole reached higher mean +/- SD plasma concentrations after administration of the solution (0.41 +/- 0.13 microg/mL) versus the capsules (0.15 +/- 0.12 microg/mL).,Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),[μg] / [ml],0.41,83067,DB01167,Itraconazole
,16273899,plasma concentrations,Itraconazole reached higher mean +/- SD plasma concentrations after administration of the solution (0.41 +/- 0.13 microg/mL) versus the capsules (0.15 +/- 0.12 microg/mL).,Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),[μg] / [ml],0.15,83068,DB01167,Itraconazole
,16273899,Bioavailability,Bioavailability after administration of capsules relative to solution was 33.83 +/- 33.08%.,Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),%,33.83,83069,DB01167,Itraconazole
,16273899,volume of distribution,"Similar to other species, itraconazole has a high volume of distribution (6.3 +/- 0.94 L/kg) and a long half-life (11.3 +/- 2.84 hours).",Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),[l] / [kg],6.3,83070,DB01167,Itraconazole
,16273899,half-life,"Similar to other species, itraconazole has a high volume of distribution (6.3 +/- 0.94 L/kg) and a long half-life (11.3 +/- 2.84 hours).",Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),h,11.3,83071,DB01167,Itraconazole
,16273899,Plasma protein binding,Plasma protein binding was 98.81 +/- 0.17%.,Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),%,98.81,83072,DB01167,Itraconazole
more,30302773,half-life (T½),"We identified a long half-life (T½) of more than 75 hr and a maximum plasma concentration (CMAX ) of 1.69 µg/ml, which is above the minimal inhibitory concentrations for different aspergillus isolates.",Population pharmacokinetics of itraconazole solution after a single oral administration in captive lesser flamingos (Phoeniconaias minor). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302773/),h,75,85146,DB01167,Itraconazole
,30302773,maximum plasma concentration (CMAX ),"We identified a long half-life (T½) of more than 75 hr and a maximum plasma concentration (CMAX ) of 1.69 µg/ml, which is above the minimal inhibitory concentrations for different aspergillus isolates.",Population pharmacokinetics of itraconazole solution after a single oral administration in captive lesser flamingos (Phoeniconaias minor). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302773/),[μg] / [ml],1.69,85147,DB01167,Itraconazole
,11019654,elimination half-life,"The elimination half-life of digoxin in case 3 patient who continued itraconazole therapy was 8.4 days, which was estimated by nonlinear least squares method from the serum concentrations of digoxin versus time curve.",[Effect of itraconazole on digoxin clearance in patients with congestive heart failure]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11019654/),d,8.4,85157,DB01167,Itraconazole
,32935287,time to steady state,"Itraconazole 200 mg/day elevated steady-state exposure to 5 mg/day balovaptan approximately 4.5-5.5-fold (Day 15 GMR [90% CI], 4.46 [4.06-4.90] for Cmax and 5.57 [5.00-6.21] for AUC) and extended the time to steady state from ~ 5 days to ~ 13-14 days.",Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935287/),d,5,87831,DB01167,Itraconazole
,32935287,time to steady state,"Itraconazole 200 mg/day elevated steady-state exposure to 5 mg/day balovaptan approximately 4.5-5.5-fold (Day 15 GMR [90% CI], 4.46 [4.06-4.90] for Cmax and 5.57 [5.00-6.21] for AUC) and extended the time to steady state from ~ 5 days to ~ 13-14 days.",Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935287/),d,13-14,87832,DB01167,Itraconazole
,28535410,elimination half-life (t1/2),"In vitro studies and Phase I trials indicate that perampanel is metabolized almost exclusively by CYP3A, with an elimination half-life (t1/2) averaging approximately 105h.",Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535410/),h,105,90742,DB01167,Itraconazole
high,28535410,AUC ratio,"Simulations further suggested that an interaction effect of ketoconazole on perampanel exposure (>2-fold) of potential clinical significance could be predicted when using larger doses of ketoconazole (e.g., 200mg every 6h) coadministered for a greater time period (e.g., 30days), with AUC ratio as high as 3.36.",Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535410/),,3.36,90743,DB01167,Itraconazole
,16238904,absolute oral bioavailability,"The absolute oral bioavailability of telithromycin is approximately 57%, which is unaffected by food intake.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),%,57,91339,DB01167,Itraconazole
,16238904,steady-state concentration,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),[μg] / [ml],2,91340,DB01167,Itraconazole
,16238904,elimination half-life,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),h,10,91341,DB01167,Itraconazole
,7814285,serum concentration,"The mean pre-dose itraconazole serum concentration at hour 0, day 8 was 385 ng/mL in the od group and 394 ng/mL in the bd group, rising to 762 and 845 ng/mL by day 15, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [ml],385,91455,DB01167,Itraconazole
,7814285,serum concentration,"The mean pre-dose itraconazole serum concentration at hour 0, day 8 was 385 ng/mL in the od group and 394 ng/mL in the bd group, rising to 762 and 845 ng/mL by day 15, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [ml],394,91456,DB01167,Itraconazole
,7814285,serum concentration,"The mean pre-dose itraconazole serum concentration at hour 0, day 8 was 385 ng/mL in the od group and 394 ng/mL in the bd group, rising to 762 and 845 ng/mL by day 15, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [ml],762,91457,DB01167,Itraconazole
,7814285,serum concentration,"The mean pre-dose itraconazole serum concentration at hour 0, day 8 was 385 ng/mL in the od group and 394 ng/mL in the bd group, rising to 762 and 845 ng/mL by day 15, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [ml],845,91458,DB01167,Itraconazole
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [h·ml],"17,310",91459,DB01167,Itraconazole
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [h·ml],"13,302",91460,DB01167,Itraconazole
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),,"24,476",91461,DB01167,Itraconazole
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [h·ml],"25,154",91462,DB01167,Itraconazole
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [h·ml],"22,621",91463,DB01167,Itraconazole
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [h·ml],"21,423",91464,DB01167,Itraconazole
,10866139,terminal elimination half-life,"After i.v. injection, serum itraconazole concentrations decreased biexponentially, with an average terminal elimination half-life, volume of distribution and systemic clearance of 4.9 h, 6.0 l/kg and 14.2 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),h,4.9,91563,DB01167,Itraconazole
,10866139,volume of distribution,"After i.v. injection, serum itraconazole concentrations decreased biexponentially, with an average terminal elimination half-life, volume of distribution and systemic clearance of 4.9 h, 6.0 l/kg and 14.2 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),[l] / [kg],6.0,91564,DB01167,Itraconazole
,10866139,systemic clearance,"After i.v. injection, serum itraconazole concentrations decreased biexponentially, with an average terminal elimination half-life, volume of distribution and systemic clearance of 4.9 h, 6.0 l/kg and 14.2 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),[ml] / [kg·min],14.2,91565,DB01167,Itraconazole
,10866139,absolute bioavailability,"When given orally, its absorption was low, with a mean absolute bioavailability of 16.6%.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),%,16.6,91566,DB01167,Itraconazole
,10866139,hepatic drug extraction ratio,The hepatic drug extraction ratio determined after femoral and portal vein administration averaged 18.5%.,"Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),%,18.5,91567,DB01167,Itraconazole
,10866139,elimination half-life,"When hydroxyitraconazole was injected i.v., the elimination half-life, volume of distribution and systemic clearance of itraconazole averaged 10.0 h, 2.4 l/kg and 3.4 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),h,10.0,91568,DB01167,Itraconazole
,10866139,volume of distribution,"When hydroxyitraconazole was injected i.v., the elimination half-life, volume of distribution and systemic clearance of itraconazole averaged 10.0 h, 2.4 l/kg and 3.4 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),[l] / [kg],2.4,91569,DB01167,Itraconazole
,10866139,systemic clearance,"When hydroxyitraconazole was injected i.v., the elimination half-life, volume of distribution and systemic clearance of itraconazole averaged 10.0 h, 2.4 l/kg and 3.4 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),[ml] / [kg·min],3.4,91570,DB01167,Itraconazole
,9010708,Cmax,Itraconazole significantly increased the Cmax of zopiclone from 49 to 63 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,49,92194,DB01167,Itraconazole
,9010708,Cmax,Itraconazole significantly increased the Cmax of zopiclone from 49 to 63 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,63,92195,DB01167,Itraconazole
,9010708,t 1/2,The t 1/2 of zopiclone was prolonged from 5.0 to 7.0 h.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),h,5,92196,DB01167,Itraconazole
,9010708,AUC(0-inifinity),The AUC(0-inifinity) of zopiclone was increased from 415 to 719 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,415,92197,DB01167,Itraconazole
,9010708,AUC(0-inifinity),The AUC(0-inifinity) of zopiclone was increased from 415 to 719 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,719,92198,DB01167,Itraconazole
,34073662,half-life,The half-life of urinary endogenous 1β-OH-DCA/ToDCA was estimated as four days.,Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug-Drug Interaction in Healthy Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34073662/),d,four,93135,DB01167,Itraconazole
,23089073,plasma concentrations,"The mean±SD of plasma concentrations of ITZ, OH-ITZ, and keto-ITZ were 833±468, 798±454, and 3.94±2.68 μg/l, respectively.",Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089073/),[μg] / [l],833,94141,DB01167,Itraconazole
,23089073,plasma concentrations,"The mean±SD of plasma concentrations of ITZ, OH-ITZ, and keto-ITZ were 833±468, 798±454, and 3.94±2.68 μg/l, respectively.",Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089073/),[μg] / [l],798,94142,DB01167,Itraconazole
,23089073,plasma concentrations,"The mean±SD of plasma concentrations of ITZ, OH-ITZ, and keto-ITZ were 833±468, 798±454, and 3.94±2.68 μg/l, respectively.",Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089073/),[μg] / [l],3.94,94143,DB01167,Itraconazole
>,10371783,Cmin,"Therapeutic through drug plasma concentration (Cmin > or = 250 ng/ml of itraconazole, or > or = 750 ng/ml of itraconazole plus hydroxyitraconazole) was not reached in 5/16 patients.",[Prevention of aspergillosis with itraconazole in neutropenic patients: importance of drug monitoring]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10371783/),[ng] / [ml],250,94665,DB01167,Itraconazole
>,10371783,Cmin,"Therapeutic through drug plasma concentration (Cmin > or = 250 ng/ml of itraconazole, or > or = 750 ng/ml of itraconazole plus hydroxyitraconazole) was not reached in 5/16 patients.",[Prevention of aspergillosis with itraconazole in neutropenic patients: importance of drug monitoring]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10371783/),[ng] / [ml],750,94666,DB01167,Itraconazole
,32391164,recoveries,The pretreatment recoveries and matrix factors were 90.1-102.2% and 99.1-102.7%.,Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including N-desalkyl itraconazole in human plasma using liquid chromatography-tandem mass spectrometry and its clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32391164/),%,90.1-102.2,95194,DB01167,Itraconazole
,32391164,matrix factors,The pretreatment recoveries and matrix factors were 90.1-102.2% and 99.1-102.7%.,Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including N-desalkyl itraconazole in human plasma using liquid chromatography-tandem mass spectrometry and its clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32391164/),%,99.1-102.7,95195,DB01167,Itraconazole
,20422948,constant flow rate,The elution was performed by a constant flow rate of 1.2 mL/min and the mobile phase consisted of acetonitrile and acetic acid 0.1% (85 :15 v/v).,Bioequivalence study of two formulations of 100 mg capsule of itraconazole. Quantification by tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422948/),[ml] / [min],1.2,97384,DB01167,Itraconazole
,9626920,limit of detection,The limit of detection for itraconazole concentration was 16 ng x ml(-1).,Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[ng] / [ml],16,97908,DB01167,Itraconazole
,9626920,AUC0-24,"The mean AUC0-24 was 3.28 vs 0.39 microg x h x ml(-1) in phase 1 and 2, respectively, in healthy normal volunteers.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],3.28,97909,DB01167,Itraconazole
,9626920,AUC0-24,"The mean AUC0-24 was 3.28 vs 0.39 microg x h x ml(-1) in phase 1 and 2, respectively, in healthy normal volunteers.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],0.39,97910,DB01167,Itraconazole
,9626920,AUC0-24,"The mean AUC0-24 was 1.07 vs 0.38 microg x h x ml(-1) in phase 1 and 2, respectively, in AIDS patients.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],1.07,97911,DB01167,Itraconazole
,9626920,AUC0-24,"The mean AUC0-24 was 1.07 vs 0.38 microg x h x ml(-1) in phase 1 and 2, respectively, in AIDS patients.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],0.38,97912,DB01167,Itraconazole
,20803125,maximum drug solubility,The itraconazole-loaded solid dispersion at the weight ratio of itraconazole/polyvinylpyrroline/poloxamer of 10/2/0.5 gave maximum drug solubility of about 20 microg/mL.,Development of novel itraconazole-loaded solid dispersion without crystalline change with improved bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20803125/),[μg] / [ml],20,99604,DB01167,Itraconazole
,1357148,peak plasma concentrations,Mean peak plasma concentrations were 446 +/- 196 and 530 +/- 214 ng mL-1 at days 8 and 15.,The pharmacokinetics of oral itraconazole in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[ng] / [ml],446,99605,DB01167,Itraconazole
,1357148,peak plasma concentrations,Mean peak plasma concentrations were 446 +/- 196 and 530 +/- 214 ng mL-1 at days 8 and 15.,The pharmacokinetics of oral itraconazole in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[ng] / [ml],530,99606,DB01167,Itraconazole
,1357148,area under the curve over 24 h (AUC0-24),"The area under the curve over 24 h (AUC0-24) was 2105 +/- 1241, 7679 +/- 3838 and 8748 +/- 4385 ng mL-1 h for days 1, 8 and 15, respectively.",The pharmacokinetics of oral itraconazole in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[h·ng] / [ml],2105,99607,DB01167,Itraconazole
,1357148,area under the curve over 24 h (AUC0-24),"The area under the curve over 24 h (AUC0-24) was 2105 +/- 1241, 7679 +/- 3838 and 8748 +/- 4385 ng mL-1 h for days 1, 8 and 15, respectively.",The pharmacokinetics of oral itraconazole in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[h·ng] / [ml],7679,99608,DB01167,Itraconazole
,1357148,area under the curve over 24 h (AUC0-24),"The area under the curve over 24 h (AUC0-24) was 2105 +/- 1241, 7679 +/- 3838 and 8748 +/- 4385 ng mL-1 h for days 1, 8 and 15, respectively.",The pharmacokinetics of oral itraconazole in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[h·ng] / [ml],8748,99609,DB01167,Itraconazole
,2155951,binding,Itraconazole binding in suction-induced blister fluid (99.54%) and cantharides-induced blister fluid (99.77%) was calculated from plasma protein binding (99.8%).,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,99.54,100792,DB01167,Itraconazole
,2155951,binding,Itraconazole binding in suction-induced blister fluid (99.54%) and cantharides-induced blister fluid (99.77%) was calculated from plasma protein binding (99.8%).,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,99.77,100793,DB01167,Itraconazole
,2155951,binding,Itraconazole binding in suction-induced blister fluid (99.54%) and cantharides-induced blister fluid (99.77%) was calculated from plasma protein binding (99.8%).,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,99.8,100794,DB01167,Itraconazole
,2155951,terminal half-life,The terminal half-life of itraconazole in serum was 22.5 +/- 3.2 hours.,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),h,22.5,100795,DB01167,Itraconazole
,2155951,penetration,"After the final dose, itraconazole penetration into cantharides-induced blister fluid was only 70%.",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,70,100796,DB01167,Itraconazole
,2155951,trough levels,"Moreover, trough levels of unbound itraconazole in suction- and cantharides-induced blister fluid were 0.239 +/- 0.115 and 0.334 +/- 0.101 ng/ml and thus were significantly lower than free itraconazole levels in serum (0.422 +/- 0.125 ng/ml).",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),[ng] / [ml],0.239,100797,DB01167,Itraconazole
,2155951,trough levels,"Moreover, trough levels of unbound itraconazole in suction- and cantharides-induced blister fluid were 0.239 +/- 0.115 and 0.334 +/- 0.101 ng/ml and thus were significantly lower than free itraconazole levels in serum (0.422 +/- 0.125 ng/ml).",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),[ng] / [ml],0.334,100798,DB01167,Itraconazole
,2155951,trough levels,"Moreover, trough levels of unbound itraconazole in suction- and cantharides-induced blister fluid were 0.239 +/- 0.115 and 0.334 +/- 0.101 ng/ml and thus were significantly lower than free itraconazole levels in serum (0.422 +/- 0.125 ng/ml).",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),[ng] / [ml],0.422,100799,DB01167,Itraconazole
,9527794,AUC0-24-,"The mean AUC0-24-based accumulation factors of itraconazole and hydroxyitraconazole from day 1 to 14 ranged from 3.3 to 8.6 and 2.3 to 11.4, respectively.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),,3.3 to 8.6,106710,DB01167,Itraconazole
,9527794,AUC0-24-,"The mean AUC0-24-based accumulation factors of itraconazole and hydroxyitraconazole from day 1 to 14 ranged from 3.3 to 8.6 and 2.3 to 11.4, respectively.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),,2.3 to 11.4,106711,DB01167,Itraconazole
,9527794,accumulation factors,"The mean AUC0-24-based accumulation factors of itraconazole and hydroxyitraconazole from day 1 to 14 ranged from 3.3 to 8.6 and 2.3 to 11.4, respectively.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),,3.3 to 8.6,106712,DB01167,Itraconazole
,9527794,accumulation factors,"The mean AUC0-24-based accumulation factors of itraconazole and hydroxyitraconazole from day 1 to 14 ranged from 3.3 to 8.6 and 2.3 to 11.4, respectively.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),,2.3 to 11.4,106713,DB01167,Itraconazole
,9527794,Cmax,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),[ng] / [ml],571,106714,DB01167,Itraconazole
,9527794,AUC0-24,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),[h·ng] / [ml],"6,930",106715,DB01167,Itraconazole
,9527794,AUC0-24,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),[ng] / [ml],631,106716,DB01167,Itraconazole
,9527794,half-life,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),h,47,106717,DB01167,Itraconazole
,9527794,half-life,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),[ng] / [ml],631,106718,DB01167,Itraconazole
,9527794,half-life,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),[h·ng] / [ml],"8,770",106719,DB01167,Itraconazole
,9527794,half-life,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),h,28.3,106720,DB01167,Itraconazole
less,9527794,oral bioavailability,The oral bioavailability of the solubilizer hydroxypropyl-beta-cyclodextrin was less than 1% in the majority of the patients.,Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),%,1,106721,DB01167,Itraconazole
,16758263,elimination half-life (t(1/2)),"Itraconazole raised the peak plasma loperamide concentration (Cmax) 2.9-fold (range, 1.2-5.0; P < 0.001) and the total area under the plasma loperamide concentration-time curve (AUC(0-infinity)) 3.8-fold (1.4-6.6; P < 0.001) and prolonged the elimination half-life (t(1/2)) of loperamide from 11.9 to 18.7 h (P < 0.001).","Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,11.,108340,DB01167,Itraconazole
,16758263,elimination half-life (t(1/2)),"Itraconazole raised the peak plasma loperamide concentration (Cmax) 2.9-fold (range, 1.2-5.0; P < 0.001) and the total area under the plasma loperamide concentration-time curve (AUC(0-infinity)) 3.8-fold (1.4-6.6; P < 0.001) and prolonged the elimination half-life (t(1/2)) of loperamide from 11.9 to 18.7 h (P < 0.001).","Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,18,108341,DB01167,Itraconazole
,16758263,t(1/2),Gemfibrozil raised the Cmax of loperamide 1.6-fold (0.9-3.2; P < 0.05) and its AUC(0-infinity) 2.2-fold (1.0-3.7; P < 0.05) and prolonged its t(1/2) to 16.7 h (P < 0.01).,"Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,16.7,108342,DB01167,Itraconazole
,16758263,t(1/2),The combination of itraconazole and gemfibrozil raised the Cmax of loperamide 4.2-fold (1.5-8.7; P < 0.001) and its AUC(0-infinity) 12.6-fold (4.3-21.8; P < 0.001) and prolonged the t(1/2) of loperamide to 36.9 h (P < 0.001).,"Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,36.9,108343,DB01167,Itraconazole
,33613287,flow rate,"An Acquity UPLC BEH reverse-phase C18 column (2.1 mm × 50 mm, 1.7 μm) was used for chromatographic separation of fedratinib and bosutinib (as internal standard (IS) in our study) under a linear gradient elution of the mobile phase, which was composed of solution A (acetonitrile) and solution B (water with 0.1% formic acid), along with 0.40 ml/min flow rate.",In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC/MS-MS Method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33613287/),[ml] / [min],0.40,109972,DB01167,Itraconazole
,18164930,AUC0-8,"Using OMS as a carrier, the AUC0-8 was boosted to 681+/-566 nM h.",Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164930/),h·nM,681,110143,DB01167,Itraconazole
,18164930,AUC0-24,"In rabbits, the AUC0-24 increased significantly from 521+/-159 nM h after oral administration of crystalline itraconazole (8 mg) to 1069+/-278 nM h when this dose was loaded into OMS.",Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164930/),h·nM,521,110144,DB01167,Itraconazole
,18164930,AUC0-24,"In rabbits, the AUC0-24 increased significantly from 521+/-159 nM h after oral administration of crystalline itraconazole (8 mg) to 1069+/-278 nM h when this dose was loaded into OMS.",Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164930/),h·nM,1069,110145,DB01167,Itraconazole
,18164930,Tmax,Tmax decreased from 9.8+/-1.8 to 4.2+/-1.8h.,Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164930/),h,9.8,110146,DB01167,Itraconazole
,18164930,Tmax,Tmax decreased from 9.8+/-1.8 to 4.2+/-1.8h.,Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164930/),h,4.2,110147,DB01167,Itraconazole
,2544431,relative systemic availability,The relative systemic availability of itraconazole capsules compared with solution averaged 39.8% in the fasting state but 102% in the post-prandial state.,The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544431/),%,39.8,113041,DB01167,Itraconazole
,2544431,relative systemic availability,The relative systemic availability of itraconazole capsules compared with solution averaged 39.8% in the fasting state but 102% in the post-prandial state.,The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544431/),%,102,113042,DB01167,Itraconazole
,34417912,IC50,"In vitro, entrectinib is a CYP3A4/5 inhibitor (IC50 2 μM) and a weak CYP3A4 inducer.","In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417912/),μM,2,114198,DB01167,Itraconazole
,34417912,IC50,Entrectinib inhibited P-glycoprotein (IC50 1.33 μM) but is a poor substrate.,"In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417912/),μM,1.33,114199,DB01167,Itraconazole
>,32457106,blood C trough levels,"At the end of the steady-state administration study, 13 of 16 volunteers obtained higher mean ITZ blood C trough levels of >1,000 ng/ml when they were administered S-ITZ (81%) than when they were administered C-ITZ (44%).",Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32457106/),[ng] / [ml],"1,000",115622,DB01167,Itraconazole
,25991065,solubility,Spherical crystal agglomerates (SCA) of itraconazole prepared by quasi emulsification solvent diffusion method using Soluplus and polyethylene glycol 4000 (PEG 4000) showed increased solubility (540 μg/ml) in 0.1 N hydrochloric acid as compared to pure drug (12 μg/ml).,Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25991065/),[μg] / [ml],540,115702,DB01167,Itraconazole
,25991065,solubility,Spherical crystal agglomerates (SCA) of itraconazole prepared by quasi emulsification solvent diffusion method using Soluplus and polyethylene glycol 4000 (PEG 4000) showed increased solubility (540 μg/ml) in 0.1 N hydrochloric acid as compared to pure drug (12 μg/ml).,Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25991065/),[μg] / [ml],12,115703,DB01167,Itraconazole
,25991065,disintegration time,The optimized SCA formulation could be easily compressed into tablet with desirable characteristics of hardness (5 kg/cm(2)) and disintegration time (6.3 min).,Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25991065/),min,6.3,115704,DB01167,Itraconazole
,25991065,relative bioavailability,In vivo pharmacokinetic showed significant enhancement in C max and AUC0-t with relative bioavailability of 225%.,Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25991065/),%,225,115705,DB01167,Itraconazole
,8591940,areas under the serum-concentration time curves,"Mean areas under the serum-concentration time curves were also markedly higher in patients receiving 5 mg/kg/day than in those receiving 2.5 mg/kg/day itraconazole and were 22,382 and 5615 micrograms.h/L on day 15 respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591940/),[h·μg] / [l],"22,382",115984,DB01167,Itraconazole
,8591940,areas under the serum-concentration time curves,"Mean areas under the serum-concentration time curves were also markedly higher in patients receiving 5 mg/kg/day than in those receiving 2.5 mg/kg/day itraconazole and were 22,382 and 5615 micrograms.h/L on day 15 respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591940/),[h·μg] / [l],5615,115985,DB01167,Itraconazole
,30374997,m/z,Quantification was performed using a QTRAP 5500 tandem mass spectrometer with positive electrospray ionization in multiple reaction monitoring mode with an ion transition m/z 468.5 → 192.0 for benzylamine triptolide and m/z 484.3 → 192.1 for benzylamine (5R)-5-hydroxytriptolide.,A sensitive LC-MS/MS method for the determination of triptolide and its application to pharmacokinetic research in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30374997/),,484.3,117903,DB01167,Itraconazole
,30374997,m/z,Quantification was performed using a QTRAP 5500 tandem mass spectrometer with positive electrospray ionization in multiple reaction monitoring mode with an ion transition m/z 468.5 → 192.0 for benzylamine triptolide and m/z 484.3 → 192.1 for benzylamine (5R)-5-hydroxytriptolide.,A sensitive LC-MS/MS method for the determination of triptolide and its application to pharmacokinetic research in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30374997/),,192.1,117904,DB01167,Itraconazole
,33428168,absolute oral availability,"Following single doses, rosuvastatin has a mean absolute oral availability of 20%, an overall mean total clearance of 28.3 L/h and an average terminal elimination half-life of approximately 20 h.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),%,20,118477,DB01167,Itraconazole
,33428168,total clearance,"Following single doses, rosuvastatin has a mean absolute oral availability of 20%, an overall mean total clearance of 28.3 L/h and an average terminal elimination half-life of approximately 20 h.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),[l] / [h],28.3,118478,DB01167,Itraconazole
,33428168,terminal elimination half-life,"Following single doses, rosuvastatin has a mean absolute oral availability of 20%, an overall mean total clearance of 28.3 L/h and an average terminal elimination half-life of approximately 20 h.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),h,20,118479,DB01167,Itraconazole
,33428168,half-life,"The clinical relevance of the statistically significant drug interactions is yet to be investigated following repeated co-administration for at least 15 days, consistent with a half-life of low-density lipoprotein of 3 days.",Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428168/),d,3,118480,DB01167,Itraconazole
,25622797,flow rate,The chromatographic analysis was performed on a Waters Alliance system using a gradient mobile phase conditions at a flow rate of 1.0 mL/min and C18 column maintained at 40 ± 1 °C.,Development and validation of a RP-HPLC method for the quantitation of tofacitinib in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622797/),[ml] / [min],1.0,119281,DB01167,Itraconazole
,25622797,total run time,"Tofacitinib and IS eluted at 6.5 and 8.3 min, respectively and the total run time was 10 min.",Development and validation of a RP-HPLC method for the quantitation of tofacitinib in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622797/),min,10,119282,DB01167,Itraconazole
,9626922,total area under the plasma zolpidem concentration-time curve (AUC0-infinity),Itraconazole had no marked effects on the pharmacokinetics of zolpidem; the total area under the plasma zolpidem concentration-time curve (AUC0-infinity) was 34% larger during the itraconazole phase (759 ng x h x ml(-1)) than during the placebo phase (567 ng x h x ml(-1)).,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626922/),[h·ng] / [ml],759,120029,DB01167,Itraconazole
,9626922,total area under the plasma zolpidem concentration-time curve (AUC0-infinity),Itraconazole had no marked effects on the pharmacokinetics of zolpidem; the total area under the plasma zolpidem concentration-time curve (AUC0-infinity) was 34% larger during the itraconazole phase (759 ng x h x ml(-1)) than during the placebo phase (567 ng x h x ml(-1)).,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626922/),[h·ng] / [ml],567,120030,DB01167,Itraconazole
,33387374,bioavailability,"Nadolol is a hydrophilic and nonselective β-adrenoceptor blocker with a bioavailability of 30%, relatively longer half-life, negligible metabolism, and predominant renal excretion.",Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P-Glycoprotein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33387374/),%,30,121647,DB01167,Itraconazole
,30713247,milk/plasma concentration ratio,"5) In breastfeeding women, the median milk/plasma concentration ratio of amlodipine was 0.85.",Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713247/),,0.85,123684,DB01167,Itraconazole
,12924542,area under plasma concentration-versus-time curve (AUC0-12h),"Median (+IQR) area under plasma concentration-versus-time curve (AUC0-12h) were 3.33 (1.96-7.34), 4.29 (3.14-7.67) and 4.07 (2.76-4.49) mg/l x h for SQV 1400 mg without itraconazole, SQV 1200 mg with itraconazole and SQV 800 mg with itraconazole, respectively.",Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12924542/),[mg] / [h·l],3.33,124676,DB01167,Itraconazole
,12924542,area under plasma concentration-versus-time curve (AUC0-12h),"Median (+IQR) area under plasma concentration-versus-time curve (AUC0-12h) were 3.33 (1.96-7.34), 4.29 (3.14-7.67) and 4.07 (2.76-4.49) mg/l x h for SQV 1400 mg without itraconazole, SQV 1200 mg with itraconazole and SQV 800 mg with itraconazole, respectively.",Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12924542/),[mg] / [h·l],4.29,124677,DB01167,Itraconazole
,12924542,area under plasma concentration-versus-time curve (AUC0-12h),"Median (+IQR) area under plasma concentration-versus-time curve (AUC0-12h) were 3.33 (1.96-7.34), 4.29 (3.14-7.67) and 4.07 (2.76-4.49) mg/l x h for SQV 1400 mg without itraconazole, SQV 1200 mg with itraconazole and SQV 800 mg with itraconazole, respectively.",Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12924542/),[mg] / [h·l],4.07,124678,DB01167,Itraconazole
,12924542,minimum effective concentration,The median Cmin was above the proposed minimum effective concentration of 0.05 mg/l for all three regimens.,Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12924542/),[mg] / [l],0.05,124679,DB01167,Itraconazole
,24535279,IC50,"IC50 values in the low micromolar range (IC50 0.6-8.0 μM for dihydro-PBDs; 0.1-0.7 μM for oxidized PBDs) confirmed the potent and selective in vitro activity of PBDs against dermatophytes, while the activity against A. fumigatus and Candida parapsilosis was slightly lower.","Pyrrolo[1,2-α][1,4]benzodiazepines show potent in vitro antifungal activity and significant in vivo efficacy in a Microsporum canis dermatitis model in guinea pigs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24535279/),μM,0.6-8.0,124760,DB01167,Itraconazole
,24535279,IC50,"IC50 values in the low micromolar range (IC50 0.6-8.0 μM for dihydro-PBDs; 0.1-0.7 μM for oxidized PBDs) confirmed the potent and selective in vitro activity of PBDs against dermatophytes, while the activity against A. fumigatus and Candida parapsilosis was slightly lower.","Pyrrolo[1,2-α][1,4]benzodiazepines show potent in vitro antifungal activity and significant in vivo efficacy in a Microsporum canis dermatitis model in guinea pigs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24535279/),μM,0.1-0.7,124761,DB01167,Itraconazole
,24535279,IC50,"Oxidized Compound O with meta-CF2CH3-substitution showed excellent IC50 values of 0.6 μM against M. canis, 2.0 μM against Trichophyton mentagrophytes and 0.7 μM against Trichophyton rubrum, matching or outperforming the activity of itraconazole (IC50 values of 2.0, 0.4 and 0.6 μM, respectively).","Pyrrolo[1,2-α][1,4]benzodiazepines show potent in vitro antifungal activity and significant in vivo efficacy in a Microsporum canis dermatitis model in guinea pigs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24535279/),μM,0.6,124762,DB01167,Itraconazole
,24535279,IC50,"Oxidized Compound O with meta-CF2CH3-substitution showed excellent IC50 values of 0.6 μM against M. canis, 2.0 μM against Trichophyton mentagrophytes and 0.7 μM against Trichophyton rubrum, matching or outperforming the activity of itraconazole (IC50 values of 2.0, 0.4 and 0.6 μM, respectively).","Pyrrolo[1,2-α][1,4]benzodiazepines show potent in vitro antifungal activity and significant in vivo efficacy in a Microsporum canis dermatitis model in guinea pigs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24535279/),μM,2.0,124763,DB01167,Itraconazole
,24535279,IC50,"Oxidized Compound O with meta-CF2CH3-substitution showed excellent IC50 values of 0.6 μM against M. canis, 2.0 μM against Trichophyton mentagrophytes and 0.7 μM against Trichophyton rubrum, matching or outperforming the activity of itraconazole (IC50 values of 2.0, 0.4 and 0.6 μM, respectively).","Pyrrolo[1,2-α][1,4]benzodiazepines show potent in vitro antifungal activity and significant in vivo efficacy in a Microsporum canis dermatitis model in guinea pigs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24535279/),μM,0.7,124764,DB01167,Itraconazole
,24535279,IC50,"Oxidized Compound O with meta-CF2CH3-substitution showed excellent IC50 values of 0.6 μM against M. canis, 2.0 μM against Trichophyton mentagrophytes and 0.7 μM against Trichophyton rubrum, matching or outperforming the activity of itraconazole (IC50 values of 2.0, 0.4 and 0.6 μM, respectively).","Pyrrolo[1,2-α][1,4]benzodiazepines show potent in vitro antifungal activity and significant in vivo efficacy in a Microsporum canis dermatitis model in guinea pigs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24535279/),μM,0.4,124765,DB01167,Itraconazole
,12619051,area under the plasma concentration-time curve from time zero to time infinity (AUC),"After intravenous administration of itraconazole to rats with PCM, the area under the plasma concentration-time curve from time zero to time infinity (AUC) of itraconazole was significantly greater (3580 compared with 2670 and 2980 microg min/ml) than those in control rats and rats with PCMC (the values between control rats and rats with PCMC were not significantly different).",Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12619051/),[min·μg] / [ml],3580,127198,DB01167,Itraconazole
,12619051,area under the plasma concentration-time curve from time zero to time infinity (AUC),"After intravenous administration of itraconazole to rats with PCM, the area under the plasma concentration-time curve from time zero to time infinity (AUC) of itraconazole was significantly greater (3580 compared with 2670 and 2980 microg min/ml) than those in control rats and rats with PCMC (the values between control rats and rats with PCMC were not significantly different).",Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12619051/),[min·μg] / [ml],2670,127199,DB01167,Itraconazole
,12619051,area under the plasma concentration-time curve from time zero to time infinity (AUC),"After intravenous administration of itraconazole to rats with PCM, the area under the plasma concentration-time curve from time zero to time infinity (AUC) of itraconazole was significantly greater (3580 compared with 2670 and 2980 microg min/ml) than those in control rats and rats with PCMC (the values between control rats and rats with PCMC were not significantly different).",Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12619051/),[min·μg] / [ml],2980,127200,DB01167,Itraconazole
,17564318,terminal half-life,The terminal half-life of itraconazole was 524 min.,"Pharmacokinetics, blood partition, and tissue distribution of itraconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564318/),min,524,127300,DB01167,Itraconazole
,17564318,total body clearance,Itraconazole was eliminated slowly in rabbits with total body clearance of 3.26 ml/min/kg.,"Pharmacokinetics, blood partition, and tissue distribution of itraconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564318/),[ml] / [kg·min],3.26,127301,DB01167,Itraconazole
,17564318,equilibrium plasma/blood cells concentration ratios,"The equilibrium plasma/blood cells concentration ratios were independent of initial rabbit blood concentrations of itraconazole, 1, 5, and 10 microg/ml; the mean value was 3.25.","Pharmacokinetics, blood partition, and tissue distribution of itraconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564318/),,3.25,127302,DB01167,Itraconazole
greater,17564318,tissue-to-plasma (T/P) ratios,The tissue-to-plasma (T/P) ratios of itraconazole were greater-than-unity in all rat tissues studied at both 1 and 24 h except in fat and stomach at 1 h.,"Pharmacokinetics, blood partition, and tissue distribution of itraconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564318/),,unity,127303,DB01167,Itraconazole
,28421603,TS/TO ratio,"To investigate the effects of liquid lipid in lipid core on itraconazole (ITZ) dissolution and release, TS/TO ratio was varied as 100/0, 90/10 and 80/20 (mg/mg).",High payload itraconazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421603/),[mg] / [mg],100/0,127326,DB01167,Itraconazole
,28421603,TS/TO ratio,"To investigate the effects of liquid lipid in lipid core on itraconazole (ITZ) dissolution and release, TS/TO ratio was varied as 100/0, 90/10 and 80/20 (mg/mg).",High payload itraconazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421603/),[mg] / [mg],90/10,127327,DB01167,Itraconazole
,28421603,TS/TO ratio,"To investigate the effects of liquid lipid in lipid core on itraconazole (ITZ) dissolution and release, TS/TO ratio was varied as 100/0, 90/10 and 80/20 (mg/mg).",High payload itraconazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421603/),[mg] / [mg],80,127328,DB01167,Itraconazole
below,28421603,polydispersity index,All HINP formulations showed particle size around 300 nm and polydispersity index below 0.3.,High payload itraconazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421603/),,0.3,127329,DB01167,Itraconazole
,8546481,concentration,"In the three-pulse treatment group, the mean concentration of itraconazole in the distal ends of the toenails ranged from 67 (month 1) to 471 (month 6) ng/g, and in the distal ends of the fingernails, it ranged from 103 (month 1) to 424 (month 6) ng/g.",Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8546481/),,103,127724,DB01167,Itraconazole
,8546481,Clinical cure rates,"Clinical cure rates between 76% and 84% and negative mycological examination findings between 72% and 80%, respectively, were observed in toenail onychomycosis.",Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8546481/),%,76,127725,DB01167,Itraconazole
,8546481,Clinical cure rates,"Clinical cure rates between 76% and 84% and negative mycological examination findings between 72% and 80%, respectively, were observed in toenail onychomycosis.",Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8546481/),%,84,127726,DB01167,Itraconazole
,27745744,CL/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],8.16,128571,DB01167,Itraconazole
,27745744,CL/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],3.05,128572,DB01167,Itraconazole
,27745744,Vz/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,192,128573,DB01167,Itraconazole
,27745744,Vz/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,75.1,128574,DB01167,Itraconazole
,27745744,t½,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,15.0,128575,DB01167,Itraconazole
,27745744,t½,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,15.6,128576,DB01167,Itraconazole
,27745744,C,"Co-administration of olaparib with rifampin resulted in a statistically significant decrease in the relative bioavailability of olaparib: Cmax treatment ratio, 0.29 (90% CI, 0.24-0.33); mean AUC treatment ratio, 0.13 (90% CI, 0.11-0.16).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),,0.29,128577,DB01167,Itraconazole
,27745744,AU,"Co-administration of olaparib with rifampin resulted in a statistically significant decrease in the relative bioavailability of olaparib: Cmax treatment ratio, 0.29 (90% CI, 0.24-0.33); mean AUC treatment ratio, 0.13 (90% CI, 0.11-0.16).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),,0.13,128578,DB01167,Itraconazole
,27745744,CL/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],6.36,128579,DB01167,Itraconazole
,27745744,CL/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],48.3,128580,DB01167,Itraconazole
,27745744,Vz/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,112,128581,DB01167,Itraconazole
,27745744,Vz/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,1076,128582,DB01167,Itraconazole
,27745744,t½,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,13.0,128583,DB01167,Itraconazole
,27745744,t½,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,15.8,128584,DB01167,Itraconazole
,32978634,steady-state AUC0-∞,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,3.23,129349,DB01167,Itraconazole
,32978634,steady-state AUC0-∞,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.90,129350,DB01167,Itraconazole
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,2.26,129351,DB01167,Itraconazole
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.90,129352,DB01167,Itraconazole
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.52,129353,DB01167,Itraconazole
,10677807,area under the curve (AUC),"In the rat, there was no difference between the Asd tablets and Sporanox capsules in the mean area under the curve (AUC) (3089.5 +/- 4332.8 ng.hr/ml and 3653.9 +/- 2348.9 ng.hr/ml, respectively) and Cmax (295.0 +/- 344.5 and 390.5 +/- 169.4 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[h·ng] / [ml],3089.5,131513,DB01167,Itraconazole
,10677807,area under the curve (AUC),"In the rat, there was no difference between the Asd tablets and Sporanox capsules in the mean area under the curve (AUC) (3089.5 +/- 4332.8 ng.hr/ml and 3653.9 +/- 2348.9 ng.hr/ml, respectively) and Cmax (295.0 +/- 344.5 and 390.5 +/- 169.4 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[h·ng] / [ml],3653.9,131514,DB01167,Itraconazole
,10677807,Cmax,"In the rat, there was no difference between the Asd tablets and Sporanox capsules in the mean area under the curve (AUC) (3089.5 +/- 4332.8 ng.hr/ml and 3653.9 +/- 2348.9 ng.hr/ml, respectively) and Cmax (295.0 +/- 344.5 and 390.5 +/- 169.4 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[ng] / [ml],295.0,131515,DB01167,Itraconazole
,10677807,Cmax,"In the rat, there was no difference between the Asd tablets and Sporanox capsules in the mean area under the curve (AUC) (3089.5 +/- 4332.8 ng.hr/ml and 3653.9 +/- 2348.9 ng.hr/ml, respectively) and Cmax (295.0 +/- 344.5 and 390.5 +/- 169.4 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[ng] / [ml],390.5,131516,DB01167,Itraconazole
,10677807,AUC (AUMC,"Also, in the rabbit, no difference was found between the two products in the mean AUC (AUMC; 19357.9 +/- 5117.5 ng.hr/ml and 23382.2 +/- 6236.5 ng.hr/ml, respectively) and Cmax (766.4 +/- 276.5 and 1127.5 +/- 577.9 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[h·ng] / [ml],19357.9,131517,DB01167,Itraconazole
,10677807,AUC (AUMC,"Also, in the rabbit, no difference was found between the two products in the mean AUC (AUMC; 19357.9 +/- 5117.5 ng.hr/ml and 23382.2 +/- 6236.5 ng.hr/ml, respectively) and Cmax (766.4 +/- 276.5 and 1127.5 +/- 577.9 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[h·ng] / [ml],23382.2,131518,DB01167,Itraconazole
,10677807,Cmax,"Also, in the rabbit, no difference was found between the two products in the mean AUC (AUMC; 19357.9 +/- 5117.5 ng.hr/ml and 23382.2 +/- 6236.5 ng.hr/ml, respectively) and Cmax (766.4 +/- 276.5 and 1127.5 +/- 577.9 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[ng] / [ml],766.4,131519,DB01167,Itraconazole
,10677807,Cmax,"Also, in the rabbit, no difference was found between the two products in the mean AUC (AUMC; 19357.9 +/- 5117.5 ng.hr/ml and 23382.2 +/- 6236.5 ng.hr/ml, respectively) and Cmax (766.4 +/- 276.5 and 1127.5 +/- 577.9 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[ng] / [ml],1127.5,131520,DB01167,Itraconazole
,18485840,total run time,"The total run time was 3.0 min and the elution of ITZ, OH-ITZ and IS occurred at 2.08 min, 1.85 min and 1.29 min, respectively; this was achieved with a mobile phase consisting of 0.2% (v/v) ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPurity C(18) (50 mm x 4.6 mm, 5 microm) column.",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18485840/),min,3.0,132539,DB01167,Itraconazole
,18485840,total run time,"The total run time was 3.0 min and the elution of ITZ, OH-ITZ and IS occurred at 2.08 min, 1.85 min and 1.29 min, respectively; this was achieved with a mobile phase consisting of 0.2% (v/v) ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPurity C(18) (50 mm x 4.6 mm, 5 microm) column.",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18485840/),min,2.08,132540,DB01167,Itraconazole
,18485840,total run time,"The total run time was 3.0 min and the elution of ITZ, OH-ITZ and IS occurred at 2.08 min, 1.85 min and 1.29 min, respectively; this was achieved with a mobile phase consisting of 0.2% (v/v) ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPurity C(18) (50 mm x 4.6 mm, 5 microm) column.",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18485840/),min,1.85,132541,DB01167,Itraconazole
,18485840,total run time,"The total run time was 3.0 min and the elution of ITZ, OH-ITZ and IS occurred at 2.08 min, 1.85 min and 1.29 min, respectively; this was achieved with a mobile phase consisting of 0.2% (v/v) ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPurity C(18) (50 mm x 4.6 mm, 5 microm) column.",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18485840/),min,1.29,132542,DB01167,Itraconazole
,18485840,flow rate,"The total run time was 3.0 min and the elution of ITZ, OH-ITZ and IS occurred at 2.08 min, 1.85 min and 1.29 min, respectively; this was achieved with a mobile phase consisting of 0.2% (v/v) ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPurity C(18) (50 mm x 4.6 mm, 5 microm) column.",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18485840/),[ml] / [min],0.50,132543,DB01167,Itraconazole
,19813178,recoveries,The recoveries of the method were found to be 69.47-71.98% for ITZ and 75.68-82.52% for OH-ITZ.,Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by liquid chromatography-isotope dilution tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813178/),%,69.47-71.98,133070,DB01167,Itraconazole
,19813178,recoveries,The recoveries of the method were found to be 69.47-71.98% for ITZ and 75.68-82.52% for OH-ITZ.,Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by liquid chromatography-isotope dilution tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813178/),%,75.68-82.52,133071,DB01167,Itraconazole
,26242842,g,Nanoemulsion with average globule size of 100.9 nm and zeta potential of -35.9 ± 1.2 mV was able to penetrate well into the intestinal membrane as confirmed by the laser confocal scanning microscopy and ex vivo intestinal permeability study.,Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242842/),,100.9,137726,DB01167,Itraconazole
,26242842,zeta potential,Nanoemulsion with average globule size of 100.9 nm and zeta potential of -35.9 ± 1.2 mV was able to penetrate well into the intestinal membrane as confirmed by the laser confocal scanning microscopy and ex vivo intestinal permeability study.,Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242842/),mv,-,137727,DB01167,Itraconazole
,26242842,zeta potential,Nanoemulsion with average globule size of 100.9 nm and zeta potential of -35.9 ± 1.2 mV was able to penetrate well into the intestinal membrane as confirmed by the laser confocal scanning microscopy and ex vivo intestinal permeability study.,Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242842/),mv,35.9,137728,DB01167,Itraconazole
,32535897,binding constant,"The in vitro binding constant between fenebrutinib and hydroxypropyl-β-cyclodextrin was determined to be 2 × 105 M-1 , and the apparent permeability of fenebrutinib across a Madin-Darby canine kidney cell monolayer decreased in a cyclodextrin concentration-dependent manner.",Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32535897/),1/[M],2 × 105,139069,DB01167,Itraconazole
,9599237,t1/2,This was attributed to its short half-life in that species (t1/2 = 1 h po).,New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9599237/),h,1,139803,DB01167,Itraconazole
,9599237,half-life,"Protection levels comparable to or higher than those of fluconazole, however, were observed in systemic candidosis models in rat and rabbit, where the half-life of the compound was found to be 6 and 9 h, respectively.",New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9599237/),h,6,139804,DB01167,Itraconazole
,9599237,half-life,"Protection levels comparable to or higher than those of fluconazole, however, were observed in systemic candidosis models in rat and rabbit, where the half-life of the compound was found to be 6 and 9 h, respectively.",New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9599237/),h,9,139805,DB01167,Itraconazole
,2848442,peak itraconazole concentrations,"Absorption appeared to be slow, with day 1 mean peak itraconazole concentrations in plasma of 110 ng/ml at 2.8 h (regimen A), 272 ng/ml at 3.0 h (regimen B), and 553 ng/ml at 3.4 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],110,141167,DB01167,Itraconazole
,2848442,peak itraconazole concentrations,"Absorption appeared to be slow, with day 1 mean peak itraconazole concentrations in plasma of 110 ng/ml at 2.8 h (regimen A), 272 ng/ml at 3.0 h (regimen B), and 553 ng/ml at 3.4 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],272,141168,DB01167,Itraconazole
,2848442,peak itraconazole concentrations,"Absorption appeared to be slow, with day 1 mean peak itraconazole concentrations in plasma of 110 ng/ml at 2.8 h (regimen A), 272 ng/ml at 3.0 h (regimen B), and 553 ng/ml at 3.4 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],553,141169,DB01167,Itraconazole
,2848442,peak itraconazole concentrations,"Mean peak itraconazole concentrations in plasma on day 15 were 412 ng/ml at 3.0 h (regimen A), 1,070 ng/ml at 4.4 h (regimen B), and 1,980 ng/ml at 6.0 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],412,141170,DB01167,Itraconazole
,2848442,peak itraconazole concentrations,"Mean peak itraconazole concentrations in plasma on day 15 were 412 ng/ml at 3.0 h (regimen A), 1,070 ng/ml at 4.4 h (regimen B), and 1,980 ng/ml at 6.0 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],"1,070",141171,DB01167,Itraconazole
,2848442,peak itraconazole concentrations,"Mean peak itraconazole concentrations in plasma on day 15 were 412 ng/ml at 3.0 h (regimen A), 1,070 ng/ml at 4.4 h (regimen B), and 1,980 ng/ml at 6.0 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],"1,980",141172,DB01167,Itraconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,15,141173,DB01167,Itraconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,34,141174,DB01167,Itraconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,20.7,141175,DB01167,Itraconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,36.5,141176,DB01167,Itraconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,25,141177,DB01167,Itraconazole
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,41.7,141178,DB01167,Itraconazole
,2848442,areas under the plasma concentration versus time curves (0 to infinity),"The areas under the plasma concentration versus time curves (0 to infinity) on day 1 were 1,320 (regimen A), 4,160 (regimen B), and 12,600 ng.h/ml (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[h·ng] / [ml],"1,320",141179,DB01167,Itraconazole
,2848442,areas under the plasma concentration versus time curves (0 to infinity),"The areas under the plasma concentration versus time curves (0 to infinity) on day 1 were 1,320 (regimen A), 4,160 (regimen B), and 12,600 ng.h/ml (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[h·ng] / [ml],"4,160",141180,DB01167,Itraconazole
,2848442,areas under the plasma concentration versus time curves (0 to infinity),"The areas under the plasma concentration versus time curves (0 to infinity) on day 1 were 1,320 (regimen A), 4,160 (regimen B), and 12,600 ng.h/ml (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[h·ng] / [ml],"12,600",141181,DB01167,Itraconazole
,15896236,Tmax,Tmax for treatment A was 3.0 +/- 0.4 and 5.1 +/- 2.7 h for treatment B.,Reduced oral itraconazole bioavailability by antacid suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15896236/),h,3.0,142622,DB01167,Itraconazole
,15896236,Tmax,Tmax for treatment A was 3.0 +/- 0.4 and 5.1 +/- 2.7 h for treatment B.,Reduced oral itraconazole bioavailability by antacid suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15896236/),h,5.1,142623,DB01167,Itraconazole
,15896236,Cmax,Cmax and AUC0-infinity of treatments A and B were 146.3 +/- 70.5 vs.,Reduced oral itraconazole bioavailability by antacid suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15896236/),,146.3,142624,DB01167,Itraconazole
,9545149,bioavailabilities,"Mean bioavailabilities of ITR and OH-ITR were 43% and 38% higher, respectively, when ITR solution was taken as a single dose under fasted conditions.",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),%,43,142938,DB01167,Itraconazole
,9545149,bioavailabilities,"Mean bioavailabilities of ITR and OH-ITR were 43% and 38% higher, respectively, when ITR solution was taken as a single dose under fasted conditions.",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),%,38,142939,DB01167,Itraconazole
,9545149,bioavailabilities,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),%,29,142940,DB01167,Itraconazole
,9545149,bioavailabilities,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),%,17,142941,DB01167,Itraconazole
,9545149,terminal half-life,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),h,39.8,142942,DB01167,Itraconazole
,9545149,terminal half-life,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),h,37.5,142943,DB01167,Itraconazole
,9545149,terminal half-life,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),h,27.3,142944,DB01167,Itraconazole
,9545149,terminal half-life,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),h,26.2,142945,DB01167,Itraconazole
,22522964,recovery,Plasma samples (50 μL) were extracted with internal standard solution (25 ng/mL of itraconazole) in acetonitrile (200 μL) with an average recovery of 44.7% and an average matrix effect of -2.9%.,Development and validation of a sensitive LC/MS/MS method for the determination of γ-tocotrienol in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22522964/),%,44.7,143210,DB01167,Itraconazole
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],0.25,143668,DB01167,Itraconazole
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],1.35,143669,DB01167,Itraconazole
,15795639,Oral clearance (CL/F),Oral clearance (CL/F) was estimated to be 22.1 L/h (95% confidence intervals [CI] 19.5-24.7 L/h).,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],22.1,143670,DB01167,Itraconazole
,15795639,relative oral bioavailability,The relative oral bioavailability of Sandimmune to Neoral was 0.82.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),,0.82,143671,DB01167,Itraconazole
,18520601,trough whole blood level,This was repeated during the period that CsA was administered and a steady-state concentration of CsA was achieved (trough whole blood level 200-400 ng/mL).,Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520601/),[ng] / [ml],200-400,145051,DB01167,Itraconazole
,10211867,percentage cumulative excretion,The percentage cumulative excretion (6.9%) of DGX in bile of the ITZ-treated group up to 6 h after administration of DGX was significantly reduced (p < 0.05) compared with 10.5% in the control.,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),%,6.9,146173,DB01167,Itraconazole
,10211867,percentage cumulative excretion,The percentage cumulative excretion (6.9%) of DGX in bile of the ITZ-treated group up to 6 h after administration of DGX was significantly reduced (p < 0.05) compared with 10.5% in the control.,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),%,10.5,146174,DB01167,Itraconazole
,10211867,percentage cumulative excretion,The percentage cumulative excretion (3.1%) of DGX in urine of the ITZ-treated group up to 6 h after administration was also one third that in the controls.,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),%,3.1,146175,DB01167,Itraconazole
,10211867,plasma unbound fraction,The plasma unbound fraction of DGX (ranged 47-58%) in the ITZ-treated group was generally similar to that in the controls (50-57%).,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),%,47-58,146176,DB01167,Itraconazole
,10211867,plasma unbound fraction,The plasma unbound fraction of DGX (ranged 47-58%) in the ITZ-treated group was generally similar to that in the controls (50-57%).,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),%,50-57,146177,DB01167,Itraconazole
,10211867,blood-to-plasma concentration ratio,The blood-to-plasma concentration ratio of DGX (range 1.28-1.42) in the absence of ITZ did not change in the presence of ITZ.,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),,1.28-1.42,146178,DB01167,Itraconazole
,10426160,elimination half-life,The mean elimination half-life of methylprednisolone was increased from 2.1+/-0.3 hr to 4.8+/-0.8 hr (P<0.001) by itraconazole.,Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),h,2.1,150097,DB01167,Itraconazole
,10426160,elimination half-life,The mean elimination half-life of methylprednisolone was increased from 2.1+/-0.3 hr to 4.8+/-0.8 hr (P<0.001) by itraconazole.,Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),h,4.8,150098,DB01167,Itraconazole
,10426160,plasma cortisol concentration,"The mean morning plasma cortisol concentration during the itraconazole phase, measured 24 hr after the administration of methylprednisolone, was only about 9% of that during the placebo phase (11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P<0.001).",Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),[ng] / [ml],11.0,150099,DB01167,Itraconazole
,10426160,plasma cortisol concentration,"The mean morning plasma cortisol concentration during the itraconazole phase, measured 24 hr after the administration of methylprednisolone, was only about 9% of that during the placebo phase (11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P<0.001).",Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),[ng] / [ml],117,150100,DB01167,Itraconazole
,24245857,solubility,The solubility of ITR was enhanced around 200 times (from 1.54 to 248.38 µg/mL) by preparing solid dispersion (SD) with hydroxypropylmethyl cellulose.,Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245857/),[μg] / [ml],1,151775,DB01167,Itraconazole
,24245857,solubility,The solubility of ITR was enhanced around 200 times (from 1.54 to 248.38 µg/mL) by preparing solid dispersion (SD) with hydroxypropylmethyl cellulose.,Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245857/),[μg] / [ml],248,151776,DB01167,Itraconazole
<,24245857,Residual camphor,Residual camphor was <0.5 wt% after sublimation.,Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245857/),wt%,0.5,151777,DB01167,Itraconazole
,24245857,AUC ratio,Mean AUC ratio of GRT/IRT was 1.36 but there was no statistical difference between AUC values.,Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245857/),,1.36,151778,DB01167,Itraconazole
,28034694,clearance,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,39,151866,DB01167,Itraconazole
,28034694,volume of distribution,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,60,151867,DB01167,Itraconazole
,28034694,volume of distribution,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,46,151868,DB01167,Itraconazole
,28034694,bioavailability,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,38,151869,DB01167,Itraconazole
,7883389,Cmax ratio,The corresponding Cmax ratio was 1.04 (range 0.91-1.17).,Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7883389/),,1.04,152653,DB01167,Itraconazole
,7883389,Cmax ratios,The Cmax ratios postprandial vs fasting ranged between 0.27 and 5.71 (median = 1.04).,Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7883389/),,1.04,152654,DB01167,Itraconazole
,25862744,m/z,"The mass transitions monitorized were as follows: m/z 511.2 → 230 for pinaverium bromide, and m/z 705.29 → 392.18 for the itraconazole.",Determination of Pinaverium Bromide in Human Plasma by a Sensitive and Robust UPLC-MS-MS Method and Application to a Pharmacokinetic Study in Mexican Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862744/),,511.2,153648,DB01167,Itraconazole
,25862744,m/z,"The mass transitions monitorized were as follows: m/z 511.2 → 230 for pinaverium bromide, and m/z 705.29 → 392.18 for the itraconazole.",Determination of Pinaverium Bromide in Human Plasma by a Sensitive and Robust UPLC-MS-MS Method and Application to a Pharmacokinetic Study in Mexican Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862744/),,230,153649,DB01167,Itraconazole
,25862744,m/z,"The mass transitions monitorized were as follows: m/z 511.2 → 230 for pinaverium bromide, and m/z 705.29 → 392.18 for the itraconazole.",Determination of Pinaverium Bromide in Human Plasma by a Sensitive and Robust UPLC-MS-MS Method and Application to a Pharmacokinetic Study in Mexican Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862744/),,705.29,153650,DB01167,Itraconazole
,25862744,m/z,"The mass transitions monitorized were as follows: m/z 511.2 → 230 for pinaverium bromide, and m/z 705.29 → 392.18 for the itraconazole.",Determination of Pinaverium Bromide in Human Plasma by a Sensitive and Robust UPLC-MS-MS Method and Application to a Pharmacokinetic Study in Mexican Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862744/),,392.18,153651,DB01167,Itraconazole
,25862744,runtime,The chromatographic method runtime is 2.5 min and was applied to characterize the pharmacokinetics of pinaverium bromide after the oral administration of 100 mg to healthy Mexican subjects.,Determination of Pinaverium Bromide in Human Plasma by a Sensitive and Robust UPLC-MS-MS Method and Application to a Pharmacokinetic Study in Mexican Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862744/),min,2.5,153652,DB01167,Itraconazole
,10215775,maximum,"The mean concentration of itraconazole in fingernail tips increased steadily from week 4, reached a maximum value at week 24 (213 ng/g), declined sharply between weeks 24 and 36 and returned to baseline by week 48; the mean concentration profile was similar for toenail tips (maximum value 305 ng/g at week 24) but decreased at a slower rate.",Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215775/),[ng] / [g],305,155257,DB01167,Itraconazole
,10215775,maximum mean concentration,"The mean concentration of itraconazole in fingernail tips reached a maximum value at week 12 (524 ng/g) and returned towards baseline by week 48; in contrast, the maximum mean concentration of itraconazole in toenail tips was 698 ng/g at week 36 and did not return to baseline by week 48.",Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215775/),[ng] / [g],698,155258,DB01167,Itraconazole
,9303409,areas under the concentration-time curve (AUC),"The mean areas under the concentration-time curve (AUC) were 152.2 microg x h/ml (standard deviation [SD], 22.5) and 129.2 microg x h/ml (SD, 41.2) and the terminal half-lives were 1.1 h (SD, 0.3) and 0.9 h (SD, 0.2) when ceftriaxone was given alone and combined with itraconazole, respectively.",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·μg] / [ml],152.2,155451,DB01167,Itraconazole
,9303409,areas under the concentration-time curve (AUC),"The mean areas under the concentration-time curve (AUC) were 152.2 microg x h/ml (standard deviation [SD], 22.5) and 129.2 microg x h/ml (SD, 41.2) and the terminal half-lives were 1.1 h (SD, 0.3) and 0.9 h (SD, 0.2) when ceftriaxone was given alone and combined with itraconazole, respectively.",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·μg] / [ml],129.2,155452,DB01167,Itraconazole
,9303409,terminal half-lives,"The mean areas under the concentration-time curve (AUC) were 152.2 microg x h/ml (standard deviation [SD], 22.5) and 129.2 microg x h/ml (SD, 41.2) and the terminal half-lives were 1.1 h (SD, 0.3) and 0.9 h (SD, 0.2) when ceftriaxone was given alone and combined with itraconazole, respectively.",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),h,1.1,155453,DB01167,Itraconazole
,9303409,terminal half-lives,"The mean areas under the concentration-time curve (AUC) were 152.2 microg x h/ml (standard deviation [SD], 22.5) and 129.2 microg x h/ml (SD, 41.2) and the terminal half-lives were 1.1 h (SD, 0.3) and 0.9 h (SD, 0.2) when ceftriaxone was given alone and combined with itraconazole, respectively.",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),h,0.9,155454,DB01167,Itraconazole
,9303409,AUC (from 0 to 8 h),"Contrary to what was expected, the AUC (from 0 to 8 h) decreased from 139.3 ng h/ml with itraconazole alone to 122.7 ng h/ml with itraconazole and ceftriaxone combined in pig 1, from 398.5 to 315.7 ng x h/ml in pig 2, and from 979.6 to 716.6 ng x h/ml in pig 3 (P of <0.01 by analysis of variance).",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·ng] / [ml],139.3,155455,DB01167,Itraconazole
,9303409,AUC (from 0 to 8 h),"Contrary to what was expected, the AUC (from 0 to 8 h) decreased from 139.3 ng h/ml with itraconazole alone to 122.7 ng h/ml with itraconazole and ceftriaxone combined in pig 1, from 398.5 to 315.7 ng x h/ml in pig 2, and from 979.6 to 716.6 ng x h/ml in pig 3 (P of <0.01 by analysis of variance).",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·ng] / [ml],122.7,155456,DB01167,Itraconazole
,9303409,AUC (from 0 to 8 h),"Contrary to what was expected, the AUC (from 0 to 8 h) decreased from 139.3 ng h/ml with itraconazole alone to 122.7 ng h/ml with itraconazole and ceftriaxone combined in pig 1, from 398.5 to 315.7 ng x h/ml in pig 2, and from 979.6 to 716.6 ng x h/ml in pig 3 (P of <0.01 by analysis of variance).",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·ng] / [ml],398.5 to 315.7,155457,DB01167,Itraconazole
,9303409,AUC (from 0 to 8 h),"Contrary to what was expected, the AUC (from 0 to 8 h) decreased from 139.3 ng h/ml with itraconazole alone to 122.7 ng h/ml with itraconazole and ceftriaxone combined in pig 1, from 398.5 to 315.7 ng x h/ml in pig 2, and from 979.6 to 716.6 ng x h/ml in pig 3 (P of <0.01 by analysis of variance).",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·ng] / [ml],979.6 to 716.6,155458,DB01167,Itraconazole
,11762559,trough plasma concentrations,"After intravenous dosing, mean trough plasma concentrations of itraconazole and hydroxyitraconazole were 906 ng/ml and 1,690 ng/ml, respectively.",Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762559/),[ng] / [ml],906,155520,DB01167,Itraconazole
,11762559,trough plasma concentrations,"After intravenous dosing, mean trough plasma concentrations of itraconazole and hydroxyitraconazole were 906 ng/ml and 1,690 ng/ml, respectively.",Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762559/),[ng] / [ml],"1,690",155521,DB01167,Itraconazole
over,11762559,steady-state trough concentration,"In conclusion, itraconazole 200 mg given intravenously twice daily for 2 days, then once daily for 5 days, rapidly achieves amean steady-state trough concentration of itraconazole of over 250 ng/ml, which is associated with clinic outcome and is effectively maintained with itraconazole oral solution 200 mg twice daily in patients with advanced HIV infection.",Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762559/),[ng] / [ml],250,155522,DB01167,Itraconazole
greater,20595406,steady-state trough plasma itraconazole concentration,A steady-state trough plasma itraconazole concentration greater than 500 ng/mL is a therapeutic target for itraconazole.,"A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),[ng] / [ml],500,158252,DB01167,Itraconazole
,20595406,flow rate,"Itraconazole and hydroxyitraconazole were separated using a mobile phase of 0.5% KH2PO4 (pH 6.0)-acetonitrile (30:70, v/v) on a CAPCELLPAK C18 MGII column at a flow rate of 0.5 mL/min and ultraviolet absorbance at 260 nm.","A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),[ml] / [min],0.5,158253,DB01167,Itraconazole
,20595406,recoveries,"The analysis required 200 microL of plasma and involved a rapid, simple solid-phase extraction with an Oasis HLB cartridge, which resulted in recoveries of 87-92% for itraconazole and 91-94% for hydroxyitraconazole.","A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),%,87-92,158254,DB01167,Itraconazole
,20595406,recoveries,"The analysis required 200 microL of plasma and involved a rapid, simple solid-phase extraction with an Oasis HLB cartridge, which resulted in recoveries of 87-92% for itraconazole and 91-94% for hydroxyitraconazole.","A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),%,91-94,158255,DB01167,Itraconazole
,20595406,steady-state plasma concentrations,"Although the steady-state plasma concentrations of itraconazole and hydroxyitraconazole ranged from 506 to 2482 ng/mL and from 766 to 2444 ng/mL, respectively, after a two-day loading dose of 400 mg/day intravenous itraconazole followed by the administration of 200 mg/day itraconazole oral solution, calibration curves of itraconazole and hydroxyitraconazole showed positive linearity in a concentration range of 5-2500 and 50-2500 ng/mL, respectively.","A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),[ng] / [ml],506 to 2482,158256,DB01167,Itraconazole
,20595406,steady-state plasma concentrations,"Although the steady-state plasma concentrations of itraconazole and hydroxyitraconazole ranged from 506 to 2482 ng/mL and from 766 to 2444 ng/mL, respectively, after a two-day loading dose of 400 mg/day intravenous itraconazole followed by the administration of 200 mg/day itraconazole oral solution, calibration curves of itraconazole and hydroxyitraconazole showed positive linearity in a concentration range of 5-2500 and 50-2500 ng/mL, respectively.","A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),[ng] / [ml],766 to 2444,158257,DB01167,Itraconazole
,19434851,AUC,"In vivo testing conducted in Sprague-Dawley rats (n = 6) demonstrated a significant improvement in oral bioavailability from the 1:2 ITZ:CAP (AUC = 4,516 +/- 1,949 ng x h/mL) compared to the Sporanox pellets (AUC = 2,132 +/- 1,273 ng x h/mL) (p < or = 0.05).",Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19434851/),[h·ng] / [ml],"4,516",161489,DB01167,Itraconazole
,19434851,AUC,"In vivo testing conducted in Sprague-Dawley rats (n = 6) demonstrated a significant improvement in oral bioavailability from the 1:2 ITZ:CAP (AUC = 4,516 +/- 1,949 ng x h/mL) compared to the Sporanox pellets (AUC = 2,132 +/- 1,273 ng x h/mL) (p < or = 0.05).",Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19434851/),[h·ng] / [ml],"2,132",161490,DB01167,Itraconazole
,19320276,m/z,"The ionization was optimized using electrospray ionization (ESI) with positive ion mode and selectivity was achieved by MS/MS analysis, m/z 705.3 --> 392.4 and m/z 374.3 --> 141.0 for itraconazole and internal standard (IS), respectively.",A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),,705.3,161919,DB01167,Itraconazole
,19320276,m/z,"The ionization was optimized using electrospray ionization (ESI) with positive ion mode and selectivity was achieved by MS/MS analysis, m/z 705.3 --> 392.4 and m/z 374.3 --> 141.0 for itraconazole and internal standard (IS), respectively.",A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),,392.4,161920,DB01167,Itraconazole
,19320276,m/z,"The ionization was optimized using electrospray ionization (ESI) with positive ion mode and selectivity was achieved by MS/MS analysis, m/z 705.3 --> 392.4 and m/z 374.3 --> 141.0 for itraconazole and internal standard (IS), respectively.",A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),,374.3,161921,DB01167,Itraconazole
,19320276,m/z,"The ionization was optimized using electrospray ionization (ESI) with positive ion mode and selectivity was achieved by MS/MS analysis, m/z 705.3 --> 392.4 and m/z 374.3 --> 141.0 for itraconazole and internal standard (IS), respectively.",A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),,141.0,161922,DB01167,Itraconazole
,19320276,retention times,The retention times of itraconazole (0.9 min) and IS (0.84 min) suggest the high throughput of the proposed method.,A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),min,0.9,161923,DB01167,Itraconazole
,19320276,retention times,The retention times of itraconazole (0.9 min) and IS (0.84 min) suggest the high throughput of the proposed method.,A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),min,0.84,161924,DB01167,Itraconazole
more,20497744,elimination half-life,Itraconazole is a potent inhibitor of cytochrome P450 (CYP) 3A with an elimination half-life of more than 30 hours.,Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20497744/),h,30,162644,DB01167,Itraconazole
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,3.8,164029,DB01167,Itraconazole
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,6,164030,DB01167,Itraconazole
,19646080,CL,"Mean population CL and V of IV-ITZ were 10 L/h and 1050 L, respectively.",Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646080/),[l] / [h],10,164760,DB01167,Itraconazole
,19646080,V,"Mean population CL and V of IV-ITZ were 10 L/h and 1050 L, respectively.",Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646080/),l,1050,164761,DB01167,Itraconazole
,19646080,trough concentration,The median simulated trough concentration of ITZ after 10 days was predicted to be about 700 ng/mL.,Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646080/),[ng] / [ml],700,164762,DB01167,Itraconazole
,34370587,area under the concentration-time curve over 24 hours (AUC24),"Itraconazole and hydroxyitraconazole pharmacokinetic variability was considerable, with area under the concentration-time curve over 24 hours (AUC24) mean ± standard deviation 3.34 ± 4.31 mg*h/litre and 3.57 ± 4.46 mg*h/litre, respectively.",Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[h·mg] / [l],3.34,165172,DB01167,Itraconazole
,34370587,area under the concentration-time curve over 24 hours (AUC24),"Itraconazole and hydroxyitraconazole pharmacokinetic variability was considerable, with area under the concentration-time curve over 24 hours (AUC24) mean ± standard deviation 3.34 ± 4.31 mg*h/litre and 3.57 ± 4.46 mg*h/litre, respectively.",Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[h·mg] / [l],3.57,165173,DB01167,Itraconazole
,34370587,minimum concentration (Cmin),Levels of both analytes were low; itraconazole minimum concentration (Cmin) 0.11 ± 0.16 mg/liter; hydroxyitraconazole Cmin 0.13 ± 0.17 mg/litre.,Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[mg] / [l],0.11,165174,DB01167,Itraconazole
,34370587,Cmin,Levels of both analytes were low; itraconazole minimum concentration (Cmin) 0.11 ± 0.16 mg/liter; hydroxyitraconazole Cmin 0.13 ± 0.17 mg/litre.,Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[mg] / [l],0.13,165175,DB01167,Itraconazole
,34370587,maximal rates of drug-induced killing,"The mean maximal rates of drug-induced killing were 0.206 and 0.208 log10 CFU/mL/h, respectively.",Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[cfu·log10] / [h·ml],0.206,165176,DB01167,Itraconazole
,34370587,maximal rates of drug-induced killing,"The mean maximal rates of drug-induced killing were 0.206 and 0.208 log10 CFU/mL/h, respectively.",Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[cfu·log10] / [h·ml],0.208,165177,DB01167,Itraconazole
,8529326,area under the concentration-time curve (AUC),"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],3203,166050,DB01167,Itraconazole
,8529326,area under the concentration-time curve (AUC),"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],224,166051,DB01167,Itraconazole
,8529326,half-life,"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,22.3,166052,DB01167,Itraconazole
,8529326,half-life,"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,3.8,166053,DB01167,Itraconazole
,8529326,AUC,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],6224,166054,DB01167,Itraconazole
,8529326,AUC,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],315,166055,DB01167,Itraconazole
,8529326,half-life,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,11.3,166056,DB01167,Itraconazole
,8529326,half-life,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,2.9,166057,DB01167,Itraconazole
,8878578,maximum concentration,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[ng] / [ml],113.0,167478,DB01167,Itraconazole
,8878578,maximum concentration,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[ng] / [ml],6.2,167479,DB01167,Itraconazole
,8878578,area under the concentration-time curve,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[h·ng] / [ml],"1,652.7",167480,DB01167,Itraconazole
,8878578,area under the concentration-time curve,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[h·ng] / [ml],75.6,167481,DB01167,Itraconazole
,25916686,terminal elimination half-life (T1/2λz ),"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15.8 ± 1.88 h; area under the curve from time zero to infinity (AUC0-∞ ) 13.9 ± 3.17 h·μg/ml; total body clearance 0.37 ± 0.08 l/h/kg; apparent volume of distribution 8.51 ± 1.92 l/kg; mean residence time 20.6 ± 3.95 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),h,15.8,168333,DB01167,Itraconazole
,25916686,area under the curve from time zero to infinity (AUC0-∞ ),"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15.8 ± 1.88 h; area under the curve from time zero to infinity (AUC0-∞ ) 13.9 ± 3.17 h·μg/ml; total body clearance 0.37 ± 0.08 l/h/kg; apparent volume of distribution 8.51 ± 1.92 l/kg; mean residence time 20.6 ± 3.95 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),[h·μg] / [ml],13.9,168334,DB01167,Itraconazole
,25916686,total body clearance,"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15.8 ± 1.88 h; area under the curve from time zero to infinity (AUC0-∞ ) 13.9 ± 3.17 h·μg/ml; total body clearance 0.37 ± 0.08 l/h/kg; apparent volume of distribution 8.51 ± 1.92 l/kg; mean residence time 20.6 ± 3.95 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),[l] / [h·kg],0.37,168335,DB01167,Itraconazole
,25916686,apparent volume of distribution,"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15.8 ± 1.88 h; area under the curve from time zero to infinity (AUC0-∞ ) 13.9 ± 3.17 h·μg/ml; total body clearance 0.37 ± 0.08 l/h/kg; apparent volume of distribution 8.51 ± 1.92 l/kg; mean residence time 20.6 ± 3.95 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),[l] / [kg],8.51,168336,DB01167,Itraconazole
,25916686,mean residence time,"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15.8 ± 1.88 h; area under the curve from time zero to infinity (AUC0-∞ ) 13.9 ± 3.17 h·μg/ml; total body clearance 0.37 ± 0.08 l/h/kg; apparent volume of distribution 8.51 ± 1.92 l/kg; mean residence time 20.6 ± 3.95 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),h,20.6,168337,DB01167,Itraconazole
,25916686,T1/2λz,"After PO administration, the principal pharmacokinetic parameters were as follows (mean ± SD): T1/2λz 15.6 ± 3.20 h; AUC0-∞ 7.94 ± 2.83 h·μg/ml; peak concentration 0.70 ± 0.14 μg/ml; time of peak 1.43 ± 0.53 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),h,15.6,168338,DB01167,Itraconazole
,25916686,AUC0-∞,"After PO administration, the principal pharmacokinetic parameters were as follows (mean ± SD): T1/2λz 15.6 ± 3.20 h; AUC0-∞ 7.94 ± 2.83 h·μg/ml; peak concentration 0.70 ± 0.14 μg/ml; time of peak 1.43 ± 0.53 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),[h·μg] / [ml],7.94,168339,DB01167,Itraconazole
,25916686,peak concentration,"After PO administration, the principal pharmacokinetic parameters were as follows (mean ± SD): T1/2λz 15.6 ± 3.20 h; AUC0-∞ 7.94 ± 2.83 h·μg/ml; peak concentration 0.70 ± 0.14 μg/ml; time of peak 1.43 ± 0.53 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),[μg] / [ml],0.70,168340,DB01167,Itraconazole
,25916686,time of peak,"After PO administration, the principal pharmacokinetic parameters were as follows (mean ± SD): T1/2λz 15.6 ± 3.20 h; AUC0-∞ 7.94 ± 2.83 h·μg/ml; peak concentration 0.70 ± 0.14 μg/ml; time of peak 1.43 ± 0.53 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),h,1.43,168341,DB01167,Itraconazole
,25916686,absolute bioavailability,The absolute bioavailability of ITR oral solution after oral administration was 52.1 ± 11.6%.,Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),%,52.1,168342,DB01167,Itraconazole
,33771716,AUC0-t,"For AST2818, the Cmax, AUC0-t, and AUC0-∞ in period II (coadministration of itraconazole) increased by 6.5 ng/mL, 1263.0 h*ng/mL, and 1067.0 h*ng/mL, respectively.","Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33771716/),[h·ng] / [ml],1263.0,168606,DB01167,Itraconazole
,33771716,AUC0-∞,"For AST2818, the Cmax, AUC0-t, and AUC0-∞ in period II (coadministration of itraconazole) increased by 6.5 ng/mL, 1263.0 h*ng/mL, and 1067.0 h*ng/mL, respectively.","Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33771716/),[h·ng] / [ml],1067.0,168607,DB01167,Itraconazole
,33771716,Cmax,"The Cmax, AUC0-t, and AUC0-∞ of AST5902 in period II decreased by 4.849 ng/mL, 415.60 h*ng/mL, and 391.4 h*ng/mL, respectively.","Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33771716/),ng,4.,168608,DB01167,Itraconazole
,33771716,AUC0-t,"The Cmax, AUC0-t, and AUC0-∞ of AST5902 in period II decreased by 4.849 ng/mL, 415.60 h*ng/mL, and 391.4 h*ng/mL, respectively.","Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33771716/),[h·ng] / [ml],415.60,168609,DB01167,Itraconazole
,33771716,AUC0-∞,"The Cmax, AUC0-t, and AUC0-∞ of AST5902 in period II decreased by 4.849 ng/mL, 415.60 h*ng/mL, and 391.4 h*ng/mL, respectively.","Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33771716/),[h·ng] / [ml],391.4,168610,DB01167,Itraconazole
,9420044,trough concentrations,"At the end of i.v. treatment, mean (+/- standard deviation) itraconazole and hydroxy-itraconazole trough concentrations in plasma were 0.344 +/- 0.140 and 0.605 +/- 0.205 microg/ml, respectively.",Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420044/),[μg] / [ml],0.344,169188,DB01167,Itraconazole
,9420044,trough concentrations,"At the end of i.v. treatment, mean (+/- standard deviation) itraconazole and hydroxy-itraconazole trough concentrations in plasma were 0.344 +/- 0.140 and 0.605 +/- 0.205 microg/ml, respectively.",Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420044/),[μg] / [ml],0.605,169189,DB01167,Itraconazole
,9420044,trough concentration,"After the 2-week oral follow-up of 200 mg once daily the mean trough concentration had decreased to 0.245 microg/ml, whereas after 200 mg b.i.d. it increased to 0.369 microg/ml.",Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420044/),[μg] / [ml],0.245,169190,DB01167,Itraconazole
,9420044,trough concentration,"After the 2-week oral follow-up of 200 mg once daily the mean trough concentration had decreased to 0.245 microg/ml, whereas after 200 mg b.i.d. it increased to 0.369 microg/ml.",Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420044/),[μg] / [ml],0.369,169191,DB01167,Itraconazole
,10473237,MIC,"UR-9825 was more potent against Candida spp. than both fluconazole and itraconazole, even against some Candida albicans and Candida krusei isolates with decreased susceptibility to fluconazole (MIC 16 mg/L).","In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473237/),[mg] / [l],16,169442,DB01167,Itraconazole
,23064325,maximum lung tissue concentration,A single dose inhalation at a predicted dose of 22.5mg/kg resulted in maximum lung tissue concentration of 21.4μg/g tissue with a terminal half-life of 25.4h.,Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064325/),[μg] / [g·tissue],21.4,174304,DB01167,Itraconazole
,23064325,terminal half-life,A single dose inhalation at a predicted dose of 22.5mg/kg resulted in maximum lung tissue concentration of 21.4μg/g tissue with a terminal half-life of 25.4h.,Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064325/),h,25.4,174305,DB01167,Itraconazole
,23064325,maximum concentration,"Serum concentrations were lower, with a maximum concentration of 104ng/ml at 4h after dosing and a terminal half-life of 10.5h.",Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064325/),[ng] / [ml],104,174306,DB01167,Itraconazole
,23064325,terminal half-life,"Serum concentrations were lower, with a maximum concentration of 104ng/ml at 4h after dosing and a terminal half-life of 10.5h.",Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064325/),h,10.5,174307,DB01167,Itraconazole
,30297369,area under the concentration-time curve,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[h·ng] / [ml],"14,183.2",176680,DB01167,Itraconazole
,30297369,area under the concentration-time curve,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[h·ng] / [ml],"18,479.8",176681,DB01167,Itraconazole
,30297369,maximum concentration at steady state,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),ng,"1,519.1",176682,DB01167,Itraconazole
,30297369,maximum concentration at steady state,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),ng,"2,085.2",176683,DB01167,Itraconazole
,30297369,trough concentration,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[ng] / [ml],"1,071.5",176684,DB01167,Itraconazole
,30297369,trough concentration,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[ng] / [ml],"1,218.5",176685,DB01167,Itraconazole
,33349869,AUC0-12,"Geometric mean (95% CI) of itraconazole and hydroxyitraconazole AUC0-12 without efavirenz were 9097 (6761-12 239) and 11 705 (8586-15 959) ng·h/mL, respectively, with a median metabolic ratio of OH-ITC : ITC of 1.3 (95% CI 0.9-1.9).",Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33349869/),[h·ng] / [ml],9097,179801,DB01167,Itraconazole
,33349869,AUC0-12,"Geometric mean (95% CI) of itraconazole and hydroxyitraconazole AUC0-12 without efavirenz were 9097 (6761-12 239) and 11 705 (8586-15 959) ng·h/mL, respectively, with a median metabolic ratio of OH-ITC : ITC of 1.3 (95% CI 0.9-1.9).",Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33349869/),[h·ng] / [ml],11 705,179802,DB01167,Itraconazole
,33349869,metabolic ratio,"Geometric mean (95% CI) of itraconazole and hydroxyitraconazole AUC0-12 without efavirenz were 9097 (6761-12 239) and 11 705 (8586-15 959) ng·h/mL, respectively, with a median metabolic ratio of OH-ITC : ITC of 1.3 (95% CI 0.9-1.9).",Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33349869/),,1.3,179803,DB01167,Itraconazole
below,33349869,trough concentrations,"With efavirenz, itraconazole trough concentrations were also below the recommended therapeutic level (0.5 μg/mL).",Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33349869/),[μg] / [ml],0.5,179804,DB01167,Itraconazole
up to,17097755,solubility,The ITZ-PM formulation remarkably increased the itraconazole solubility up to 15 mg/mL in aqueous media and provided stable solutions at a wide range of concentrations and pH's.,"A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097755/),[mg] / [ml],15,179977,DB01167,Itraconazole
,17304149,peak plasma concentration (Cmax),"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[ng] / [ml],6.7,180180,DB01167,Itraconazole
,17304149,peak plasma concentration (Cmax),"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[ng] / [ml],9.0,180181,DB01167,Itraconazole
,17304149,area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)],"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[h·ng] / [ml],137,180182,DB01167,Itraconazole
,17304149,area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)],"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[h·ng] / [ml],199,180183,DB01167,Itraconazole
,17304149,elimination half-life,"Although elimination half-life differed significantly (16.1 +/- 3.4 versus 18.8 +/- 5.9 hours, P < 0.05), the alteration was small (1.1 fold).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),h,16.1,180184,DB01167,Itraconazole
,17304149,elimination half-life,"Although elimination half-life differed significantly (16.1 +/- 3.4 versus 18.8 +/- 5.9 hours, P < 0.05), the alteration was small (1.1 fold).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),h,18.8,180185,DB01167,Itraconazole
,29330782,absolute oral bioavailability,The absolute oral bioavailability of vilaprisan was ~ 60%.,"Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29330782/),%,60,180557,DB01167,Itraconazole
,29330782,clearance,The mean clearance was ~ 7 L/h and the volume of distribution at steady state was ~ 360 L.,"Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29330782/),[l] / [h],7,180558,DB01167,Itraconazole
,29330782,volume of distribution at steady state,The mean clearance was ~ 7 L/h and the volume of distribution at steady state was ~ 360 L.,"Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29330782/),l,360,180559,DB01167,Itraconazole
,29330782,total recovery,"Excretion occurred primarily via feces (73.5 ± 3.70% of dose; urine: 13.1 ± 1.71%; total recovery: 86.6 ± 2.81%), mostly in a metabolized form.","Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29330782/),%,86.6,180560,DB01167,Itraconazole
> or =,16122280,Absorption,Absorption of telithromycin in humans is estimated to be > or = 90%.,"Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),%,90,180625,DB01167,Itraconazole
,16122280,absolute bioavailability,Its absolute bioavailability is 57% and is unaffected by food.,"Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),%,57,180626,DB01167,Itraconazole
,16122280,volume of distribution,The volume of distribution of telithromycin after intravenous infusion is 2.9 L/kg.,"Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),[l] / [kg],2.9,180627,DB01167,Itraconazole
,16122280,peak plasma concentration,"In healthy subjects receiving telithromycin 800 mg once daily, the peak plasma concentration achieved is 2.27 microg/mL.","Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),[μg] / [ml],2.27,180628,DB01167,Itraconazole
,16122280,disposition half-life,"Plasma concentrations of telithromycin show a biphasic decrease over time, with an initial disposition half-life of 2.9 hours and a terminal elimination half-life of approximately 10 hours after multiple dose administration.","Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),h,2.9,180629,DB01167,Itraconazole
,16122280,terminal elimination half-life,"Plasma concentrations of telithromycin show a biphasic decrease over time, with an initial disposition half-life of 2.9 hours and a terminal elimination half-life of approximately 10 hours after multiple dose administration.","Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122280/),h,10,180630,DB01167,Itraconazole
,29193123,AUC(0-24) ratios,"Predicted and observed metoprolol geometric least-squares mean AUC(0-24) ratios in UM vs EM were also similar (0.46 and 0.55, respectively), suggesting that system components related to CYP2D6 in the PBPK model were properly established.",Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29193123/),,0.46,180852,DB01167,Itraconazole
,29193123,AUC(0-24) ratios,"Predicted and observed metoprolol geometric least-squares mean AUC(0-24) ratios in UM vs EM were also similar (0.46 and 0.55, respectively), suggesting that system components related to CYP2D6 in the PBPK model were properly established.",Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29193123/),,0.55,180853,DB01167,Itraconazole
,20230761,oral bioavailability,"It has good oral bioavailability in rat and dog but not in rhesus monkey (respective oral bioavailability values of 36, 54, and 1%), and in all the three species the half-life after i.v. administration was relatively short (0.6-1.5 h).",Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230761/),%,36,181374,DB01167,Itraconazole
,20230761,oral bioavailability,"It has good oral bioavailability in rat and dog but not in rhesus monkey (respective oral bioavailability values of 36, 54, and 1%), and in all the three species the half-life after i.v. administration was relatively short (0.6-1.5 h).",Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230761/),%,54,181375,DB01167,Itraconazole
,20230761,oral bioavailability,"It has good oral bioavailability in rat and dog but not in rhesus monkey (respective oral bioavailability values of 36, 54, and 1%), and in all the three species the half-life after i.v. administration was relatively short (0.6-1.5 h).",Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230761/),%,1,181376,DB01167,Itraconazole
,20230761,half-life,"It has good oral bioavailability in rat and dog but not in rhesus monkey (respective oral bioavailability values of 36, 54, and 1%), and in all the three species the half-life after i.v. administration was relatively short (0.6-1.5 h).",Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230761/),h,0.6-1.5,181377,DB01167,Itraconazole
,20230761,half-life,"In man, TPA023 has a half-life of around 3-6h when administered as an immediate release formulation, but exposure was more prolonged when it was formulated into a controlled release, gel extrusion module (GEM) tablet.",Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230761/),h,3-6,181378,DB01167,Itraconazole
,20230761,maximum tolerated doses,"The maximum tolerated doses in healthy, normal volunteers were 2 and 8mg for the immediate-release and GEM formulations, respectively.",Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230761/),mg,2,181379,DB01167,Itraconazole
,20230761,maximum tolerated doses,"The maximum tolerated doses in healthy, normal volunteers were 2 and 8mg for the immediate-release and GEM formulations, respectively.",Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230761/),mg,8,181380,DB01167,Itraconazole
,9371367,Cmin,"At day 14, Cmin values of itraconazole were 643 +/- 304 and 592 +/- 401 ng/ml for groups A and B, respectively, and Cmin values of hydroxyitraconazole were 1,411 +/- 594 and 1,389 +/- 804 ng/ml for groups A and B, respectively.",Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371367/),[ng] / [ml],643,183167,DB01167,Itraconazole
,9371367,Cmin,"At day 14, Cmin values of itraconazole were 643 +/- 304 and 592 +/- 401 ng/ml for groups A and B, respectively, and Cmin values of hydroxyitraconazole were 1,411 +/- 594 and 1,389 +/- 804 ng/ml for groups A and B, respectively.",Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371367/),[ng] / [ml],592,183168,DB01167,Itraconazole
,9371367,Cmin,"At day 14, Cmin values of itraconazole were 643 +/- 304 and 592 +/- 401 ng/ml for groups A and B, respectively, and Cmin values of hydroxyitraconazole were 1,411 +/- 594 and 1,389 +/- 804 ng/ml for groups A and B, respectively.",Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371367/),[ng] / [ml],"1,411",183169,DB01167,Itraconazole
,9371367,Cmin,"At day 14, Cmin values of itraconazole were 643 +/- 304 and 592 +/- 401 ng/ml for groups A and B, respectively, and Cmin values of hydroxyitraconazole were 1,411 +/- 594 and 1,389 +/- 804 ng/ml for groups A and B, respectively.",Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371367/),[ng] / [ml],"1,389",183170,DB01167,Itraconazole
,10320950,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[μg] / [l],2.5,183615,DB01167,Itraconazole
under,10320950,time to reach the peak,"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,1,183616,DB01167,Itraconazole
,10320950,absolute bioavailability,The absolute bioavailability of buspirone is approximately 4%.,"Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),%,4,183617,DB01167,Itraconazole
,10320950,volume of distribution,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [kg],5.3,183618,DB01167,Itraconazole
,10320950,systemic clearance,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [h·kg],1.7,183619,DB01167,Itraconazole
,10320950,elimination half-life,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,2.5,183620,DB01167,Itraconazole
,20102737,C(max),"In systemic circulation, Wet-milled ITZ and URF-ITZ achieved C(max) of 50 and 180ng/mL at 2.7 and 4.0h, and AUC(0-24) of 662 and 2543ngh/mL, respectively, based on a one-compartmental analysis.",Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102737/),[ng] / [ml],50,183775,DB01167,Itraconazole
,20102737,C(max),"In systemic circulation, Wet-milled ITZ and URF-ITZ achieved C(max) of 50 and 180ng/mL at 2.7 and 4.0h, and AUC(0-24) of 662 and 2543ngh/mL, respectively, based on a one-compartmental analysis.",Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102737/),[ng] / [ml],180,183776,DB01167,Itraconazole
,20102737,AUC(0-24),"In systemic circulation, Wet-milled ITZ and URF-ITZ achieved C(max) of 50 and 180ng/mL at 2.7 and 4.0h, and AUC(0-24) of 662 and 2543ngh/mL, respectively, based on a one-compartmental analysis.",Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102737/),[ngh] / [ml],662,183777,DB01167,Itraconazole
,20102737,AUC(0-24),"In systemic circulation, Wet-milled ITZ and URF-ITZ achieved C(max) of 50 and 180ng/mL at 2.7 and 4.0h, and AUC(0-24) of 662 and 2543ngh/mL, respectively, based on a one-compartmental analysis.",Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102737/),[ngh] / [ml],2543,183778,DB01167,Itraconazole
,32286696,maximum concentration,An average maximum concentration of 0.22 µg/ml ± 0.11 was detected 4 hr after administration.,Plasma concentrations of itraconazole following a single oral dose in juvenile California sea lions (Zalophus californianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32286696/),[μg] / [ml],0.22,185040,DB01167,Itraconazole
,32286696,concentration,The average concentration fell to 0.12 µg/ml ± 0.11 by 6 hr and 0.02 µg/ml ± 0.02 at 12 hr.,Plasma concentrations of itraconazole following a single oral dose in juvenile California sea lions (Zalophus californianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32286696/),[μg] / [ml],0.12,185041,DB01167,Itraconazole
,32286696,concentration,The average concentration fell to 0.12 µg/ml ± 0.11 by 6 hr and 0.02 µg/ml ± 0.02 at 12 hr.,Plasma concentrations of itraconazole following a single oral dose in juvenile California sea lions (Zalophus californianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32286696/),[μg] / [ml],0.02,185042,DB01167,Itraconazole
,23298433,AUC/MIC ratios,"Moreover, integration of in vivo pharmacokinetic data with the in vitro minimum inhibitory concentration (MIC) provided iodiconazole AUC/MIC ratios in rat dermis and blood of 347.7h and 18.8h, respectively, with an iodiconazole cream (2%) dosage of 0.033 g/cm² (3 cm×5 cm).","In vivo pharmacokinetics and in vitro antifungal activity of iodiconazole, a new triazole, determined by microdialysis sampling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23298433/),h,347.7,185112,DB01167,Itraconazole
,23298433,AUC/MIC ratios,"Moreover, integration of in vivo pharmacokinetic data with the in vitro minimum inhibitory concentration (MIC) provided iodiconazole AUC/MIC ratios in rat dermis and blood of 347.7h and 18.8h, respectively, with an iodiconazole cream (2%) dosage of 0.033 g/cm² (3 cm×5 cm).","In vivo pharmacokinetics and in vitro antifungal activity of iodiconazole, a new triazole, determined by microdialysis sampling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23298433/),h,18.8,185113,DB01167,Itraconazole
,14517708,area under the plasma concentration-time curve,"The mean (+/-SD) values of area under the plasma concentration-time curve and elimination half-life for placebo versus itraconazole were 1328+/-330 ng h/ml versus 1445+/-419 ng h/ml and 32.1+/-9.3 h versus 31.1+/-8.4 h, respectively.",The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517708/),[h·ng] / [ml],1328,185458,DB01167,Itraconazole
,14517708,area under the plasma concentration-time curve,"The mean (+/-SD) values of area under the plasma concentration-time curve and elimination half-life for placebo versus itraconazole were 1328+/-330 ng h/ml versus 1445+/-419 ng h/ml and 32.1+/-9.3 h versus 31.1+/-8.4 h, respectively.",The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517708/),[h·ng] / [ml],1445,185459,DB01167,Itraconazole
,14517708,elimination half-life,"The mean (+/-SD) values of area under the plasma concentration-time curve and elimination half-life for placebo versus itraconazole were 1328+/-330 ng h/ml versus 1445+/-419 ng h/ml and 32.1+/-9.3 h versus 31.1+/-8.4 h, respectively.",The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517708/),h,32.1,185460,DB01167,Itraconazole
,14517708,elimination half-life,"The mean (+/-SD) values of area under the plasma concentration-time curve and elimination half-life for placebo versus itraconazole were 1328+/-330 ng h/ml versus 1445+/-419 ng h/ml and 32.1+/-9.3 h versus 31.1+/-8.4 h, respectively.",The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517708/),h,31.1,185461,DB01167,Itraconazole
,7997384,peak serum itraconazole concentration,"A mean +/- SD peak serum itraconazole concentration of 0.90 +/- 0.30 micrograms/ml was observed at 3.0 +/- 0.7 hours when itraconazole was administered alone, compared with undetectable levels in all patients during therapy with ddI.",Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997384/),[μg] / [ml],0.90,185520,DB01167,Itraconazole
,15289787,systemic clearance,"However, during the inhibited metabolic state, the CYP3A5*3/*3 group showed a greater decrease in systemic clearance than was seen in the CYP3A5*1/*1 group (8.5 +/- 3.8 L. h(-1). 70 kg(-1) versus 13.5 +/- 2.7 L. h(-1). 70 kg(-1), P =.027).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),[l] / [70·h·kg],8.5,187223,DB01167,Itraconazole
,15289787,systemic clearance,"However, during the inhibited metabolic state, the CYP3A5*3/*3 group showed a greater decrease in systemic clearance than was seen in the CYP3A5*1/*1 group (8.5 +/- 3.8 L. h(-1). 70 kg(-1) versus 13.5 +/- 2.7 L. h(-1). 70 kg(-1), P =.027).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),[l] / [70·h·kg],13.5,187224,DB01167,Itraconazole
,15289787,area under the plasma concentration-time curve ratio,"The 1'-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratio was also significantly lower in the CYP3A5*3/*3 group (0.58 +/- 0.35 versus 1.09 +/- 0.37 for the homozygous wild-type group, P =.026).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),,0.58,187225,DB01167,Itraconazole
,15289787,area under the plasma concentration-time curve ratio,"The 1'-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratio was also significantly lower in the CYP3A5*3/*3 group (0.58 +/- 0.35 versus 1.09 +/- 0.37 for the homozygous wild-type group, P =.026).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),,1.09,187226,DB01167,Itraconazole
,24869944,flow rate,"The mobile phase was a mixture of acetonitrile and 10mM ammonium acetate buffer (36:64, v/v), adjusted to pH 9.4 with 20% ammonium solution at a flow rate of 1.0mL/min.",Determination of domperidone in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24869944/),[ml] / [min],1.0,187970,DB01167,Itraconazole
,24869944,Retention times,"Retention times for domperidone and internal standard (propranolol) were 8.3min and 11.2min, respectively.",Determination of domperidone in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24869944/),min,8.3,187971,DB01167,Itraconazole
,24869944,Retention times,"Retention times for domperidone and internal standard (propranolol) were 8.3min and 11.2min, respectively.",Determination of domperidone in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24869944/),min,11.2,187972,DB01167,Itraconazole
,9784084,area under the concentration-time curves from 0 h to infinity,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),[h·ng] / [ml],252,188054,DB01167,Itraconazole
,9784084,area under the concentration-time curves from 0 h to infinity,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),[h·ng] / [ml],671,188055,DB01167,Itraconazole
,9784084,apparent oral clearance,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),[ml] / [kg·min],0.89,188056,DB01167,Itraconazole
,9784084,apparent oral clearance,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),[ml] / [kg·min],0.35,188057,DB01167,Itraconazole
,9784084,elimination half-life,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),h,15.7,188058,DB01167,Itraconazole
,9784084,elimination half-life,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),h,40.3,188059,DB01167,Itraconazole
,20739919,half maximal inhibitory concentration (IC(50)),The in vivo half maximal inhibitory concentration (IC(50)) for ITZ ranged from 5 to 132 nmol/l in the six subjects.,Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20739919/),[nM] / [l],5 to 132,191471,DB01167,Itraconazole
,9690949,Cmax,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[ng] / [ml],190,193159,DB01167,Itraconazole
,9690949,Cmax,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[ng] / [ml],197,193160,DB01167,Itraconazole
,9690949,total AUC,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[h·ng] / [ml],368,193161,DB01167,Itraconazole
,9690949,total AUC,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[h·ng] / [ml],324,193162,DB01167,Itraconazole
,9690949,"t1/2,z","However, the t1/2,z of fluvastatin was slightly prolonged by itraconazole (2.8 +/- 0.49 h vs 2.4 +/- 0.51 h; P < 0.05).",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,2.8,193163,DB01167,Itraconazole
,9690949,"t1/2,z","However, the t1/2,z of fluvastatin was slightly prolonged by itraconazole (2.8 +/- 0.49 h vs 2.4 +/- 0.51 h; P < 0.05).",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,2.4,193164,DB01167,Itraconazole
,9690949,"t1/2,z","The t1/2,z of lovastatin averaged 3.7 +/- 3.8 h and that of lovastatin acid 4.7 +/- 4.0 h during the itraconazole phase; these variables could not be determined in all subjects during the placebo phase.",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,3.7,193165,DB01167,Itraconazole
,9690949,"t1/2,z","The t1/2,z of lovastatin averaged 3.7 +/- 3.8 h and that of lovastatin acid 4.7 +/- 4.0 h during the itraconazole phase; these variables could not be determined in all subjects during the placebo phase.",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,4.7,193166,DB01167,Itraconazole
,16084853,area under the curve from time 0 to infinity (AUC(0-infinity)),"In the placebo phase, pharmacokinetic parameters of fexofenadine showed no statistically significant difference between 2 MDR1 haplotypes; the area under the curve from time 0 to infinity (AUC(0-infinity)) of fexofenadine in the T/T and G/C groups was 5194.0 +/- 1910.8 and 4040.4 +/- 1832.2 ng.mL(-1).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [ml],5194.0,194084,DB01167,Itraconazole
,16084853,area under the curve from time 0 to infinity (AUC(0-infinity)),"In the placebo phase, pharmacokinetic parameters of fexofenadine showed no statistically significant difference between 2 MDR1 haplotypes; the area under the curve from time 0 to infinity (AUC(0-infinity)) of fexofenadine in the T/T and G/C groups was 5194.0 +/- 1910.8 and 4040.4 +/- 1832.2 ng.mL(-1).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [ml],4040.4,194085,DB01167,Itraconazole
,16084853,oral clearance (CL/F),"h(-1), respectively (P = .271), and the oral clearance (CL/F) was 530.9 +/- 191.1 and 806.0 +/- 355.3 mL.h(-1).kg(-1), respectively (P = .096).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],530.9,194086,DB01167,Itraconazole
,16084853,oral clearance (CL/F),"h(-1), respectively (P = .271), and the oral clearance (CL/F) was 530.9 +/- 191.1 and 806.0 +/- 355.3 mL.h(-1).kg(-1), respectively (P = .096).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],806.0,194087,DB01167,Itraconazole
,16084853,AUC(0-infinity),"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [h·ml],"15,630.6",194088,DB01167,Itraconazole
,16084853,AUC(0-infinity),"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [h·ml],9252.9,194089,DB01167,Itraconazole
,16084853,CL/F,"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],167.0,194090,DB01167,Itraconazole
,16084853,CL/F,"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],292.3,194091,DB01167,Itraconazole
,26356245,intestinal availability,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.45,194246,DB01167,Itraconazole
,26356245,hepatic availability,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.31,194247,DB01167,Itraconazole
,26356245,fraction absorbed,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.89,194248,DB01167,Itraconazole
,9218932,AUC,"The mean AUC was 1.12 vs 2.02 micrograms.h.m1-1, the mean Cmax was 0.14 vs 0.31 micrograms.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),[h·μg] / [m1],1.12,195642,DB01167,Itraconazole
,9218932,AUC,"The mean AUC was 1.12 vs 2.02 micrograms.h.m1-1, the mean Cmax was 0.14 vs 0.31 micrograms.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),[h·μg] / [m1],2.02,195643,DB01167,Itraconazole
,9218932,Cmax,"The mean AUC was 1.12 vs 2.02 micrograms.h.m1-1, the mean Cmax was 0.14 vs 0.31 micrograms.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),μg,0.14,195644,DB01167,Itraconazole
,9218932,Cmax,"The mean AUC was 1.12 vs 2.02 micrograms.h.m1-1, the mean Cmax was 0.14 vs 0.31 micrograms.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),μg,0.31,195645,DB01167,Itraconazole
,9218932,tmax,"m1-1 and the mean tmax was 2.56 vs 3.38 h in treatments I and II, respectively.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),h,2.56,195646,DB01167,Itraconazole
,9218932,tmax,"m1-1 and the mean tmax was 2.56 vs 3.38 h in treatments I and II, respectively.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),h,3.38,195647,DB01167,Itraconazole
,15078426,total sum,It then gradually decreased to a total sum of 10.3 ng g(-1) on average at 8 weeks following the completion of administration.,Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15078426/),[ng] / [g],10.3,197309,DB01167,Itraconazole
,15078426,minimum inhibitory concentration (MIC),"When compared with the geometric mean minimum inhibitory concentration (MIC) of ITCZ against fresh clinical isolates of dermatophytes (Trichophyton rubrum) (0.06 microg ml(-1)), the stratum corneum ITCZ concentration in this study was 2.1-fold of the geometric mean MIC at 2 weeks following the completion of administration, and 2.4-fold at 4 weeks.",Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15078426/),[μg] / [ml],0.06,197310,DB01167,Itraconazole
,23340005,PFS times,"The median PFS times were 11.9 weeks and 35.9 weeks, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),weeks,11.9,200375,DB01167,Itraconazole
,23340005,PFS times,"The median PFS times were 11.9 weeks and 35.9 weeks, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),weeks,35.9,200376,DB01167,Itraconazole
,23340005,response rates,"PSA response rates were 0% and 14.3%, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),%,0,200377,DB01167,Itraconazole
,23340005,response rates,"PSA response rates were 0% and 14.3%, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),%,14.3,200378,DB01167,Itraconazole
,27810562,absolute bioavailability (BA),"Although the oral absorption of crystalline ITZ was negligible, SMSD/ITZ showed an improved pharmacokinetic profile in normal rats, with an absolute bioavailability (BA) of 2.9%, and even 6.3% in the hypochlorhydric model.",Improved oral absorption profile of itraconazole in hypochlorhydria by self-micellizing solid dispersion approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27810562/),%,2.9,200449,DB01167,Itraconazole
,27810562,absolute bioavailability (BA),"Although the oral absorption of crystalline ITZ was negligible, SMSD/ITZ showed an improved pharmacokinetic profile in normal rats, with an absolute bioavailability (BA) of 2.9%, and even 6.3% in the hypochlorhydric model.",Improved oral absorption profile of itraconazole in hypochlorhydria by self-micellizing solid dispersion approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27810562/),%,6.3,200450,DB01167,Itraconazole
,14697925,peak,Mean peak and trough itraconazole levels were 1.64 +/- 0.82 and 1.23 +/- 0.90 microg/mL respectively.,Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],1.64,200851,DB01167,Itraconazole
,14697925,trough itraconazole levels,Mean peak and trough itraconazole levels were 1.64 +/- 0.82 and 1.23 +/- 0.90 microg/mL respectively.,Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],1.23,200852,DB01167,Itraconazole
,14697925,peak,"Mean peak and trough hydroxy-itraconazole levels were 2.37 +/- 1.55 and 2.20 +/- 1.48 microg/mL, respectively.",Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],2.37,200853,DB01167,Itraconazole
,14697925,trough hydroxy,"Mean peak and trough hydroxy-itraconazole levels were 2.37 +/- 1.55 and 2.20 +/- 1.48 microg/mL, respectively.",Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],2.20,200854,DB01167,Itraconazole
,7648762,peak time,Grapefruit juice postponed the peak time of triazolam from 1.6 hours to 2.5 hours (p < 0.05).,Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648762/),h,1.6,202529,DB01167,Itraconazole
,7648762,peak time,Grapefruit juice postponed the peak time of triazolam from 1.6 hours to 2.5 hours (p < 0.05).,Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648762/),h,2.5,202530,DB01167,Itraconazole
,10702889,AUCt ratios,"The mean AUCt ratios for lovastatin given with 150 mg cilostazol/lovastatin given alone were 1.6 and 2.0 for lovastatin and its metabolite, respectively.",Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702889/),,1.6,206127,DB01167,Itraconazole
,10702889,AUCt ratios,"The mean AUCt ratios for lovastatin given with 150 mg cilostazol/lovastatin given alone were 1.6 and 2.0 for lovastatin and its metabolite, respectively.",Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702889/),,2.0,206128,DB01167,Itraconazole
,10722490,maximum concentrations (C(max)s),"SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),[μg] / [ml],7.31,206494,DB01167,Itraconazole
,10722490,maximum concentrations (C(max)s),"SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),[μg] / [ml],6.29,206495,DB01167,Itraconazole
,10722490,maximum concentrations (C(max)s),"SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),[μg] / [ml],6.16,206496,DB01167,Itraconazole
,10722490,maximum concentrations (C(max)s),"SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),[μg] / [ml],3.41,206497,DB01167,Itraconazole
greater,10722490,bioavailability,"SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),%,45,206498,DB01167,Itraconazole
,10722490,areas under the concentration-time curve from time zero to infinity (AUC(0-infinity)s),The areas under the concentration-time curve from time zero to infinity (AUC(0-infinity)s) after administration of a single intravenous dose of 20 mg/kg to mice varied between 25.0 and 63.6 microg.,Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),μg,25.0 and 63.6,206499,DB01167,Itraconazole
,10722490,half-life,The half-life was in the range of 4.5 to 6 h.,Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),h,4.5 to 6,206500,DB01167,Itraconazole
,10722490,bioavailability,"In Sprague-Dawley rats there was no significant difference in AUC(0-infinity) after administration of a single intravenous dose of 20 mg/kg, but on oral administration, the bioavailability of SYN-2836 was extremely low, while that of SYN-2869 was only 14.7%.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),%,14.7,206501,DB01167,Itraconazole
,10722490,C(max),"On the other hand, in beagle dogs the C(max) and AUC(0-infinity) of SYN-2836 after administration of a single oral dose of 30 mg/kg were 4.82 +/- 1.54 microg/ml and 41.8 +/- 15.7 microg.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),[μg] / [ml],4.82,206502,DB01167,Itraconazole
,10722490,AUC(0-infinity),"On the other hand, in beagle dogs the C(max) and AUC(0-infinity) of SYN-2836 after administration of a single oral dose of 30 mg/kg were 4.82 +/- 1.54 microg/ml and 41.8 +/- 15.7 microg.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),μg,41.8,206503,DB01167,Itraconazole
,18359202,Clearance,"Clearance, volume of distribution and the absorption rate constant were 12.7 L/h, 333 L and 1.72 h(-1), respectively.",Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359202/),[l] / [h],12.7,209792,DB01167,Itraconazole
,18359202,volume of distribution,"Clearance, volume of distribution and the absorption rate constant were 12.7 L/h, 333 L and 1.72 h(-1), respectively.",Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359202/),l,333,209793,DB01167,Itraconazole
,18359202,absorption rate constant,"Clearance, volume of distribution and the absorption rate constant were 12.7 L/h, 333 L and 1.72 h(-1), respectively.",Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359202/),1/[h],1.72,209794,DB01167,Itraconazole
>,18359202,trough concentrations,"Assuming a normal distribution, we predicted the trough concentrations of 94.5% of the patients receiving 200 mg/day ITC solution to be >250 ng/mL, indicating that administration of 200mg/day might be suitable for prophylaxis.",Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359202/),[ng] / [ml],250,209795,DB01167,Itraconazole
,12687332,half-life (t(1/2)),Gemfibrozil raised the area under the plasma concentration-time curve (AUC) of repaglinide 8.1-fold (range 5.5- to 15.0-fold; p<0.001) and prolonged its half-life (t(1/2)) from 1.3 to 3.7 h (p<0.001).,"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,1.3,210928,DB01167,Itraconazole
,12687332,half-life (t(1/2)),Gemfibrozil raised the area under the plasma concentration-time curve (AUC) of repaglinide 8.1-fold (range 5.5- to 15.0-fold; p<0.001) and prolonged its half-life (t(1/2)) from 1.3 to 3.7 h (p<0.001).,"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,3.7,210929,DB01167,Itraconazole
,12687332,t(1/2),"Although itraconazole alone raised repaglinide AUC only 1.4-fold (1.1- to 1.9-fold; p<0.001), the gemfibrozil-itraconazole combination raised it 19.4-fold (12.9- to 24.7-fold) and prolonged the t(1/2) of repaglinide to 6.1 h (p<0.001).","Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,6.1,210930,DB01167,Itraconazole
,18770050,n,Formulations exhibited drug release fitting Peppas model with value of n ranging from 0.61 to 1.18.,Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770050/),,0.61 to 1.18,210979,DB01167,Itraconazole
,18770050,C (max),"The formulation showed C (max) 1898 +/- 75.23 ng/ml, t (max) of the formulation was 2 h and AUC was observed to be 28604.9 ng h/ml.",Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770050/),[ng] / [ml],1898,210980,DB01167,Itraconazole
,18770050,t (max),"The formulation showed C (max) 1898 +/- 75.23 ng/ml, t (max) of the formulation was 2 h and AUC was observed to be 28604.9 ng h/ml.",Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770050/),h,2,210981,DB01167,Itraconazole
,18770050,AUC,"The formulation showed C (max) 1898 +/- 75.23 ng/ml, t (max) of the formulation was 2 h and AUC was observed to be 28604.9 ng h/ml.",Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770050/),[h·ng] / [ml],28604.9,210982,DB01167,Itraconazole
,30302786,terminal half-life,Risdiplam exhibited linear PK over the dose range with a multi-phasic decline with a mean terminal half-life of 40-69 h.,"A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302786/),h,40-69,211840,DB01167,Itraconazole
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],16.7,216921,DB01167,Itraconazole
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],8.9,216922,DB01167,Itraconazole
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],9.9,216923,DB01167,Itraconazole
,10463320,Plasma concentrations,Plasma concentrations of reduced bromperidol during itraconazole coadministration (3.6+/-2.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (1.8+/-1.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],3.6,216924,DB01167,Itraconazole
,10463320,Plasma concentrations,Plasma concentrations of reduced bromperidol during itraconazole coadministration (3.6+/-2.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (1.8+/-1.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],1.8,216925,DB01167,Itraconazole
,8891121,MICs,"ER-30346, with MICs at which 90% of the strains tested are inhibited (MIC90s) ranging from 0.025 to 0.78 microgram/ml, was 4 to 32 times more active than itraconazole, fluconazole, and amphotericin B against Candida albicans, Candida parapsilosis, and Candida glabrata.","In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891121/),[μg] / [ml],0.025 to 0.78,217460,DB01167,Itraconazole
,8891121,MIC90,"Against Candida tropicalis, ER-30346, with an MIC90 of 12.5 micrograms/ml, was 2 to > 8 times more active than itraconazole and fluconazole, but was 16 times less active than amphotericin B. ER-30346 (MIC90, 0.78 microgram/ml) was four to eight times more active than fluconazole and amphotericin B and had activity comparable to that of itraconazole against Trichosporon beigelli.","In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891121/),[μg] / [ml],12.5,217461,DB01167,Itraconazole
,8891121,MIC90,"Against Candida tropicalis, ER-30346, with an MIC90 of 12.5 micrograms/ml, was 2 to > 8 times more active than itraconazole and fluconazole, but was 16 times less active than amphotericin B. ER-30346 (MIC90, 0.78 microgram/ml) was four to eight times more active than fluconazole and amphotericin B and had activity comparable to that of itraconazole against Trichosporon beigelli.","In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891121/),[μg] / [ml],0.78,217462,DB01167,Itraconazole
,8891121,MIC90s,The MIC90s of ER-30346 were 0.10 microgram/ml for Cryptococcus neoformans and 0.39 microgram/ml for Aspergillus fumigatus.,"In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891121/),[μg] / [ml],0.10,217463,DB01167,Itraconazole
,8891121,MIC90s,The MIC90s of ER-30346 were 0.10 microgram/ml for Cryptococcus neoformans and 0.39 microgram/ml for Aspergillus fumigatus.,"In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891121/),[μg] / [ml],0.39,217464,DB01167,Itraconazole
,8891121,MICs,"ER-30346 also showed good activity against dermatophytes, with MICs ranging from 0.05 to 0.39 microgram/ml, and its activity was comparable to or 2 to 16 times higher than those of itraconazole and amphotericin B and > 32 times higher than that of fluconazole.","In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891121/),[μg] / [ml],0.05 to 0.39,217465,DB01167,Itraconazole
,1662191,maximum concentrations (Cmax),At day 7 for ITRA-PEL (n = 8) the mean +/- one standard deviation and median maximum concentrations (Cmax) were 307 +/- 155 ng/mL and 275 ng/mL respectively and for ITRA-PEG (n = 6) 272 +/- 212 ng/mL and 193 ng/mL.,Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],275,218705,DB01167,Itraconazole
,1662191,maximum concentrations (Cmax),At day 7 for ITRA-PEL (n = 8) the mean +/- one standard deviation and median maximum concentrations (Cmax) were 307 +/- 155 ng/mL and 275 ng/mL respectively and for ITRA-PEG (n = 6) 272 +/- 212 ng/mL and 193 ng/mL.,Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],193,218706,DB01167,Itraconazole
,1662191,Cmax,"At day 14 for ITRA-PEL (n = 8) the mean +/- S.D. and median Cmax were 412 +/- 227 ng/mL and 375 ng/mL respectively and for ITRA-PEG (n = 5), 315 +/- 177 ng/mL and 327 ng/mL.",Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],375,218707,DB01167,Itraconazole
,1662191,Cmax,"At day 14 for ITRA-PEL (n = 8) the mean +/- S.D. and median Cmax were 412 +/- 227 ng/mL and 375 ng/mL respectively and for ITRA-PEG (n = 5), 315 +/- 177 ng/mL and 327 ng/mL.",Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],327,218708,DB01167,Itraconazole
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],2.1,219182,DB01167,Itraconazole
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],3.3,219183,DB01167,Itraconazole
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],0.5,219184,DB01167,Itraconazole
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],1.0,219185,DB01167,Itraconazole
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],5.5,219186,DB01167,Itraconazole
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],6.6,219187,DB01167,Itraconazole
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,34.4,219188,DB01167,Itraconazole
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,60.2,219189,DB01167,Itraconazole
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,7.4,219190,DB01167,Itraconazole
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,18.9,219191,DB01167,Itraconazole
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,101,219192,DB01167,Itraconazole
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,134,219193,DB01167,Itraconazole
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,23.1,219194,DB01167,Itraconazole
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,37.2,219195,DB01167,Itraconazole
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,33.2,219196,DB01167,Itraconazole
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,48.3,219197,DB01167,Itraconazole
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,15.7,219198,DB01167,Itraconazole
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,45.6,219199,DB01167,Itraconazole
,20965798,flow rate,Elution was achieved with a mobile phase gradient varying the proportion of a 2 mM ammonium acetate aqueous solution containing 0.1% formic acid (solvent A) and a 0.1% formic acid in methanol solution (solvent B) at a flow rate of 300 μL/min.,LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20965798/),[μl] / [min],300,219367,DB01167,Itraconazole
,20965798,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 435.9→163.6 and 706.7→392.6 for etravirine and the internal standard, respectively.",LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20965798/),,435.9,219368,DB01167,Itraconazole
,20965798,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 435.9→163.6 and 706.7→392.6 for etravirine and the internal standard, respectively.",LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20965798/),,163.6,219369,DB01167,Itraconazole
,20965798,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 435.9→163.6 and 706.7→392.6 for etravirine and the internal standard, respectively.",LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20965798/),,706.7,219370,DB01167,Itraconazole
,20965798,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 435.9→163.6 and 706.7→392.6 for etravirine and the internal standard, respectively.",LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20965798/),,392.6,219371,DB01167,Itraconazole
,28627123,relative bioavailability,"The mean relative bioavailability of the capsule was 85% that of the solution, but drug absorption was variable, and overall drug concentrations were similar between formulations.",Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28627123/),%,85,223030,DB01167,Itraconazole
,28627123,elimination half-lives,Mean elimination half-lives of both formulations were nearly identical at approximately 33 hours.,Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28627123/),h,33,223031,DB01167,Itraconazole
,19790241,hepatic blood flow,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),[ml] / [kg·min],50,223122,DB01167,Itraconazole
,19790241,hepatic blood flow,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,80,223123,DB01167,Itraconazole
,19790241,apparent intestinal,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,80,223124,DB01167,Itraconazole
,19790241,hepatic extraction,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,13,223125,DB01167,Itraconazole
,19790241,apparent intestinal extraction,"Intraintestinally administered itraconazole (20 mg/kg) changed the apparent intestinal extraction by 0.26-fold from 0.829 to 0.215, but the hepatic availability of everolimus was almost unchanged after the intravenous or intraintestinal administration of itraconazole even at a dose of 50 mg/kg from 0.871 to 0.923 or 0.867, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),,0.829,223126,DB01167,Itraconazole
,19790241,apparent intestinal extraction,"Intraintestinally administered itraconazole (20 mg/kg) changed the apparent intestinal extraction by 0.26-fold from 0.829 to 0.215, but the hepatic availability of everolimus was almost unchanged after the intravenous or intraintestinal administration of itraconazole even at a dose of 50 mg/kg from 0.871 to 0.923 or 0.867, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),,0.215,223127,DB01167,Itraconazole
,15105131,area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )),"After intravenous administration at a dose of 30 mg/kg, the area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )) was significantly greater than those at 10 and 20 mg/kg (1,090, 1,270, and 1,760 micro g. min/ml for 10, 20, and 30 mg/kg, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],"1,090",223184,DB01167,Itraconazole
,15105131,area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )),"After intravenous administration at a dose of 30 mg/kg, the area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )) was significantly greater than those at 10 and 20 mg/kg (1,090, 1,270, and 1,760 micro g. min/ml for 10, 20, and 30 mg/kg, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],"1,270",223185,DB01167,Itraconazole
,15105131,area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )),"After intravenous administration at a dose of 30 mg/kg, the area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )) was significantly greater than those at 10 and 20 mg/kg (1,090, 1,270, and 1,760 micro g. min/ml for 10, 20, and 30 mg/kg, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],"1,760",223186,DB01167,Itraconazole
,15105131,AUC(0- infinity ),"After oral administration, the AUC(0- infinity ) was significantly different for three oral doses (380, 687, and 934 micro g. min/ml for 10, 30, and 50 mg/kg, respectively, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],380,223187,DB01167,Itraconazole
,15105131,AUC(0- infinity ),"After oral administration, the AUC(0- infinity ) was significantly different for three oral doses (380, 687, and 934 micro g. min/ml for 10, 30, and 50 mg/kg, respectively, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],687,223188,DB01167,Itraconazole
,15105131,AUC(0- infinity ),"After oral administration, the AUC(0- infinity ) was significantly different for three oral doses (380, 687, and 934 micro g. min/ml for 10, 30, and 50 mg/kg, respectively, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],934,223189,DB01167,Itraconazole
,15105131,absolute oral bioavailability (F),The extent of absolute oral bioavailability (F) was 34.9% after an oral dose at 10 mg/kg.,Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),%,34.9,223190,DB01167,Itraconazole
,8388198,maximum concentration,The mean maximum concentration in plasma of unmetabolized itraconazole after fasting (140 ng/ml) was about 59% that after the standard meal (239 ng/ml).,Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],140,224495,DB01167,Itraconazole
,8388198,maximum concentration,The mean maximum concentration in plasma of unmetabolized itraconazole after fasting (140 ng/ml) was about 59% that after the standard meal (239 ng/ml).,Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],239,224496,DB01167,Itraconazole
,8388198,terminal half-life,"The rate of elimination was not affected (terminal half-life, approximately 21 h).",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),h,21,224497,DB01167,Itraconazole
,8388198,maximum concentration,"The mean maximum concentration in plasma of hydroxyitraconazole after fasting was about 72% the postmeal concentration (287 and 397 ng/ml, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],287,224498,DB01167,Itraconazole
,8388198,maximum concentration,"The mean maximum concentration in plasma of hydroxyitraconazole after fasting was about 72% the postmeal concentration (287 and 397 ng/ml, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],397,224499,DB01167,Itraconazole
,8388198,terminal half-life,The terminal half-life of hydroxyitraconazole was approximately 12 h.,Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),h,12,224500,DB01167,Itraconazole
,8388198,steady-state concentrations,"The average steady-state concentrations were approximately 1,900 ng/ml for itraconazole and 3,200 ng/ml for hydroxyitraconazole.",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],"1,900",224501,DB01167,Itraconazole
,8388198,steady-state concentrations,"The average steady-state concentrations were approximately 1,900 ng/ml for itraconazole and 3,200 ng/ml for hydroxyitraconazole.",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],"3,200",224502,DB01167,Itraconazole
> or =,11550120,trough plasma levels,"After receiving iv itraconazole, concentrations increased rapidly, with trough plasma levels > or =250 ng/mL in 91% of patients and in all patients by day 7.","Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550120/),[ng] / [ml],250,224830,DB01167,Itraconazole
,11550120,trough concentrations,"Mean trough concentrations after 2 and 14 days were 670 and 850 ng/mL, respectively.","Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550120/),[ng] / [ml],670,224831,DB01167,Itraconazole
,11550120,trough concentrations,"Mean trough concentrations after 2 and 14 days were 670 and 850 ng/mL, respectively.","Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550120/),[ng] / [ml],850,224832,DB01167,Itraconazole
,30559132,volume of distribution,"The volume of distribution (217 liters) was greater than that of extracellular fluid, which suggests distribution beyond the central compartment.",Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30559132/),l,217,226567,DB01167,Itraconazole
<,7625808,MICs,"SCH 51048 inhibited C. immitis in vitro; MICs for 13 isolates ranged from < or = 0.39 to 0.78 micrograms/ml, and minimum fungicidal concentrations ranged from < or = 0.39 to 1.6 micrograms/ml.",Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625808/),[μg] / [ml],0.39 to 0.78,227469,DB01167,Itraconazole
<,7625808,minimum fungicidal concentrations,"SCH 51048 inhibited C. immitis in vitro; MICs for 13 isolates ranged from < or = 0.39 to 0.78 micrograms/ml, and minimum fungicidal concentrations ranged from < or = 0.39 to 1.6 micrograms/ml.",Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625808/),[μg] / [ml],0.39 to 1.6,227470,DB01167,Itraconazole
>,7625808,peak levels,"Pharmacokinetic studies showed peak levels in serum of > 14 micrograms/ml, with an estimated half-life of > 12 h.",Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625808/),[μg] / [ml],14,227471,DB01167,Itraconazole
>,7625808,half-life,"Pharmacokinetic studies showed peak levels in serum of > 14 micrograms/ml, with an estimated half-life of > 12 h.",Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625808/),h,12,227472,DB01167,Itraconazole
,12386638,terminal half-life,"The mean terminal half-life of budesonide was prolonged from 1.6 to 6.2 hours (ie, 3.7-fold; range, 1.5-fold to 9.3-fold; P <.001) by itraconazole.",Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386638/),h,1.6 to 6.2,227770,DB01167,Itraconazole
,9884817,absolute availability,The absolute availability of capsules in healthy volunteers under fasting conditions is about 55% and is increased after a meal.,Optimisation of itraconazole therapy using target drug concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884817/),%,55,228688,DB01167,Itraconazole
,9884817,apparent volume of distribution,Itraconazole is 99.8% bound to human plasma proteins and its apparent volume of distribution is about 11 L/kg.,Optimisation of itraconazole therapy using target drug concentrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884817/),[l] / [kg],11,228689,DB01167,Itraconazole
,9884817,blood clearance,Mean total itraconazole blood clearance determined in healthy volunteers following a single intravenous infusion was 39.6 L/h.,Optimisation of itraconazole therapy using target drug concentrations. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884817/),[l] / [h],39.6,228690,DB01167,Itraconazole
,9884817,terminal elimination half-life,"After a single oral dose, the terminal elimination half-life of itraconazole is about 24 hours.",Optimisation of itraconazole therapy using target drug concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884817/),h,24,228691,DB01167,Itraconazole
,11181397,trough plasma itraconazole concentration,The mean trough plasma itraconazole concentration at the end of the intravenous treatment was 0.54 +/- 0.20 microg/ml.,Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181397/),[μg] / [ml],0.54,229543,DB01167,Itraconazole
,11181397,trough itraconazole concentration,"This concentration was not maintained during once-daily oral treatment but increased further in the twice-daily treatment group, with a trough itraconazole concentration of 1.12 +/- 0.73 microg/ml at the end of oral treatment.",Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181397/),[μg] / [ml],1.12,229544,DB01167,Itraconazole
,29319446,half-life,Mean half-life of itraconazole in reference formulations was 18 to 26 hours.,Comparison of absorption characteristics of oral reference and compounded itraconazole formulations in healthy cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29319446/),h,18 to 26,231382,DB01167,Itraconazole
,29319446,Relative absorption,Relative absorption of compounded formulations was only 2% to 8% of reference formulation values.,Comparison of absorption characteristics of oral reference and compounded itraconazole formulations in healthy cats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29319446/),%,2,231383,DB01167,Itraconazole
,29319446,Relative absorption,Relative absorption of compounded formulations was only 2% to 8% of reference formulation values.,Comparison of absorption characteristics of oral reference and compounded itraconazole formulations in healthy cats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29319446/),%,8,231384,DB01167,Itraconazole
,24167844,clearance (CL,"The population mean clearance (CL; liter/h) was estimated as 5.15-0.0673 x(Age-62) L/h, the population mean volume of distribution (V; liter) was determined as 878L and the bioavailability (F) was determined as 0.665.",Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24167844/),[l] / [h],5.15-0.0673,231413,DB01167,Itraconazole
,24167844,volume of distribution (V;,"The population mean clearance (CL; liter/h) was estimated as 5.15-0.0673 x(Age-62) L/h, the population mean volume of distribution (V; liter) was determined as 878L and the bioavailability (F) was determined as 0.665.",Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24167844/),l,878,231414,DB01167,Itraconazole
,24167844,bioavailability (F),"The population mean clearance (CL; liter/h) was estimated as 5.15-0.0673 x(Age-62) L/h, the population mean volume of distribution (V; liter) was determined as 878L and the bioavailability (F) was determined as 0.665.",Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24167844/),,0.665,231415,DB01167,Itraconazole
,18556158,absorption half-life,"The predicted absorption half-life for 230 nm amorphous ITZ particles was only 15 min, as a result of the small particle size and high supersaturation, in general agreement with the in vivo results.",High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18556158/),min,15,232388,DB01167,Itraconazole
,15044430,peak plasma concentrations,"On day 14 average peak plasma concentrations were 404 +/- 268 ng/mL (<16 years, n = 5) and 779 +/- 470 ng/mL (>/=16 years, n = 11 excluding one patient concurrently receiving oral clarithromycin).",Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15044430/),[ng] / [ml],404,233315,DB01167,Itraconazole
,15044430,peak plasma concentrations,"On day 14 average peak plasma concentrations were 404 +/- 268 ng/mL (<16 years, n = 5) and 779 +/- 470 ng/mL (>/=16 years, n = 11 excluding one patient concurrently receiving oral clarithromycin).",Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15044430/),[ng] / [ml],779,233316,DB01167,Itraconazole
>,15044430,plasma steady-state trough concentration,All the younger patients and 50% of the older patients failed to achieve a plasma steady-state trough concentration of >250 ng/mL.,Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15044430/),[ng] / [ml],250,233317,DB01167,Itraconazole
>,15044430,Plasma concentrations,Plasma concentrations of >250 ng/mL were not reached in the paediatric cohort or in 50% of the adult cohort.,Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15044430/),ng,250,233318,DB01167,Itraconazole
,9674858,Cmin ITRA,"The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1.",Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],287,233553,DB01167,Itraconazole
,9674858,Cmin ITRA,"The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1.",Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],629,233554,DB01167,Itraconazole
,9674858,Cmin ITRA,"The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1.",Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],378,233555,DB01167,Itraconazole
,9674858,OH-ITRA,"The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1.",Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],629,233556,DB01167,Itraconazole
,9674858,OH-ITRA,"The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1.",Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],725,233557,DB01167,Itraconazole
at least,9674858,residual plasma concentrations,Six patients at day -1 (54%) and 8 at day +1 (72%) had satisfactory residual plasma concentrations of at least 250 ng/ml of unchanged ITRA.,Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],250,233558,DB01167,Itraconazole
,19566113,absolute bioavailability,"The absolute bioavailability is 20-25%, and administration of cinacalcet with low- or high-fat meals increases exposure (area under the plasma concentration-time curve from time zero to infinity [AUC(infinity)]) 1.5- to 1.8-fold.",Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566113/),%,20-25,235608,DB01167,Itraconazole
,19566113,terminal elimination half-life,"The terminal elimination half-life is 30-40 hours, and steady-state concentrations are achieved within 7 days.",Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566113/),h,30-40,235609,DB01167,Itraconazole
,15521894,apparent oral clearance (CL/F),"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),,16.47,237083,DB01167,Itraconazole
,15521894,apparent oral clearance (CL/F),"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),,3.91,237084,DB01167,Itraconazole
,15521894,area under the concentration-time curves (AUC) from 0 h to 24 h,"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),[ml·ng] / [h],28.37,237085,DB01167,Itraconazole
,15521894,area under the concentration-time curves (AUC) from 0 h to 24 h,"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),[ml·ng] / [h],68.71,237086,DB01167,Itraconazole
,15521894,elimination half-life,"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),h,4.56,237087,DB01167,Itraconazole
,15521894,elimination half-life,"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),h,23.27,237088,DB01167,Itraconazole
,28749305,minimum inhibitory concentration (MIC),"Itraconazole concentrations were measured using high performance liquid chromatography, and the minimum inhibitory concentration (MIC) of itraconazole (0.032 μg/ml) for B. dendrobatidis was used to determine whether therapeutic concentrations were attained.",THE PHARMACOKINETICS OF TOPICAL ITRACONAZOLE IN PANAMANIAN GOLDEN FROGS (ATELOPUS ZETEKI). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749305/),[μg] / [ml],0.032,238075,DB01167,Itraconazole
,28749305,disappearance half-life,"With the 0.001% bath, itraconazole exceeded the MIC and declined with a disappearance half-life that markedly varied (14.1-1,244 min).",THE PHARMACOKINETICS OF TOPICAL ITRACONAZOLE IN PANAMANIAN GOLDEN FROGS (ATELOPUS ZETEKI). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749305/),min,"14.1-1,244",238076,DB01167,Itraconazole
,16669847,peak plasma concentration (Cmax),"Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],699,239417,DB01167,Itraconazole
,16669847,peak plasma concentration (Cmax),"Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],1346,239418,DB01167,Itraconazole
,16669847,"area under the plasma concentration-time curve [AUC0,infinity]","Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],4133,239419,DB01167,Itraconazole
,16669847,"area under the plasma concentration-time curve [AUC0,infinity]","Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],11287,239420,DB01167,Itraconazole
,16669847,Cmax,"In contrast, diltiazem pretreatment did not affect Cmax (704+/-316 ng ml-1, 95% CI -145, 155), AUC0, infinity (4433+/-1565 ng ml-1 h, 95% CI -1353, 754), or other pharmacokinetic parameters of fexofenadine.","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],704,239421,DB01167,Itraconazole
,16669847,"AUC0, infinity","In contrast, diltiazem pretreatment did not affect Cmax (704+/-316 ng ml-1, 95% CI -145, 155), AUC0, infinity (4433+/-1565 ng ml-1 h, 95% CI -1353, 754), or other pharmacokinetic parameters of fexofenadine.","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],4433,239422,DB01167,Itraconazole
,16415110,K(s),"Despite these differences in metabolism, all four ITZ stereoisomers induced a type II binding spectrum with CYP3A4, characteristic of coordination of the triazole nitrogen to the heme iron (K(s) 2.2-10.6 nM).",Stereochemical aspects of itraconazole metabolism in vitro and in vivo. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415110/),nM,2.2-10.6,242694,DB01167,Itraconazole
,16415110,IC(50),All four stereoisomers of ITZ inhibited the CYP3A4-catalyzed hydroxylation of midazolam with high affinity (IC(50) 3.7-14.8 nM).,Stereochemical aspects of itraconazole metabolism in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415110/),nM,3.7-14.8,242695,DB01167,Itraconazole
,31873806,clearance (CL),"The population estimate of the clearance (CL) was 30.4 L/h, the volume of distribution (V) was 874.0 L and the bioavailability (F) was 81.1%.",Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873806/),[l] / [h],30.4,242781,DB01167,Itraconazole
,31873806,volume of distribution (V),"The population estimate of the clearance (CL) was 30.4 L/h, the volume of distribution (V) was 874.0 L and the bioavailability (F) was 81.1%.",Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873806/),l,874.0,242782,DB01167,Itraconazole
,31873806,bioavailability (F),"The population estimate of the clearance (CL) was 30.4 L/h, the volume of distribution (V) was 874.0 L and the bioavailability (F) was 81.1%.",Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873806/),%,81.1,242783,DB01167,Itraconazole
,8758480,Cmax,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[ng] / [ml],113.0,244925,DB01167,Itraconazole
,8758480,Cmax,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[ng] / [ml],6.2,244926,DB01167,Itraconazole
,8758480,AUC,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[h·ng] / [ml],1652.7,244927,DB01167,Itraconazole
,8758480,AUC,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[h·ng] / [ml],75.6,244928,DB01167,Itraconazole
<,17589527,plasma steady-state trough voriconazole levels,"The plasma steady-state trough voriconazole levels around the time the infection occurred were <0.2, <0.2, 0.33, 0.55, 0.63 and 1.78 microg/ml in the six candidiasis cases.",Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589527/),[μg] / [ml],0.2,244952,DB01167,Itraconazole
,17589527,plasma steady-state trough voriconazole levels,"The plasma steady-state trough voriconazole levels around the time the infection occurred were <0.2, <0.2, 0.33, 0.55, 0.63 and 1.78 microg/ml in the six candidiasis cases.",Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589527/),[μg] / [ml],0.33,244953,DB01167,Itraconazole
,17589527,plasma steady-state trough voriconazole levels,"The plasma steady-state trough voriconazole levels around the time the infection occurred were <0.2, <0.2, 0.33, 0.55, 0.63 and 1.78 microg/ml in the six candidiasis cases.",Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589527/),[μg] / [ml],0.55,244954,DB01167,Itraconazole
,17589527,plasma steady-state trough voriconazole levels,"The plasma steady-state trough voriconazole levels around the time the infection occurred were <0.2, <0.2, 0.33, 0.55, 0.63 and 1.78 microg/ml in the six candidiasis cases.",Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589527/),[μg] / [ml],0.63,244955,DB01167,Itraconazole
,17589527,plasma steady-state trough voriconazole levels,"The plasma steady-state trough voriconazole levels around the time the infection occurred were <0.2, <0.2, 0.33, 0.55, 0.63 and 1.78 microg/ml in the six candidiasis cases.",Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589527/),[μg] / [ml],1.78,244956,DB01167,Itraconazole
,8118163,peak plasma level,It possesses an excellent digestive adsorption and its peak plasma level after oral administration of 100 mg is 0.16 microgram/ml at 3 or 4 h after drug intake.,Itraconazole: pharmacokinetics and indications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8118163/),[μg] / [ml],0.16,245831,DB01167,Itraconazole
,8118163,Half-life,"Half-life of itraconazole ranges between 17 to 21 h and 99.8% binds to plasmatic proteins, especially albumin.",Itraconazole: pharmacokinetics and indications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8118163/),h,17 to 21,245832,DB01167,Itraconazole
,15801544,Ki,"Itraconazole inhibited the formation of OQ from quazepam, HOQ from OQ and DOQ from OQ in human liver microsomes with Ki values of 8.40, 0.08 and 0.39 microM, respectively.",In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801544/),μM,8.40,247133,DB01167,Itraconazole
,15801544,Ki,"Itraconazole inhibited the formation of OQ from quazepam, HOQ from OQ and DOQ from OQ in human liver microsomes with Ki values of 8.40, 0.08 and 0.39 microM, respectively.",In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801544/),μM,0.08,247134,DB01167,Itraconazole
,15801544,Ki,"Itraconazole inhibited the formation of OQ from quazepam, HOQ from OQ and DOQ from OQ in human liver microsomes with Ki values of 8.40, 0.08 and 0.39 microM, respectively.",In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801544/),μM,0.39,247135,DB01167,Itraconazole
,14531725,oral bioavailability,"However, atorvastatin acid is subject to extensive first-pass metabolism in the gut wall as well as in the liver, as oral bioavailability is 14%.",Clinical pharmacokinetics of atorvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),%,14,249256,DB01167,Itraconazole
,14531725,volume of distribution,"The volume of distribution of atorvastatin acid is 381L, and plasma protein binding exceeds 98%.",Clinical pharmacokinetics of atorvastatin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),l,381,249257,DB01167,Itraconazole
exceeds,14531725,plasma protein binding,"The volume of distribution of atorvastatin acid is 381L, and plasma protein binding exceeds 98%.",Clinical pharmacokinetics of atorvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),%,98,249258,DB01167,Itraconazole
,14531725,total plasma clearance,The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours.,Clinical pharmacokinetics of atorvastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),[ml] / [min],625,249259,DB01167,Itraconazole
,14531725,half-life,The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours.,Clinical pharmacokinetics of atorvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),h,7,249260,DB01167,Itraconazole
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],2773,252860,DB01167,Itraconazole
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],7011,252861,DB01167,Itraconazole
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,3.2,252862,DB01167,Itraconazole
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,5.5,252863,DB01167,Itraconazole
,29341245,terminal elimination phase half-life,"Coadministration of a single 20-mg dose of avatrombopag with fluconazole at steady-state resulted in 2.16-fold increase of AUC of avatrombopag, prolonged terminal elimination phase half-life (from 19.7 h to 39.9 h) and led to a clinically significant increase in maximum platelet count (1.66-fold).",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,19.7,253568,DB01167,Itraconazole
,29341245,terminal elimination phase half-life,"Coadministration of a single 20-mg dose of avatrombopag with fluconazole at steady-state resulted in 2.16-fold increase of AUC of avatrombopag, prolonged terminal elimination phase half-life (from 19.7 h to 39.9 h) and led to a clinically significant increase in maximum platelet count (1.66-fold).",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,39.9,253569,DB01167,Itraconazole
,29341245,terminal elimination phase half-life,"Coadministration of rifampicin caused a 0.5-fold decrease in AUC and shortened terminal elimination phase half-life (from 20.3 h to 9.84 h), but has no impact on maximum platelet count.",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,20.3,253570,DB01167,Itraconazole
,29341245,terminal elimination phase half-life,"Coadministration of rifampicin caused a 0.5-fold decrease in AUC and shortened terminal elimination phase half-life (from 20.3 h to 9.84 h), but has no impact on maximum platelet count.",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,9.84,253571,DB01167,Itraconazole
>,25865750,therapeutic trough concentrations,The dosage regimen achieved average therapeutic trough concentrations (>0.5 μg/mL) within 3 weeks.,Alternate-day dosing of itraconazole in healthy adult cats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25865750/),[μg] / [ml],0.5,253572,DB01167,Itraconazole
,25865750,peak concentration,"At 8 weeks, an average peak concentration of 1.79 ± 0.952 μg/mL (95% CI: 0.996-2.588) and an average trough concentration of 0.761 ± 0.540 μg/mL (95% CI: 0.314-1.216) were achieved.",Alternate-day dosing of itraconazole in healthy adult cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25865750/),[μg] / [ml],1.79,253573,DB01167,Itraconazole
,25865750,trough concentration,"At 8 weeks, an average peak concentration of 1.79 ± 0.952 μg/mL (95% CI: 0.996-2.588) and an average trough concentration of 0.761 ± 0.540 μg/mL (95% CI: 0.314-1.216) were achieved.",Alternate-day dosing of itraconazole in healthy adult cats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25865750/),[μg] / [ml],0.761,253574,DB01167,Itraconazole
,25813936,clearance (CL),"After i.v. administration of 1 mg/kg cobimetinib to wild-type [(WT) FVB], Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice, clearance (CL) (26-35 ml/min/kg) was similar in the CYP3A4 transgenic and WT mice.","Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813936/),[ml] / [kg·min],26-35,253713,DB01167,Itraconazole
,25813936,area under the curve (AUC),"After oral administration of 5 mg/kg cobimetinib, the area under the curve (AUC) values of cobimetinib in WT, Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice were 1.35, 3.39, 1.04, and 0.701 μM⋅h, respectively.","Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813936/),h·μM,1.35,253714,DB01167,Itraconazole
,25813936,area under the curve (AUC),"After oral administration of 5 mg/kg cobimetinib, the area under the curve (AUC) values of cobimetinib in WT, Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice were 1.35, 3.39, 1.04, and 0.701 μM⋅h, respectively.","Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813936/),h·μM,3.39,253715,DB01167,Itraconazole
,25813936,area under the curve (AUC),"After oral administration of 5 mg/kg cobimetinib, the area under the curve (AUC) values of cobimetinib in WT, Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice were 1.35, 3.39, 1.04, and 0.701 μM⋅h, respectively.","Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813936/),h·μM,1.04,253716,DB01167,Itraconazole
,25813936,area under the curve (AUC),"After oral administration of 5 mg/kg cobimetinib, the area under the curve (AUC) values of cobimetinib in WT, Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice were 1.35, 3.39, 1.04, and 0.701 μM⋅h, respectively.","Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813936/),h·μM,0.701,253717,DB01167,Itraconazole
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],94,253963,DB01167,Itraconazole
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],66.7,253964,DB01167,Itraconazole
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],47.9,253965,DB01167,Itraconazole
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],21.7,253966,DB01167,Itraconazole
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],14.9,253967,DB01167,Itraconazole
,16982783,half-life,"The results of both the SAD and the MAD studies indicated that there was a dose dependency in the half-life of itraconazole from the novel formulation, increasing from 44 h (100 mg) to more than 150 h (300 mg) once steady state was achieved.",Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982783/),h,44,255340,DB01167,Itraconazole
more,16982783,half-life,"The results of both the SAD and the MAD studies indicated that there was a dose dependency in the half-life of itraconazole from the novel formulation, increasing from 44 h (100 mg) to more than 150 h (300 mg) once steady state was achieved.",Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982783/),h,150,255341,DB01167,Itraconazole
,9661037,bioavailabilities,"The bioavailabilities of the solutions itraconazole and hydroxyitraconazole were 30 to 33% and 35 to 37% greater, respectively, than those of either capsule.",Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661037/),%,30 to 33,257266,DB01167,Itraconazole
,9661037,bioavailabilities,"The bioavailabilities of the solutions itraconazole and hydroxyitraconazole were 30 to 33% and 35 to 37% greater, respectively, than those of either capsule.",Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661037/),%,35 to 37,257267,DB01167,Itraconazole
,9226621,area under the curve,Values from an elimination graph of the concentrations of area under the curve (377.21 micrograms.hr/ml) and terminal elimination half-life (48.3 hr) were obtained for itraconazole in spiny lizard plasma.,Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226621/),[h·μg] / [ml],377.21,257632,DB01167,Itraconazole
,9226621,terminal elimination half-life,Values from an elimination graph of the concentrations of area under the curve (377.21 micrograms.hr/ml) and terminal elimination half-life (48.3 hr) were obtained for itraconazole in spiny lizard plasma.,Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226621/),h,48.3,257633,DB01167,Itraconazole
,9226621,Peak itraconazole concentration,Peak itraconazole concentration of 2.48 micrograms/ml was obtained in two half-lives and would be expected to achieve steady state at approximately 3.1 micrograms/ml plasma concentration in 10 days.,Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226621/),[μg] / [ml],2.48,257634,DB01167,Itraconazole
,9226621,Peak liver concentration,Peak liver concentration of 4.27 micrograms/ml was attained in 89.95 hr.,Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226621/),[μg] / [ml],4.27,257635,DB01167,Itraconazole
,26149987,relative bioavailability,The relative bioavailability of SUBA-itraconazole compared to that of Sporanox was 173% and was 21% less variable between subjects.,Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149987/),%,173,257874,DB01167,Itraconazole
,26149987,relative bioavailability,The relative bioavailability of SUBA-itraconazole compared to that of Sporanox was 173% and was 21% less variable between subjects.,Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149987/),%,21,257875,DB01167,Itraconazole
,9797792,total area under the plasma methylprednisolone concentration-time curve,Itraconazole increased the total area under the plasma methylprednisolone concentration-time curve 3.9-fold compared with placebo (1968 +/- 470 ng.hr/mL versus 520 +/- 125 ng.hr/mL [mean +/- SD]; P < .001).,Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[h·ng] / [ml],1968,258033,DB01167,Itraconazole
,9797792,total area under the plasma methylprednisolone concentration-time curve,Itraconazole increased the total area under the plasma methylprednisolone concentration-time curve 3.9-fold compared with placebo (1968 +/- 470 ng.hr/mL versus 520 +/- 125 ng.hr/mL [mean +/- SD]; P < .001).,Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[h·ng] / [ml],520,258034,DB01167,Itraconazole
,9797792,peak plasma concentration,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],221,258035,DB01167,Itraconazole
,9797792,peak plasma concentration,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],118,258036,DB01167,Itraconazole
,9797792,elimination half-life,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),h,4.4,258037,DB01167,Itraconazole
,9797792,elimination half-life,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),h,1.9,258038,DB01167,Itraconazole
,9797792,plasma cortisol concentration,"The mean plasma cortisol concentration during the itraconazole phase, measured 24 hours after ingestion of methylprednisolone, was only about 13% of that during the placebo phase (18 +/- 23 ng/mL versus 139 +/- 60 ng/mL; P < .001).",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],18,258039,DB01167,Itraconazole
,9797792,plasma cortisol concentration,"The mean plasma cortisol concentration during the itraconazole phase, measured 24 hours after ingestion of methylprednisolone, was only about 13% of that during the placebo phase (18 +/- 23 ng/mL versus 139 +/- 60 ng/mL; P < .001).",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],139,258040,DB01167,Itraconazole
,28833380,clearance (CL),"For the median subject, not taking interacting drugs, estimates for clearance (CL) and central volume of distribution (V2) for selumetinib in the final joint model were 12.7 l h-1 and 35.6 l, respectively.",Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833380/),[l] / [h],12.7,260345,DB01167,Itraconazole
,28833380,central volume of distribution (V2),"For the median subject, not taking interacting drugs, estimates for clearance (CL) and central volume of distribution (V2) for selumetinib in the final joint model were 12.7 l h-1 and 35.6 l, respectively.",Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833380/),l,35.6,260346,DB01167,Itraconazole
,8039534,bioavailability,"The bioavailability (90% confidence intervals) of itraconazole relative to that after the full meal, was 54% (41-77%) on an empty stomach and 86% (65-102%) after a light meal.","Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039534/),%,54,262509,DB01167,Itraconazole
,8039534,bioavailability,"The bioavailability (90% confidence intervals) of itraconazole relative to that after the full meal, was 54% (41-77%) on an empty stomach and 86% (65-102%) after a light meal.","Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039534/),%,86,262510,DB01167,Itraconazole
,8039534,bioavailability,"In contrast, the bioavailability (90% CI) of fluconazole relative to the full meal was 110% pre-prandially (100-115%) and 102% after the light meal (88-103%), and the criteria for bioequivalence were attained.","Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039534/),%,110,262511,DB01167,Itraconazole
,8039534,bioavailability,"In contrast, the bioavailability (90% CI) of fluconazole relative to the full meal was 110% pre-prandially (100-115%) and 102% after the light meal (88-103%), and the criteria for bioequivalence were attained.","Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039534/),%,102,262512,DB01167,Itraconazole
,11475469,nail : plasma ratio,The nail : plasma ratio stabilises at around 1 by week 18 of treatment.,Pharmacokinetics of antifungal agents in onychomycoses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),,1,264431,DB01167,Itraconazole
,11475469,elimination half-life,"The elimination half-life of itraconazole from nails is long, ranging from 32 to 147 days.",Pharmacokinetics of antifungal agents in onychomycoses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),d,32 to 147,264432,DB01167,Itraconazole
,11475469,time to reach effective concentrations,"Terbinafine is well absorbed from the gastrointestinal tract, and the time to reach effective concentrations in nail is 1 to 2 weeks.",Pharmacokinetics of antifungal agents in onychomycoses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),weeks,1 to 2,264433,DB01167,Itraconazole
,11475469,half-life,"The half-life is from 24 to 156 days, explaining the observed persistence of terbinafine in nails for longer than 252 days.",Pharmacokinetics of antifungal agents in onychomycoses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),d,24 to 156,264434,DB01167,Itraconazole
,11475469,nail : plasma ratios,"The uptake of fluconazole by nail increases with the length of treatment, and nail : plasma ratios are generally 1.5 to 2 at steady state.",Pharmacokinetics of antifungal agents in onychomycoses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),,1.5 to 2,264435,DB01167,Itraconazole
,11475469,half-life,"Fluconazole concentrations fall slowly after the drug is stopped, with a half-life of 50 to 87 days, and fluconazole is still detectable in nails 5 months after the end of treatment.",Pharmacokinetics of antifungal agents in onychomycoses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475469/),d,50 to 87,264436,DB01167,Itraconazole
,14756383,relative bioavailability,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,111.6,265643,DB01167,Itraconazole
,14756383,C(max) ratio,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,103.7,265644,DB01167,Itraconazole
,14756383,AUC ratio,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,107.7,265645,DB01167,Itraconazole
,14756383,C(max) ratio,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,105.8,265646,DB01167,Itraconazole
≤,25605358,MIC,"We report here that the investigational agent VT-1161 displays potent in vitro antifungal activity against dermatophytes, with MIC values in the range of ≤0.016 to 0.5 μg/ml.",VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25605358/),[μg] / [ml],0,265941,DB01167,Itraconazole
,25605358,MIC,"VT-1161 was distributed into skin and hair, with plasma and tissue concentrations in all treatment and regimen groups ranging from 0.8 to 40 μg/ml (or μg/g), at or above the MIC against the isolate used in the model (0.5 μg/ml).",VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25605358/),[μg] / [ml],0.5,265942,DB01167,Itraconazole
,12121932,peak concentration of drug in plasma (C(max)),"After 15 days of treatment, the peak concentration of drug in plasma (C(max)), the area under the plasma concentration-time curve (AUC) from 0 to 24 h (AUC(0-24)), the concentration in plasma at the end of the dosing interval (predose) (C(min)), and the terminal half-life of itraconazole (ITRA) were (means and standard deviations) 0.604 +/- 0.53 microg/ml, 6.80 +/- 7.4 microg.","Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121932/),[μg] / [ml],0.604,266704,DB01167,Itraconazole
,12121932,AUC-based accumulation factors,"The mean AUC-based accumulation factors for ITRA on day 15 were 4.14 +/- 0.9 and 3.53 +/- 0.6, respectively.","Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121932/),,4.14,266705,DB01167,Itraconazole
,12121932,AUC-based accumulation factors,"The mean AUC-based accumulation factors for ITRA on day 15 were 4.14 +/- 0.9 and 3.53 +/- 0.6, respectively.","Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121932/),,3.53,266706,DB01167,Itraconazole
,12121932,metabolic ratios (AUC,"The mean metabolic ratios (AUC of hydroxyitraconazole/AUC of ITRA) at day 15 were 1.96 +/- 0.1 for the QD regimen and 1.29 +/- 0.2 for the BID regimen, respectively (P < 0.05).","Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121932/),,1.96,266707,DB01167,Itraconazole
,12121932,metabolic ratios (AUC,"The mean metabolic ratios (AUC of hydroxyitraconazole/AUC of ITRA) at day 15 were 1.96 +/- 0.1 for the QD regimen and 1.29 +/- 0.2 for the BID regimen, respectively (P < 0.05).","Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121932/),,1.29,266708,DB01167,Itraconazole
,17978491,absorption lag time (ALAG),"The mean values of the absorption lag time (ALAG) and absorption rate constant (KA) were estimated to be 0.805 h and 2.65 h(-1), respectively.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),h,0.805,267522,DB01167,Itraconazole
,17978491,absorption rate constant (KA),"The mean values of the absorption lag time (ALAG) and absorption rate constant (KA) were estimated to be 0.805 h and 2.65 h(-1), respectively.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),1/[h],2.65,267523,DB01167,Itraconazole
,17978491,volume of the central (V(1)/F,"The mean volume of the central (V(1)/F) and peripheral (V(2)/F) compartment was 3.84 and 1.54 l/kg, respectively, and the mean value of inter-compartment clearance (Q/F) was 0.168 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [kg],3.84,267524,DB01167,Itraconazole
,17978491,peripheral (V(2)/F,"The mean volume of the central (V(1)/F) and peripheral (V(2)/F) compartment was 3.84 and 1.54 l/kg, respectively, and the mean value of inter-compartment clearance (Q/F) was 0.168 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [kg],1.54,267525,DB01167,Itraconazole
,17978491,inter-compartment clearance (Q/F),"The mean volume of the central (V(1)/F) and peripheral (V(2)/F) compartment was 3.84 and 1.54 l/kg, respectively, and the mean value of inter-compartment clearance (Q/F) was 0.168 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.168,267526,DB01167,Itraconazole
,17978491,Oral clearance (CL/F),"Oral clearance (CL/F) was estimated to be 0.0645 l/h/kg in the group with CYP2D6*1/*1, *1/*2 and *2/*2.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0645,267527,DB01167,Itraconazole
,17978491,CL/F,"The decrease in CL/F was estimated to be 0.0135 l/h/kg in the group with CYP2D6*1/*5, *1/*10, *2/*5, *2/*10, and *2/*41, and 0.0293 l/h/kg in the group with CYP2D6*5/*10, *10/*10, and *41/*41.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0135,267528,DB01167,Itraconazole
,17978491,CL/F,"The decrease in CL/F was estimated to be 0.0135 l/h/kg in the group with CYP2D6*1/*5, *1/*10, *2/*5, *2/*10, and *2/*41, and 0.0293 l/h/kg in the group with CYP2D6*5/*10, *10/*10, and *41/*41.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0293,267529,DB01167,Itraconazole
,17978491,CL/F,"The plasma concentration of aripiprazole was increased by coadministration of itraconazole, and the decrease in CL/F was estimated to be 0.0181 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0181,267530,DB01167,Itraconazole
,30485754,DL,"DL and EE values of ITR-M were 5.70 ± 0.12% and 91.30 ± 1.90%, respectively.",Itraconazole-loaded micelles based on linear-dendritic poly (ethylene glycol)-b-poly (ε-caprolactone). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30485754/),%,5.70,267587,DB01167,Itraconazole
,30485754,EE,"DL and EE values of ITR-M were 5.70 ± 0.12% and 91.30 ± 1.90%, respectively.",Itraconazole-loaded micelles based on linear-dendritic poly (ethylene glycol)-b-poly (ε-caprolactone). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30485754/),%,91.30,267588,DB01167,Itraconazole
up to,30485754,solubility,The micelle formulation enhanced the ITR solubility up to 30.42 μg/mL.,Itraconazole-loaded micelles based on linear-dendritic poly (ethylene glycol)-b-poly (ε-caprolactone). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30485754/),[μg] / [ml],30.42,267589,DB01167,Itraconazole
up to,23837910,loading efficiencies,"High loading efficiencies of itraconazole (up to 20%) and stable liquid formulations were obtained at neutral pH, and full dispersion of itraconazole was reached in 2 h in simulated intestinal fluid (pH 6.8).",PEGylated bile acids for use in drug delivery systems: enhanced solubility and bioavailability of itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23837910/),%,20,269256,DB01167,Itraconazole
,11254202,flow-rate,An aliquot of 25 microl of the mixture was injected onto a BDS Hypersil C18 column (50x2 mm; 3 microm) at a flow-rate of 0.3 ml/min.,Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254202/),[ml] / [min],0.3,269294,DB01167,Itraconazole
,11254202,extraction recovery,The extraction recovery of ITZ was 96%.,Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254202/),%,96,269295,DB01167,Itraconazole
,12485722,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],3,269443,DB01167,Itraconazole
,12485722,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],2.1,269444,DB01167,Itraconazole
,12485722,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],0.7,269445,DB01167,Itraconazole
,12485722,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],3,269446,DB01167,Itraconazole
,12485722,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],2.1,269447,DB01167,Itraconazole
,12485722,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],0.7,269448,DB01167,Itraconazole
,22446981,V,"The final model formula was: CL = 28.2 × [1 - 0.0263 × (HCT - 26.62)] × [1 - 0.0289 × (ALB - 37.63)] × [1 - 0.146 × ITR] (L/h); V = 1,080 (L); K (a) = 1.28 (h⁻¹); F = 0.711.",Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446981/),l,"1,080",270121,DB01167,Itraconazole
,22446981,K (a),"The final model formula was: CL = 28.2 × [1 - 0.0263 × (HCT - 26.62)] × [1 - 0.0289 × (ALB - 37.63)] × [1 - 0.146 × ITR] (L/h); V = 1,080 (L); K (a) = 1.28 (h⁻¹); F = 0.711.",Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446981/),h⁻¹,1.28,270122,DB01167,Itraconazole
,22336695,extraction recoveries,"The accuracies for the assay were 97-104%, inter- and intra-day coefficients of variation were <7.5% and extraction recoveries were 98% for voriconazole, posaconazole, isavuconazole and the internal standard (UK115794), and 79% and 88% for itraconazole and hydroxy-itraconazole respectively.","Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22336695/),%,98,270240,DB01167,Itraconazole
,22336695,extraction recoveries,"The accuracies for the assay were 97-104%, inter- and intra-day coefficients of variation were <7.5% and extraction recoveries were 98% for voriconazole, posaconazole, isavuconazole and the internal standard (UK115794), and 79% and 88% for itraconazole and hydroxy-itraconazole respectively.","Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22336695/),%,79,270241,DB01167,Itraconazole
,22336695,extraction recoveries,"The accuracies for the assay were 97-104%, inter- and intra-day coefficients of variation were <7.5% and extraction recoveries were 98% for voriconazole, posaconazole, isavuconazole and the internal standard (UK115794), and 79% and 88% for itraconazole and hydroxy-itraconazole respectively.","Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22336695/),%,88,270242,DB01167,Itraconazole
,23815436,lung concentrations,"Upon multiple dose administration of 10% suspension, mean lung concentrations reached 104.9 ± 10.1 μg/g.",A model for treating avian aspergillosis: serum and lung tissue kinetics for Japanese quail (Coturnix japonica) following single and multiple aerosol exposures of a nanoparticulate itraconazole suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23815436/),[μg] / [g],104.9,271067,DB01167,Itraconazole
,23815436,terminal half-lives,"Drug clearance from the lungs was slow with terminal half-lives of 19.7 h and 35.8 h following inhalation of 1% and 10% suspension, respectively.",A model for treating avian aspergillosis: serum and lung tissue kinetics for Japanese quail (Coturnix japonica) following single and multiple aerosol exposures of a nanoparticulate itraconazole suspension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23815436/),h,19.7,271068,DB01167,Itraconazole
,23815436,terminal half-lives,"Drug clearance from the lungs was slow with terminal half-lives of 19.7 h and 35.8 h following inhalation of 1% and 10% suspension, respectively.",A model for treating avian aspergillosis: serum and lung tissue kinetics for Japanese quail (Coturnix japonica) following single and multiple aerosol exposures of a nanoparticulate itraconazole suspension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23815436/),h,35.8,271069,DB01167,Itraconazole
